NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

TABLE OF CONTENTS

CHAPTER Ph 100 ORGANIZATIONAL RULES
PART Ph 101 PURPOSE AND SCOPE
  Section Ph 101.01 Purpose and Scope

PART Ph 102 DEFINITIONS
  Section Ph 102.01 Statutory Definitions Adopted
  Section Ph 102.02 Other Definitions

PART Ph 103 AGENCY ORGANIZATION
  Section Ph 103.01 Composition
  Section Ph 103.02 Officers
  Section Ph 103.03 Address
  Section Ph 103.04 Meetings

PART Ph 104 PUBLIC INFORMATION
  Section Ph 104.01 Records
  Section Ph 104.02 Copies
  Section Ph 104.03 Lists of Licensees/Registrants

CHAPTER Ph 200 PRACTICE AND PROCEDURE
PART Ph 201 INTRODUCTION AND DEFINITIONS
  Section Ph 201.01 Procedure Governed
  Section Ph 201.02 Definitions

PART Ph 202 FILING AND SERVICE OF DOCUMENTS
  Section Ph 202.01 Filing of Documents
  Section Ph 202.02 Subscription and Veracity of Documents
  Section Ph 202.03 Service of Documents
  Section Ph 202.04 Voluntary Production of Information
  Section Ph 202.05 Motions to Compel Production of Information and Documents

PART Ph 203 HEARINGS AND PROCEEDINGS
  Section Ph 203.01 Mandatory Pre-Hearing Disclosure of Witnesses and Exhibits
  Section Ph 203.02 Representatives
  Section Ph 203.03 Computation of Time
  Section Ph 203.04 Change in Allowed Times
  Section Ph 203.05 Recess and Adjournment
  Section Ph 203.06 Waiver
  Section Ph 203.07 Docket
  Section Ph 203.08 Consolidation
  Section Ph 203.09 Severance

PART Ph 204 ADJUDICATIVE PROCEEDINGS
  Section Ph 204.01 Applicability
  Section Ph 204.02 Place of an Adjudicative Proceeding
  Section Ph 204.03 Commencement of Adjudicative Proceeding
  Section Ph 204.04 Notice
  Section Ph 204.05 Continuances
  Section Ph 204.06 Emergency Orders
  Section Ph 204.07 Intervention
  Section Ph 204.08 Access to Board Records

i
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

Section Ph 204.09  Filing Requirements
Section Ph 204.10  Stipulations
Section Ph 204.11  Evidence
Section Ph 204.12  Withdrawal of Presiding Officer
Section Ph 204.13  Hearing Procedure
Section Ph 204.14  Burden of Proof
Section Ph 204.15  Decisions
Section Ph 204.16  Failure to Appear
Section Ph 204.17  Informal Settlement

PART Ph 205  REHEARINGS AND APPEALS
Section Ph 205.01  Motion for Rehearing
Section Ph 205.02  Action on Motion for Rehearing
Section Ph 205.03  Burden of Proof
Section Ph 205.04  Decisions

PART Ph 206  DECLARATORY RULINGS
Section Ph 206.01  Petitions
Section Ph 206.02  Action on Petition

PART Ph 207  RULEMAKING PETITIONS
Section Ph 207.01  Rulemaking Petitions
Section Ph 207.02  Incomplete Rulemaking Petitions
Section Ph 207.03  Action on Rulemaking Petition

PART Ph 208  RULEMAKING HEARINGS
Section Ph 208.01  Public Notice of Rulemaking Hearing
Section Ph 208.02  Presiding Officer
Section Ph 208.03  Order of the Rulemaking Hearing
Section Ph 208.04  Oral Comment
Section Ph 208.05  Written Comment

PART Ph 209  EXPLANATION OF ADOPTED RULES
Section Ph 209.01  Requests for Explanation of Adopted Rules
Section Ph 209.02  Contents of Explanation

CHAPTER Ph 300  LICENSING OF PHARMACISTS AND PHARMACIES
PART Ph 301  LICENSING OF PHARMACISTS BY EXAMINATION
Section Ph 301.01  Application
Section Ph 301.02  Additional Requirements
Section Ph 301.03  Required Examinations
Section Ph 301.04  Required Examination Score
Section Ph 301.05  Notice and Election of Re-examination
Section Ph 301.06  Issuance or Denial of Original License

PART Ph 302  LICENSING OF PHARMACISTS BY RECIPROCITY
Section Ph 302.01  Reciprocity
Section Ph 302.02  Application
Section Ph 302.03  Requirements
Section Ph 302.04  Reciprocity Application Time Limitation
Section Ph 302.05  NH MPJE Examination Required Scores and Fees
Section Ph 302.06  NH MPJE Re-Examination Notice and Election
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

Section Ph 302.07 Reciprocity License Issuance or Denial

PART Ph 303 PHARMACY PERMIT OPTIONS
   Section Ph 303.01 Licensing the Entire Store Area
   Section Ph 303.02 Licensing Only the Prescription Department

PART Ph 304 PHARMACY PERMIT APPLICATION
   Section Ph 304.01 Obtaining and Filing a Permit Application
   Section Ph 304.02 Application Contents

PART Ph 305 PHARMACY PERMIT PROCEDURE
   Section Ph 305.01 Pharmacy Permit Conference
   Section Ph 305.02 Site Inspection for Pharmacy Permit
   Section Ph 305.03 Issuance and Denial of Pharmacy Permit

PART Ph 306 PHARMACY PERMITS - CHANGES IN SUPPORTING DATA
   Section Ph 306.01 Pharmacy Ownership Transfer
   Section Ph 306.02 Reporting Changes
   Section Ph 306.03 Change in Pharmacy Name or Location - Prohibited
   Section Ph 306.04 Renovations
   Section Ph 306.05 Special Permit Provisions for Sudden Termination of Pharmacist-In-Charge (PIC)

PART Ph 307 RENEWAL AND REPLACEMENT PHARMACY PERMITS
   Section Ph 307.01 Renewal Permits Required
   Section Ph 307.02 Renewal Application Where Obtained and Filed
   Section Ph 307.03 Renewal Application Contents and When Filed
   Section Ph 307.04 Renewal Application Deficiencies
   Section Ph 307.05 Issuance or Denial of Renewal Permit
   Section Ph 307.06 Replacement Permit Application and Contents

PART Ph 308 REVOCATION AND SUSPENSION OF A PHARMACY PERMIT
   Section Ph 308.01 Grounds for Revocation or Suspension
   Section Ph 308.02 Effect of Revocation
   Section Ph 308.03 Effect of Suspension
   Section Ph 308.04 Voluntary Surrender When Permitted
   Section Ph 308.05 Hearing
   Section Ph 308.06 Other Examination Fees - REPEALED

PART Ph 309 STANDARDS OF PRACTICE FOR MANUFACTURERS, WHOLESALERS AND DISTRIBUTORS
   Section Ph 309.01 License Required
   Section Ph 309.02 Obtaining and Filing a License Application
   Section Ph 309.03 Application Contents
   Section Ph 309.04 Storage Conditions
   Section Ph 309.05 Facilities
   Section Ph 309.06 Security
   Section Ph 309.07 Recordkeeping
   Section Ph 309.08 Inspections
   Section Ph 309.09 Written Policies and Procedures
   Section Ph 309.10 Returned Goods
   Section Ph 309.11 Handling Recalls
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

Section Ph 309.12 Responsibility for Operation
Section Ph 309.13 Compliance with State and Federal Law
Section Ph 309.14 Violations

CHAPTER Ph 400 CONTINUED STATUS
PART Ph 401 RENEWAL AND REPLACEMENT LICENSES
Section Ph 401.01 Obtaining and Filing Renewal Applications
Section Ph 401.02 Renewal Application Contents and Filing Deadline
Section Ph 401.03 Renewal Application Deficiencies
Section Ph 401.04 Renewal License Issuance and Denial
Section Ph 401.05 Duplicate/Replacement Original Certificate of Licensure or Renewal License - Issuance
Section Ph 401.06 Reinstatement
Section Ph 401.07 Gold Certificates

PART Ph 402 DISCIPLINARY MATTERS
Section Ph 402.01 Effect of Revocation
Section Ph 402.02 Effect of Suspension
Section Ph 402.03 Voluntary Surrender of License
Section Ph 402.04 Hearing

PART Ph 403 CONTINUING EDUCATION REQUIREMENTS
Section Ph 403.01 Definitions
Section Ph 403.02 Renewal Requirements
Section Ph 403.03 Excess CEU’s
Section Ph 403.04 CEU’s from Other States
Section Ph 403.05 Credit for Instructors of Continuing Education
Section Ph 403.06 Postgraduate Pharmacy Curricula
Section Ph 403.07 Audio/Visual Continuing Education
Section Ph 403.08 Waiver
Section Ph 403.09 Military Personnel
Section Ph 403.10 Reinstatement
Section Ph 403.11 Penalty
Section Ph 403.12 In-State Approved Providers of Continuing Pharmacy Education
Section Ph 403.13 Continuing Education Advisory Council Membership

PART Ph 404 STANDARDS FOR COMPOUNDING AND DISPENSING STERILE AND NON-STERILE PHARMACEUTICALS
Section Ph 404.01 Purpose and Scope
Section Ph 404.02 Definitions
Section Ph 404.03 Non-Sterile Pharmaceutical Compounding
Section Ph 404.04 Regulatory Requirements for Sterile Compounding
Section Ph 404.05 Sterile Quality Requirements
Section Ph 404.06 Compounding Environment
Section Ph 404.07 Engineering Controls
Section Ph 404.08 Compounding Procedures
Section Ph 404.09 Records Management

PART Ph 405 STANDARDS OF PRACTICE FOR NUCLEAR/RADIOLOGIC PHARMACY
Section Ph 405.01 Purpose
Section Ph 405.02 Definitions
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

Section Ph 405.03 General Requirements for Pharmacies Providing Radiopharmaceutical Services
Section Ph 405.04 Minimum Equipment

CHAPTER Ph 500 ETHICAL STANDARDS
PART Ph 500 CODE OF ETHICS
Section Ph 501.01 Standards of Conduct

CHAPTER Ph 600 LIMITED RETAIL DRUG DISTRIBUTOR
PART Ph 601 LICENSING OF LIMITED RETAIL DRUG DISTRIBUTORS
Section Ph 601.01 License Required
Section Ph 601.02 Obtaining and Filing a License Application
Section Ph 601.03 Application Contents
Section Ph 601.04 Consultant Pharmacist
Section Ph 601.05 Changes in Supporting Information
Section Ph 601.06 Renewal Applications
Section Ph 601.07 Temperature
Section Ph 601.08 Quarantine
Section Ph 601.09 Space
Section Ph 601.10 Security
Section Ph 601.11 Dispensing Practices
Section Ph 601.12 Deliveries
Section Ph 601.13 Access to Drug Supply
Section Ph 601.14 Dispensing Records
Section Ph 601.15 Prescription Labels
Section Ph 601.16 Labeling Exemption
Section Ph 601.17 Violations

CHAPTER Ph 700 STANDARDS OF PRACTICE
PART Ph 701 REFERENCES AND DEFINITIONS
Section Ph 701.01 Applicability
Section Ph 701.02 Definitions
Section Ph 701.03 References

PART Ph 702 PHARMACY FACILITIES AND EQUIPMENT
Section Ph 702.01 Area, Space and Fixtures
Section Ph 702.02 Temperature
Section Ph 702.03 Quarantine
Section Ph 702.04 Security
Section Ph 702.05 Limitations on Access
Section Ph 702.06 Minimum Drug Standards
Section Ph 702.07 Minimum Standard of Technical Equipment and Stock

PART Ph 703 RECORDS AND REPORTS
Section Ph 703.01 Recordkeeping Requirements
Section Ph 703.02 Prepackaging of Drugs
Section Ph 703.03 Controlled Drug Losses
Section Ph 703.04 Automated Data Processing Systems
Section Ph 703.05 Federal DEA #222 Order Forms
Section Ph 703.06 Inspection Report

PART Ph 704 DISPENSING OF DRUGS AND DEVICES
Section Ph 704.01 Presence of Pharmacists
Section Ph 704.02 Pre-signed Prescription Blanks
Section Ph 704.03 Transmission of Prescription Drug Order by Prescriber
Section Ph 704.04 Transfer of Prescriptions
Section Ph 704.05 Schedule V Controlled Substances
Section Ph 704.06 Drug Product Selection
Section Ph 704.07 Return of Drugs and Devices
Section Ph 704.08 Prescription Pick-up and Delivery
Section Ph 704.09 Dispensing Adulterated or Misbranded Drugs
Section Ph 704.10 Out-of-State Prescriptions
Section Ph 704.11 Pharmacist-in-Charge/Corporate Entity Requirements/Duties
Section Ph 704.12 Termination of Pharmacist-in-Charge Notice
Section Ph 704.13 Termination of Pharmacist-in-Charge - Inventory
Section Ph 704.14 Prescription Refill Limitations
Section Ph 704.15 Prescription Refill - Interim Supply
Section Ph 704.16 Acts Prohibited

PART Ph 705 STORAGE OF DRUGS
   Section Ph 705.01 Prescription Drugs
   Section Ph 705.02 Emergency Drug Kits for Long Term Care Facilities/Specialized Care Facilities

PART Ph 706 PHARMACEUTICAL CARE STANDARDS
   Section Ph 706.01 Patient Records
   Section Ph 706.02 Prospective Drug Review
   Section Ph 706.03 Patient Counseling

PART Ph 707 DISPOSAL AND DESTRUCTION OF CONTROLLED DRUGS
   Section Ph 707.01 Controlled Drug Destruction
   Section Ph 707.02 Request for Destruction
   Section Ph 707.03 Board Authorized Controlled Drug Destruction
   Section Ph 707.04 Controlled Drug Destruction by the Board of Pharmacy
   Section Ph 707.05 Record of Controlled Drug Destruction
   Section Ph 707.06 Exemption

PART Ph 708 TERMINATION OF A PHARMACY OPERATION
   Section Ph 708.01 Notification of Closing
   Section Ph 708.02 Disposition of Drugs/Records
   Section Ph 708.03 Final Written Report

PART Ph 709 INSTITUTIONAL PRACTICES
   Section Ph 709.01 Definitions
   Section Ph 709.02 Licensing and Practice Standards
   Section Ph 709.03 Environment
   Section Ph 709.04 Drug Security
   Section Ph 709.05 Dispensing Practices
   Section Ph 709.06 Access to the Pharmacy
   Section Ph 709.07 Drug Control in Ambulatory Patient Treatment Areas
   Section Ph 709.08 Investigational Drugs
   Section Ph 709.09 Purchase of Drugs

PART Ph 710 ADMINISTRATIVE FINES
   Section Ph 710.01 Liability for Administrative Fines
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

Section Ph 710.02  Severity of Fine

CHAPTER Ph 800  PHARMACY TECHNICIANS
PART Ph 801  PURPOSE AND SCOPE
  Section Ph 801.01  Purpose and Scope

PART Ph 802  DEFINITIONS
  Section Ph 802.01  Definitions

PART Ph 803  REGISTRATION
  Section Ph 803.01  Application

PART Ph 804  REGISTRATIONS - CHANGES IN SUPPORTING DATA
  Section Ph 804.01  Reporting Changes

PART Ph 805  REVOCATION AND DENIAL
  Section Ph 805.01  Effect of Revocation and Denial

PART Ph 806  RENEWAL OF REGISTRATIONS
  Section Ph 806.01  Renewal Registrations Required
  Section Ph 806.02  Renewal Application Where Obtained and Filed
  Section Ph 806.03  Renewal Application Contents and When Filed
  Section Ph 806.04  Continuing Education Requirements for Certified Pharmacy Technicians
  Section Ph 806.05  Penalty
  Section Ph 806.06  Excess CEU’s
  Section Ph 806.07  CEU’s from Other States

PART Ph 807  PHARMACY TECHNICIANS - STANDARDS OF PRACTICE
  Section Ph 807.01  Responsibilities and Duties
  Section Ph 807.02  Registered Pharmacy Technician Duties
  Section Ph 807.03  Certified Pharmacy Technician Duties

CHAPTER Ph 900  MAIL-ORDER PHARMACY
PART Ph 901  PURPOSE AND SCOPE
  Section Ph 901.01  Scope

PART Ph 902  DEFINITIONS
  Section Ph 902.01  Mail-Order Pharmacy

PART Ph 903  REGISTRATION
  Section Ph 903.01  Application

PART Ph 904  REGISTRATIONS – CHANGES IN SUPPORTING DATA
  Section Ph 904.01  Reporting Changes

PART Ph 905  REVOCATION AND DENIAL
  Section Ph 905.01  Effect of Revocation and Denial

PART Ph 906  RENEWAL OF REGISTRATIONS
  Section Ph 906.01  Renewal Registrations Required
  Section Ph 906.02  Renewal Application Where Obtained and Filed
  Section Ph 906.03  Renewal Application Contents and When Filed
  Section Ph 906.04  Failure to Comply
PART Ph 907 CONDITIONS OF REGISTRATION
Section Ph 907.01 Compliance

CHAPTER Ph 1000 EMERGENCY CONTRACEPTION
PART Ph 1001 COLLABORATIVE PRACTICE FOR EMERGENCY CONTRACEPTION
Section Ph 1001.01 Collaborative Practice Authorized
Section Ph 1001.02 Education and Training
Section Ph 1001.03 Emergency Contraception Collaborative Agreement
Section Ph 1001.04 Informed Consent
Section Ph 1001.05 Patient Assessment
Section Ph 1001.06 Provision of Standardized Fact Sheet Required
Section Ph 1001.07 Records to be Kept
Section Ph 1001.08 Confidentiality

CHAPTER Ph 1100 COLLABORATIVE PHARMACY PRACTICE
PART Ph 1101 PURPOSE AND SCOPE
Section Ph 1101.01 Purpose
Section Ph 1101.02 Scope

PART Ph 1102 DEFINITIONS
Section Ph 1102.01 Attending Practitioner
Section Ph 1102.02 Collaborative Pharmacy Practice
Section Ph 1102.03 Collaborative Pharmacy Practice Agreement
Section Ph 1102.04 Medication Therapy Management

PART Ph 1103 COLLABORATIVE PHARMACIST QUALIFICATIONS AND APPLICATION
Section Ph 1103.01 Qualifications
Section Ph 1103.02 Application

PART Ph 1104 COLLABORATIVE PRACTICE AGREEMENTS AND PRACTICE THEREUNDER
Section Ph 1104.01 Collaborative Practice Agreements
Section Ph 1104.02 Informed Consent of Patient or Patient’s Authorized Representative
Section Ph 1104.03 Practice Under a Collaborative Practice Agreement

CHAPTER Ph 1200 CENTRAL PRESCRIPTION PROCESSING
PART Ph 1201 PURPOSE AND SCOPE
Section Ph 1201.01 Purpose
Section Ph 1201.02 Scope

PART Ph 1202 DEFINITIONS
Section 1202.01 Central Fill Pharmacy
Section 1202.02 Central Prescription Processing
Section 1202.03 Central Processing Pharmacy
Section 1202.04 Claims Adjudication
Section 1202.05 Dispensing Pharmacy
Section 1202.06 Intake Pharmacy

PART Ph 1203 CENTRAL PRESCRIPTION PROCESSING
Section 1203.01 General Requirements for Engaging in Central Prescription Processing
Section 1203.02 Policy and Procedure Manual Required
Section 1203.03 Patient Counseling
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

Section 1203.04 Prohibitions and Limitations
Section 1203.05 Record Keeping

CHAPTER Ph 1300 PHARMACIST ADMINISTRATION OF VACCINES
PART Ph 1301 PURPOSE AND SCOPE
Section Ph 1301.01 Purpose
Section Ph 1301.02 Scope

PART Ph 1302 DEFINITIONS
Section Ph 1302.01 Administer
Section Ph 1302.02 Licensed Pharmacist
Section Ph 1302.03 Practitioner or Licensed Practitioner

PART Ph 1303 PHARMACIST ADMINISTRATION OF VACCINES QUALIFICATIONS AND APPLICATION
Section Ph 1303.01 Qualifications
Section Ph 1303.02 Application

PART Ph 1304 PHARMACIST ADMINISTRATION OF VACCINES PROCEDURAL AND RECORDKEEPING REQUIREMENTS
Section Ph 1304.01 Vaccine Administration Requirements
Section Ph 1304.02 Recordkeeping

CHAPTER Ph 1400 UNUSED PRESCRIPTION DRUG PROGRAM RULES
PART Ph 1401 PURPOSE
Section Ph 1401.01 Purpose

PART Ph 1402 DEFINITIONS
Section Ph 1402.01 Abandoned Drug
Section Ph 1402.02 Agent
Section Ph 1402.03 Charitable Provider
Section Ph 1402.04 Dispense
Section Ph 1402.05 Donate
Section Ph 1402.06 Eligible Prescription Drug (EPD)
Section Ph 1402.07 Manifest
Section Ph 1402.08 Pharmacy
Section Ph 1402.09 Practitioner
Section Ph 1402.10 Program Pharmacist
Section Ph 1402.11 Redispense
Section Ph 1402.12 Underinsured
Section Ph 1402.13 Uninsured

PART Ph 1403 ELIGIBILITY TO DONATE PRESCRIPTION DRUGS (EDP) AND MEDICAL DEVICES
Section Ph 1403.01 Eligible Donating Entities
Section Ph 1403.02 Unused Prescription Property
Section Ph 1403.03 Conditions Required for Unused Prescription Drugs

PART Ph 1404 ELIGIBILITY TO ACCEPT DONATIONS (EAD)
Section Ph 1404.01 Eligible Accepting Entities

PART Ph 1405 ELIGIBILITY TO REDISPENSE
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

Section Ph 1405.01 Eligible Redispensing Entities

PART Ph 1406 PROGRAM PHARMACIST RESPONSIBILITIES
   Section Ph 1406.01 Program Pharmacist

PART Ph 1407 ELIGIBLE PRESCRIPTION DRUG FORMULARY
   Section Ph 1407.01 Formulary

PART Ph 1408 REQUIREMENTS FOR PHARMACIES DISPENSING UNUSED PRESCRIPTION DRUGS
   Section Ph 1408.01 Dispensing Requirements

PART Ph 1409 RESPONSIBILITIES OF CHARITABLE PROVIDERS
   Section Ph 1409.01 Charitable Providers
   Section Ph 1409.02 Labeling
   Section Ph 1409.03 Handling Fee
   Section Ph 1409.04 Recordkeeping

PART Ph 1410 FORMS
   Section Ph 1410.01 Transfer Manifests

PART Ph 1411 PARTICIPANT IMMUNITY
   Section Ph 1411.01 Participant Immunity

PART Ph 1412 VIOLATIONS
   Section Ph 1412.01 Violations of the Unused Prescription Drug Program

CHAPTER Ph 1500 NEW HAMPSHIRE CONTROLLED DRUG PRESCRIPTION HEALTH AND SAFETY PROGRAM

PART Ph 1501 PURPOSE
   Section Ph 1501.01 Purpose

PART Ph 1502 DEFINITIONS
   Section Ph 1502.01 Definitions

PART Ph 1503 REGISTRATION OF PRESCRIBERS AND DISPENSERS
   Section Ph 1503.01 Registration of Prescribers and Dispensers

PART Ph 1504 REQUIREMENTS FOR DISPENSERS
   Section Ph 1504.01 Reporting of Controlled Substances Dispensed
   Section Ph 1504.02 Waivers
   Section Ph 1504.03 Extensions

PART Ph 1505 ACCESS TO PRESCRIPTION DRUG MONITORING INFORMATION
   Section Ph 1505.01 Patient Access
   Section Ph 1505.02 Prescriber and Dispenser Access
   Section Ph 1505.03 Law Enforcement Access
   Section Ph 1505.04 Regulatory Board Access
   Section Ph 1505.05 Other Access

PART Ph 1506 REVIEW AND REPORTING OF PRESCRIPTION DRUG MONITORING INFORMATION
   Section Ph 1506.01 Review of Program Data
   Section Ph 1506.02 Reporting of Program Data
CHAPTER Ph 1600 PHARMACY INTERNS
PART Ph 1601 PURPOSE AND SCOPE
   Section Ph 1601.01 Purpose and Scope

PART Ph 1602 DEFINITIONS
   Section Ph 1602.01 Definitions

PART Ph 1603 IDENTIFICATION
   Section Ph 1603.01 Identification

PART Ph 1604 REGISTRATION
   Section Ph 1604.01 Application

PART Ph 1605 REGISTRATIONS – CHANGES IN SUPPORTING DATA
   Section Ph 1605.01 Reporting Changes

PART Ph 1606 PHARMACY INTERNS – STANDARDS OF PRACTICE
   Section Ph 1606.01 Responsibilities and Duties
   Section Ph 1606.02 Registered Pharmacy Intern Duties
   Section Ph 1606.03 Registered Pharmacy Interns Duty Restrictions

PART Ph 1607 REVOCATION AND DENIAL
   Section Ph 1607.01 Effect of Revocation and Denial

PART Ph 1608 RENEWAL OF REGISTRATIONS
   Section Ph 1608.01 Renewal Registrations Required
   Section Ph 1608.02 Renewal Application Where Obtained and Filed
   Section Ph 1608.03 Renewal Application Contents and When Filed

CHAPTER Ph 100 ORGANIZATIONAL RULES

PART Ph 101 PURPOSE AND SCOPE

Ph 101.01 Purpose and Scope. The rules of this title implement the statutory responsibilities of the
New Hampshire board of pharmacy created by RSA 318, as amended, and RSA 318-B, as amended.
These provisions regulate the licensing of pharmacies and pharmacists, the practice of pharmacy in the
state of New Hampshire, the safekeeping and distribution of pharmaceuticals and legend drugs, and the
inspection of pharmacies and other licensed and unlicensed locations where legend drugs are held, stored
or offered for sale.
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

PART Ph 102 DEFINITIONS

Ph 102.01 Statutory Definitions Adopted. All terms used in these rules shall have the same meaning as in RSA 318:1, RSA 318-B:1 and RSA 541-A:1.

Ph 102.02 Other Definitions.

(a) "Board" means the New Hampshire board of pharmacy created by RSA 318.

(b) "Evidence" means all oral or documentary material received by the board. Evidence includes, but is not limited to, testimony under oath or affirmation, documents, exhibits, and sworn statements of witnesses who are unable to appear at the proceedings.

(c) "Executive secretary" means the board's staff director, a person with delegated authority to perform administrative and clerical functions for the board.

(d) "Licensed" means a person or place lawfully authorized to engage in the practice of pharmacy under RSA 318:18 and RSA 318:37 and includes "registered" when used to refer to pharmacists or pharmacies.

(e) "Order" means the whole or any part of the final decision, whether affirmative, negative or declaratory in form, of the board in any matter other than rulemaking, but including licensing. An order has particularized effect on each party to the proceeding.

PART Ph 103 AGENCY ORGANIZATION

Ph 103.01 Composition. The New Hampshire board of pharmacy is composed of 7 board members, appointed by the governor and council for a term of 5 years, limited to no more than 2 consecutive terms. At least one member shall be a hospital pharmacist, and one member shall be a public member.
Ph 103.02 Officers. Annually, in September, the board members shall elect, from among their number, a president, a vice president, a secretary and a treasurer.

Source. #6181-A, eff 2-5-96

Ph 103.03 Address.

(a) The board shall maintain an office at 121 South Fruit Street, Concord, N.H. 03301. All correspondence with the board shall be addressed as follows:

State of New Hampshire Board of Pharmacy
121 South Fruit Street
Concord, New Hampshire 03301.

(b) The telephone number of the board shall be (603) 271-2350. The fax number shall be (603)271-2856.

Source. #6181-A, eff 2-5-96

Ph 103.04 Meetings.

(a) The board shall meet in its office on the third Wednesday of each month. Special meetings shall be held at the call of the president or by any officer.

(b) A majority of the board may take action by telephone poll or written ballot provided that such action is ratified at a subsequent meeting of the board.

Source. #6181-A, eff 2-5-96

PART Ph 104 PUBLIC INFORMATION

Ph 104.01 Records. Except as exempted by law, all records of the board may be examined by any person at the board office, during weekdays, excluding holidays, from 8:00 a.m. to 4:00 p.m.

Source. #6181-A, eff 2-5-96

Ph 104.02 Copies.

(a) At the time and place identified in Ph 104.01, any person examining a document may make a copy of that document by any means not injurious to the document provided that the person wishing to make the copy supplies the means of doing so in the office of the board. In the event a person does not have a means of copying those documents, the board shall make copies of the documents examined upon request.

(b) The prescribed fee for copies of documents made by this board shall be a minimum of $5.00 which includes up to 20 pages then 0.25¢ for each additional page thereafter and shall be payable in advance by bank draft, money order, certified check or cash.

Source. #6181-A, eff 2-5-96
Ph 104.03  Lists of Licensees/Registrants.

(a) Instead of the examination and copying permitted by Ph 104.01 and Ph 104.02, any person may request the board to provide that person with a complete mailing list of the board’s licensees/registrants. This request shall be accompanied by the prescribed fee for each list requested and shall be paid by check or money order.

(b) The fees for the lists shall be:

- Pharmacist data file by e-mail: $125.
- Pharmacist data file on CD-ROM: $150.
- Pharmacist pre-printed mailing labels: $200.
- Pharmacy Technician data file by e-mail: $125.
- Pharmacy Technician data file on CD-ROM: $150.
- Pharmacy Technician pre-printed mailing labels: $200.
- In-State Pharmacy data file by e-mail: $75.
- In-State Pharmacy data file on CD-ROM: $100.
- In-State Pharmacy pre-printed mailing labels: $150.
- Out-of-State Pharmacy data file by e-mail: $75.
- Out-of-State Pharmacy data file on CD-ROM: $100.
- Out-of-State Pharmacy pre-printed mailing labels: $150.
- Drug Manufacturer/Wholesaler data file by e-mail: $75.
- Drug Manufacturer/Wholesaler data file on CD-ROM: $100.
- Drug Manufacturer/Wholesaler pre-printed mailing labels: $150.

Source. #6181-A, eff 2-5-96; ss by #9139-A, eff 4-25-08
CHAPTER Ph 200 PRACTICE AND PROCEDURE

PART Ph 201 INTRODUCTION AND DEFINITIONS

Ph 201.01 Procedure Governed. This chapter governs practice and procedure before the board in both adjudicative and non-adjudicative proceedings.

(a) "Adjudicative proceeding" means the procedure to be followed in contested cases, as set forth in RSA 541-A:31 through RSA 541-A:36.

(b) "Board" means the New Hampshire pharmacy board.

(c) "Declaratory ruling" means a ruling by the board as to the specific applicability of any statutory provision or of any rule or order of the board.

(d) "Licensee" means a person, partnership, corporation, or any other legal or commercial entity however organized, duly licensed by the board pursuant to the provisions of RSA 318, RSA 318-B, or other applicable law.

(e) "Opponent" means any person who objects, on the grounds of public or private interest, to the approval, determination, consent, certification or authorization of any petition which the board might have under consideration.

(f) "Party" means each person named or admitted as a party, or properly seeking and entitled as a right to be admitted as a party in an adjudicative proceeding.

(g) "Presiding officer" means the board president or an individual to whom the board president has delegated the authority to preside over an adjudicative proceeding, a rehearing, or a rulemaking hearing.

(h) "Proponent" means any person who supports, on the grounds of public or private interest, the approval, determination, consent, certification or authorization of any petition which the board may have under consideration.

Ph 201.02 Definitions.

(a) "Adjudicative proceeding" means the procedure to be followed in contested cases, as set forth in RSA 541-A:31 through RSA 541-A:36.

(b) "Board" means the New Hampshire pharmacy board.

(c) "Declaratory ruling" means a ruling by the board as to the specific applicability of any statutory provision or of any rule or order of the board.

(d) "Licensee" means a person, partnership, corporation, or any other legal or commercial entity however organized, duly licensed by the board pursuant to the provisions of RSA 318, RSA 318-B, or other applicable law.

(e) "Opponent" means any person who objects, on the grounds of public or private interest, to the approval, determination, consent, certification or authorization of any petition which the board might have under consideration.

(f) "Party" means each person named or admitted as a party, or properly seeking and entitled as a right to be admitted as a party in an adjudicative proceeding.

(g) "Presiding officer" means the board president or an individual to whom the board president has delegated the authority to preside over an adjudicative proceeding, a rehearing, or a rulemaking hearing.

(h) "Proponent" means any person who supports, on the grounds of public or private interest, the approval, determination, consent, certification or authorization of any petition which the board may have under consideration.
PART Ph 202  FILING AND SERVICE OF DOCUMENTS

Ph 202.01  Filing of Documents.

(a) A document shall be considered filed when it is actually received at the board's office in Concord and conforms to the requirements of this chapter.

(b) All documents filed shall be either originals or legible copies bearing original signatures. Only a single copy of routine correspondence, license applications, and consumer complaints against licensees shall be filed.

Source.  #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8315-A, eff 3-26-05

Ph 202.02  Subscription and Veracity of Documents.

(a) All complaints, petitions, motions, and replies filed with the board shall be signed by the proponent of the document or, if the party appears by a representative, by the representative.

(b) The signature on a document filed with the board shall constitute a certification that:

(1) The signor has read the document;

(2) The signor is authorized to file it;

(3) To the best of the signor's knowledge, information, and belief, there are good grounds to support it; and

(4) The document has not been filed for purposes of delay or harassment.

Source.  #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8315-A, eff 3-26-05

Ph 202.03  Service of Documents.

(a) Complaints against licensees of the board shall be filed with the board without service upon the licensee which is the subject of the complaint.

(b) Petitions for rulemaking and petitions for declaratory rulings shall be filed with the board without service upon other persons.
(c) All motions, replies, exhibits, memoranda, or other documents filed in an adjudicatory proceeding shall be served by the proponent upon all parties to the proceeding by:

1. Sending a copy of the document by U.S. mail, first class postage prepaid, addressed to the last address given to the board by the party being served, no later than the day the document is filed with the board; or
2. Delivering a copy of the document in hand on or before the date it is filed with the board.

(d) All notices, orders, decisions or other documents issued by the board in the course of an adjudicatory proceeding shall be served by the board upon all parties to the proceeding by either:

1. Sending a copy of the document by U.S. mail, first class postage prepaid, addressed to the last address given to the board by the party being served; or
2. Delivering a copy of the document in hand to the party.

(e) When a party has appeared by a representative, service shall be upon the representative.

(f) Except for exhibits distributed at a prehearing conference or a hearing, every document filed with the board and required to be served upon the parties to an adjudicatory proceeding shall be accompanied by a certificate of service, signed by the person making service, attesting to the method and date of service, and the persons served.

Source. #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96; New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8315-A, eff 3-26-05

Ph 202.04 Voluntary Production of Information.

(a) Each party and intervenor shall attempt in good faith to make complete and timely response to requests for the voluntary production of information and documents relevant to the hearing.

(b) When a dispute arises concerning a request for the voluntary production of information or documents, any party or intervenor may file a motion to compel the production of the requested information or documents.

Source. #8315-A, eff 3-26-05

Ph 202.05 Motions to Compel Production of Information and Documents.

(a) Any party or intervenor may make a motion seeking an order for compliance with an information or document request. The motion shall be filed at least 20 days before the date scheduled for the hearing and in any event as soon as possible after receiving the notice of the hearing and failing in an attempt to obtain the requested information or documents through voluntary production.

(b) The motion to compel shall:

1. Set forth in detail those facts which justify the request for information or documents; and
(2) List with specificity the information or documents being sought.

(c) Objections to motion to compel shall be filed within 10 days of the delivery of the motion.

(d) The presiding officer shall grant the motion to compel if its proponent has demonstrated that an order for compliance is necessary for a full and fair presentation of evidence at the hearing.

Source. #8315-A, eff 3-26-05

PART Ph 203  HEARINGS AND PROCEEDINGS

Ph 203.01 Mandatory Pre-Hearing Disclosure of Witnesses and Exhibits. At least 5 days before the hearing, the parties and intervenors shall provide to the other parties and intervenors:

(a) A list of witnesses intended to be called at the hearing including the names, their addresses and their telephone numbers;

(b) Brief summaries of the testimony of the witnesses to be called;

(c) A list of documents and exhibits intended to be offered as evidence at the hearing;

(d) A copy of each document intended to be offered as evidence at the hearing; and

(e) An offer to allow the inspection on non-documentary exhibits intended to be offered as evidence at the hearing at times and places of convenience to the parties and intervenors.

Source. #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED:

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8315-A, eff 3-26-05

Ph 203.02 Representatives.

(a) Any person may represent himself/herself in a proceeding before the board or may be represented by an attorney or a competent individual of good character.

(b) A representative under (a) above shall be someone who:

(1) Is an attorney holding a current and active New Hampshire license who has filed a written appearance with the board containing his or her business address and telephone number; or

(2) Is not a New Hampshire licensed attorney, but has filed a motion for leave to appear as a representative which has been granted by the board.

(c) Motions made pursuant to Ph 203.01 (b)(2) shall:

(1) Describe the proposed representative's qualifications including, but not limited to, the following:

a. Education;
Ph 203.03 Computation of Time. Any time period specified in this chapter shall begin with the day following the act, event, or default, and shall include the last day of the period, unless it is a Saturday, Sunday, or state legal holiday, in which event the period shall run until the end of the next day which is not a Saturday, Sunday, or state legal holiday. When the period prescribed or allowed is less than 7 days, intermediate Saturdays, Sundays, and state legal holidays shall be excluded from the computation.

Ph 203.04 Change in Allowed Times.

(a) Except where a time period is fixed by statute, a party may file a motion to change a time period which shall set forth specific facts to support their request to enlarge or shorten the time provided for the filing of any document, or advance or postpone the time set for any oral hearing, prehearing conference, or other activity.

(b) The board shall grant such motion:

(1) If all parties consent; or

(2) For good cause shown from the facts presented.

(c) Good cause under (b) (2) above shall include the following:
(1) Unavoidable unavailability of witnesses, parties, their attorneys, or their authorized representatives; or

(2) Other exigent circumstances beyond the control of the parties, their attorneys, or their representatives.

(d) A consent of the parties under (b)(1) above shall be:

(1) Made in writing;

(2) Signed by all parties; and

(3) Filed with the board prior to a scheduled date or the expiration of a time period.

Source. #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8315-A, eff 3-26-05

Ph 203.05 Recess and Adjournment.

(a) The presiding officer shall recess or adjourn any proceeding for good cause, which shall include but not be limited to the following:

(1) Other exigent business of the board;

(2) The end of the business day; or

(3) Inclement weather.

Source. #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8315-A, eff 3-26-05

Ph 203.06 Waiver.

(a) Any interested person may request the board to waive or suspend provisions of the Ph 200 rules by filing an original and 2 copies of a petition which identifies the rule in question and sets forth specific facts and arguments which support the requested waiver.

(b) Petitions for rule waivers shall address whether:

(1) Adherence to the rule would cause the petitioner hardship. "Hardship" in this context means that because of petitioner's unique circumstances strict adherence to a rule would be unreasonable or result in unfair advantage to another party.
(2) Other good cause for waiving the rule exists, including the following:

a. Repeal or amendment of the enabling statute for provisions of rules from which a waiver is sought; or

b. Other circumstances which render a rule inapplicable, unenforceable, or illegal.

(c) If examination of the petition reveals that other persons would be substantially affected by the proposed relief, the board shall require service of the petition on such persons and advise them that they may file a reply to the petition.

(d) Petitions for waiver shall be acted upon by the board within 45 days of receipt. The board shall give written notice of the decision to all interested parties.

(e) A granted waiver shall only apply to the proceedings under review at the time of the petition.

(f) Provisions of Ph 200 rules which include provisions of New Hampshire statutes shall not be waived.

(g) A consent of the parties under (f) above shall:

1. Be made in writing;

2. Identify the specific rule provision to which the waiver applies;

3. Be signed by all parties; and

4. Be filed with the board.

Source. #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8315-A, eff 3-26-05

Ph 203.07 Docket. The board shall maintain a docket of all proceedings, hearings, and rehearsings pending before the board.

Source. #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8315-A, eff 3-26-05
Ph 203.08 Consolidation.

(a) A party may file a motion to consolidate whenever 2 or more proceedings involve substantially similar or related issues.

(b) A motion to consolidate may include a request for a single hearing, a single decision, or both.

(c) The board shall grant a motion to consolidate upon finding that:

(1) A requested consolidation would further the interests of fairness and efficiency; and

(2) A requested consolidation would not impair consideration of the issues presented by each individual matter.

Source. #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8315-A, eff 3-26-05

Ph 203.09 Severance.

(a) A party may file a motion to sever one or more issues from a proceeding and dispose of those issues in another proceeding whenever it shall appear that injury to the substantive rights of a party or undue delay might be thereby avoided.

(b) The board shall grant a motion for severance upon finding that:

(1) A requested severance would further the interests of fairness and efficiency; and

(2) A requested severance would not impair the proceeding from which the issue or issues are removed.

Source. #8315-A, eff 3-26-05

PART Ph 204 ADJUDICATIVE PROCEEDINGS

Ph 204.01 Applicability. This part shall govern adjudicative proceedings before the board.

Source. #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8315-A, eff 3-26-05
Ph 204.02 **Place of an Adjudicative Proceeding.** Adjudicative proceedings before the board shall be held at the offices of the board, 121 South Fruit Street, Concord, New Hampshire.

Source. #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96; New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8315-A, eff 3-26-05

Ph 204.03 **Commencement of Adjudicative Proceeding.**

(a) Pursuant to RSA 541-A:31, II, the board shall commence an adjudicative proceeding at any time as a result of the following actions by a licensee:

1. Failure to file requisite reports within 30 days of applicable deadlines;
2. Failure to pay fees or fines within 60 days of invoice date;
3. Engaging in licensed activity with a suspended, revoked, or expired license;
4. Failure to allow board personnel access, authorized by law, to the books, papers, records, files or similar documents for purposes of conducting examinations; or
5. Any other failure to comply with the laws, rules or orders of the board governing the licensee's activities.

Source. #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;
New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8315-A, eff 3-26-05

Ph 204.04 **Notice.**

(a) Notice of an adjudicative proceeding shall be governed by the following provisions, unless otherwise provided by law:

1. The board shall give written notice to a party at least 30 days prior to a scheduled hearing date by first class mail, postage prepaid, or by personal service upon a party or a party's agent;
(2) Contents of the notice shall be governed by the provisions of RSA 541-A:31, III.

Ph 204.05  Continuances.

(a) Any party or intervenor may make an oral or written motion that a hearing be delayed or continued to a later date or time.

(b) A motion for a delay or a continuance shall be granted if the presiding officer determines that a delay or continuance would assist in resolving the case fairly.

(c) If the later date, time and place are known when the hearing is being delayed or continued, the information shall be stated on the record. If the later date, time and place are not known at that time, the presiding officer shall as soon as practicable issue a written scheduling order stating the date, time and place of the delayed or continued hearing.

Ph 204.06  Emergency Orders.

(a) Pursuant to RSA 318:30-a, if the board finds that public welfare requires emergency action against a licensee, and the board incorporates a finding to that effect in an order, the board shall order the immediate suspension of a license pending an adjudicative proceeding which shall be commenced not later than 30 working days after the date of the board's order suspending the license.

(b) An emergency order shall be served upon the licensee by certified mail-return receipt requested, or by personal service upon the licensee, or by personal service upon the licensee's agent as identified on the most recent license application submitted to the board.
Ph 204.07 Intervention.

(a) A person filing a complaint which becomes the subject of a disciplinary hearing shall be served with the hearing notice and notified that he/she may petition to intervene in the proceeding.

(b) The board shall grant one or more petitions for intervention if:

1. The petition is submitted in writing to the board, with copies mailed to all parties named in the notice of hearing, at least 3 days before the hearing;

2. The petition states facts demonstrating that the petitioner's rights, duties, privileges, immunities or other substantial interests might be affected by the proceeding; and

3. The interests of justice and the orderly and prompt conduct of the proceedings would not be impaired by allowing the intervention.

(c) Once granted leave to intervene, an intervenor shall enter the proceeding as it stands at the time. No portion of the proceeding shall be repeated because of the fact of intervention.

Source. #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8315-A, eff 3-26-05

Ph 204.08 Access to Board Records.

(a) Parties shall have access to any statements, documents, or other information in the board's files pertinent to an adjudicative proceeding. However, confidential information pursuant to RSA 318:30,I, including consumer complaints and confidential material otherwise protected by law shall not be disclosed or provided to any party other than the board.

(b) The intervenor shall have access to all materials permitted by Ph 204.07 (a).

Source. #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8315-A, eff 3-26-05

Ph 204.09 Filing Requirements. Copies of all documents, pleadings, motions, objections, requests, memorandums, correspondence, accounts, and the like, which are filed by a party with the board shall be provided to other parties to the same proceeding as follows:

(a) A party shall send copies of all documents filed by first class mail, postage prepaid, to all other parties, or shall deliver such documents in hand to all other parties; and
(b) A party shall certify compliance with Ph 204.08 (a) by submitting a certificate of service with the documents filed.

Source.  #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED:
1-19-96;

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8315-A, eff 3-26-05

Ph 204.10  Stipulations.  The parties to an adjudicative proceeding may by written stipulation agree upon facts or issues of proof relating to the subject matter of the proceeding. The stipulation shall be filed with the board and approved by the presiding officer in order to be considered in rendering a decision.

Source.  #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED:
1-19-96;

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8315-A, eff 3-26-05

Ph 204.11  Evidence.

(a) Proceedings shall not be conducted under the rules of evidence, but the evidentiary privileges recognized by the law of New Hampshire shall apply to proceedings under this chapter.

(b) Pursuant to RSA 541-A:33, II, the board shall receive all material and relevant evidence bearing upon the subject matter of the proceeding.

(c) The presiding officer shall determine the admissibility of evidence and shall exclude irrelevant, immaterial or unduly repetitious evidence.

(d) All witnesses appearing before the board shall testify under oath or affirmation and subject to the penalties specified in RSA 641:1 and RSA 641:2.

(e) Oaths or affirmations shall be administered by the presiding officer.

Source.  #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED:
1-19-96;

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8315-A, eff 3-26-05

Ph 204.12  Withdrawal of Presiding Officer.
(a) Upon his or her own initiative or upon the motion of any party or intervenor, the presiding officer shall withdraw from any adjudicative proceeding for good cause.

(b) Good cause shall exist if the presiding officer:

(1) Has a direct interest in the outcome of the matter, including but not limited to, a financial or family relationship with any party or intervenor;

(2) Has made statements or engaged in behavior which objectively demonstrates that he or she had prejudged the facts of the case; or

(3) Personally believes that he or she cannot fairly judge the facts of the case.

(c) Mere knowledge of the issues or acquaintance with any party, intervenor or witness shall not constitute good cause for withdrawal.

Source.  #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96; New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04 New.  #8315-A, eff 3-26-05

Ph 204.13  Hearing Procedure.

(a) After calling the hearing to order, the presiding officer shall identify the proceeding for the record by name and docket number, shall briefly state the nature of the proceeding, and shall request those present to identify themselves for the record.

(b) The presiding officer shall afford an opportunity for opening statements or direct testimony by the board representative and the licensee or licensee's representative.

(c) After any opening statements, the board representative shall present witnesses and exhibits, followed by presentation of witnesses and exhibits by the licensee or licensee's representative.

(d) Opportunity shall be afforded to either party to cross-examine each witness of the other party at the conclusion of the witness's direct testimony.

(e) The presiding officer shall if additional information is required pose questions to any witness during or subsequent to direct testimony or cross-examination.

(f) After all testimony and evidence is presented, the presiding officer shall allow closing statements by the board representative and by the licensee or licensee's representative.

(g) After all information has been presented, the presiding officer shall declare the hearing closed.
(h) The presiding officer shall afford intervenors the same opportunities for presenting testimony, evidence, or witnesses, and for conducting cross-examinations and for making closing statements as other parties to the proceeding.

Source.  #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8315-A, eff 3-26-05

Ph 204.14  Burden of Proof.

(a) The party asserting the affirmative of a proposition shall have the burden of proving the truth of that proposition by a preponderance of the evidence.

(b) Without limiting the generality of Ph 204.12 (a), all moving parties and all petitioners shall have the burden to show that their motion or petition should be granted.

Source.  #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8315-A, eff 3-26-05

Ph 204.15  Decisions.

(a) If the board finds that the licensee has complied with the statutory requirements and the rules adopted pursuant thereto, the board shall enter a decision favorable to the licensee.

(b) If the board finds that the licensee has not complied with the statutory requirements or any rule adopted pursuant thereto, the board shall enter a decision adverse to the licensee.

(c) The board's decision shall be set forth in writing.

(d) The decision shall include findings of fact and conclusions of law, separately stated.

(e) If any party has submitted proposed findings of fact, the board's decision shall include a ruling on each proposed finding.
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(f) The board shall give written notice of decisions to parties within 7 days after the date of decision by first class mail, postage prepaid.

Source. #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96; New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8315-A, eff 3-26-05

Ph 204.16  Failure to Appear.

(a) Failure of a licensee to appear in person or by representative at the adjudicative proceeding shall constitute a default.

(b) A default for failure to appear shall constitute:

(1) A waiver of licensee's right to an adjudicative proceeding;

(2) Admission of the facts alleged; and

(3) Consent to the board's determination on the matter.

(c) The board shall strike a default for failure to appear based upon a written request and information submitted by the licensee within 7 days after the originally scheduled hearing date which sets forth good cause. Good cause shall include illness, accident, the death of family member, or other circumstances beyond the control of the licensee.

(d) The board shall give written notice to parties of a decision either to grant or deny a request to strike a default for failure to appear within 7 days of the date of decision by first class mail, postage prepaid.

(e) If a request to strike a default for failure to appear is granted, the board shall give notice of a rescheduled hearing in accordance with Ph 204.04.

Source. #8315-A, eff 3-26-05

Ph 204.17  Informal Settlement.

(a) Any informal settlement of matters by nonadjudicative processes shall be reflected in writing and made part of the record for a particular matter.

Source. #8315-A, eff 3-26-05

PART Ph 205  REHEARINGS AND APPEALS

Ph 205.01  Motion for Rehearing.

(a) A motion for rehearing shall be considered only after a decision or order has been made by the board.

(b) Any party to the proceeding may apply for a rehearing in respect to any matter determined in the action or proceeding, or covered or included in the order.
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(c) Motions for rehearing shall be filed with the board within 30 days of the date of the final decision or order.

(d) Motions for rehearing shall set forth fully every ground upon which it is claimed that the decision or order complained of is unlawful or unreasonable, or based upon a mistake of law or fact.

(e) A party may submit a memorandum of law in support of a motion for rehearing.

Source. #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8315-A, eff 3-26-05

Ph 205.02 Action on Motion for Rehearing.

(a) Pursuant to RSA 541:5, within 10 days of receiving a motion for rehearing, the board shall render a decision either to grant or deny the motion, or suspend the order or decision complained of pending further consideration.

(b) Pursuant to RSA 541:3, the board shall grant such motion if good reason for the rehearing is provided.

(c) Good reason shall include, but not be limited to, the following:

(1) New information which was not available at the time of hearing;

(2) A change in law relied upon by the board in reaching a decision on the hearing, including amendment or repeal of statutes or administrative rules, and changes in common law based upon decisions of the supreme court; or

(3) Other factors beyond the control of the moving party causing the decision to be unreasonable or unlawful, or to be based upon a mistake of law or fact.

(d) The board shall give written notice of decision on a motion for rehearing to the parties within 7 days after the date of decision by first class mail, postage prepaid.

(e) If a motion for rehearing is granted, the board shall give written notice to the parties at least 30 days prior to the scheduled rehearing date by first class mail, postage prepaid, or by personal service.

Source. #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8315-A, eff 3-26-05
Ph 205.03  **Burden of Proof.** The burden of proof shall be on the moving party to show by preponderance of the evidence that the board's decision was unlawful or unreasonable, or was based upon a mistake of law or fact.

**Source.** #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96; New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

Ph 205.04  **Decisions.**

(a) The board shall issue a written decision within 20 days of the date of the rehearing which clearly states the reasons for the decision.

(b) The decision shall include information on the rights of appeal to the supreme court pursuant to RSA 541, if the decision is adverse to the party who appeals.

(c) The board shall keep a final decision in its records for at least 5 years following their dates of issuance, unless the director of the division of records management and archives of the department of state sets a different retention period pursuant to rules adopted under RSA 5:40.

**Source.** #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96; New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8315-A, eff 3-26-05

PART Ph 206  **DECLARATORY RULINGS**

Ph 206.01  **Petitions.**

(a) A person may request a declaratory ruling from the board on matters within its jurisdiction by filing an original and 2 copies of a petition with the board.

(b) All petitions shall contain the following information:

(1) The name and address of the petitioner;

(2) The name and address of the petitioner's representative, if any;

(3) A statement of the issue or question for which the petitioner seeks a declaratory ruling;

(4) A statement of all relevant and material facts related to the petitioner's request; and

(5) The identification of any statutes, rules, orders, or other legal authority which support the petitioner's request.
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(c) A petition for a declaratory ruling may include the following:

(1) Legal memoranda, supporting affidavits, tables, exhibits, and other relevant documentation; and

(2) A statement explaining how the requested ruling would benefit the petitioner or the public at large.

Source. #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8315-A, eff 3-26-05

Ph 206.02 Action on Petition.

(a) Within 90 days of the receipt of the petition for a declaratory ruling, the board shall:

(1) Respond to the petitioner in writing, stating the board's declaratory ruling on the issues or questions raised in the petition; and

(2) File the declaratory ruling with the director of legislative services in accordance with RSA 541-A:16, II (b).

Source. #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8315-A, eff 3-26-05

PART Ph 207 RULEMAKING PETITIONS

Ph 207.01 Rulemaking Petitions.

(a) A person may request the adoption, amendment, or repeal of a board rule by filing an original and 2 copies of a rulemaking petition with the board.

(b) A rulemaking petition filed with the board shall include the following:

(1) The name and address of the petitioner;

(2) The name and address of the petitioner's representative, if any;

(3) A statement of the justification for the adoption, amendment, or repeal of a rule;

(4) Any supporting data, information, exhibits, illustrations, or other documentation;
(5) The identification of any statutes, rules, orders, or other legal authority which support the petition; and

(6) A draft of the proposed rule.

Source.  #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8315-A, eff 3-26-05

Ph 207.02 Incomplete Rulemaking Petitions.

(a) The board shall notify the petitioner of deficiencies in the petition within 15 days of the submission of a petition to adopt, amend, or repeal a rule.

(b) Any corrected petition which is filed with the board shall be deemed to be the first submission of the petition for the purposes of applicable deadlines.

Source.  #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8315-A, eff 3-26-05

Ph 207.03 Action on Rulemaking Petition.

(a) Within 30 days after the submission of a rulemaking petition, the board shall either grant or deny the petition and:

(1) Notify the petitioner in writing of a decision to deny the petition with reasons for the denial clearly stated; or

(2) Notify the petitioner in writing of a decision to grant the petition, and commence rulemaking proceedings by requesting a fiscal impact statement pursuant to RSA 541-A:5 within 120 days of receipt of the petition and continuing the proceeding in accordance with the applicable provisions of RSA 541-A:3.

(b) Any denial shall be based upon a finding by the board that:

(1) The petition for rule or amendment or repeal of an existing rule would not be consistent with established standards for the practice of pharmacy and the licensees of the board;

(2) The petition lacks rulemaking authority; or
(3) The petition is contrary to legislative intent.

Source. #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8315-A, eff 3-26-05

PART Ph 208 RULEMAKING HEARINGS

Ph 208.01 Public Notice of Rulemaking Hearing. The board shall cause to be published in the New Hampshire Rulemaking Register a notice of its intent to conduct a rulemaking hearing pursuant to RSA 541-A:6.

Source. #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8315-A, eff 3-26-05

Ph 208.02 Presiding Officer.

(a) The presiding officer shall:

(1) Maintain order during the rulemaking hearing, and order any person causing disorder or a disruption to the orderly conduct of the hearing to leave the hearing room;

(2) Recognize speakers who have placed their names on the speakers list;

(3) Receive all written comment that is submitted during the course of a hearing; and

(4) Adjourn the hearing.

Source. #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8315-A, eff 3-26-05

Ph 208.03 Order of the Rulemaking Hearing. The hearing shall proceed as follows:

(a) The presiding officer shall make opening remarks;
(b) Proponents of the adoption, amendment or repeal of the rule shall be called by the presiding officer to provide comment;

(c) Opponents of the adoption, amendment or repeal of the rule shall be called by the presiding officer to provide comment;

(d) After all persons wishing to comment have been heard, the presiding officer shall receive any written comment not previously submitted to the board; and

(e) After all written comment has been collected, the presiding officer shall make closing remarks and adjourn the hearing.

Source. #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8315-A, eff 3-26-05

Ph 208.04 Oral Comment.

(a) Any proponent of or opponent to the adoption, amendment or repeal of a rule may make oral comment relative to such rule at the rulemaking hearing.

(b) In order to be recognized at the hearing, any person wishing to comment shall sign the speakers list at the hearing and wait to be called by the presiding officer.

Source. #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96;

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8315-A, eff 3-26-05

Ph 208.05 Written Comment.

(a) Any proponent or opponent may submit written comment to the board pertaining to the adoption, amendment or repeal of a rule.

(b) All written comment relative to proposed rulemaking shall be submitted to the board in accordance with the notice of rulemaking, which shall set forth a deadline allowing a minimum of 5 days time after adjournment of the rulemaking hearing.
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(c) Written comment shall be submitted by filing an original and 2 copies with the board.

Source.  #1639, eff 11-1-80; ss by #1909, 1-7-82; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96; New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8315-A, eff 3-26-05

PART Ph 209  EXPLANATION OF ADOPTED RULES

Ph 209.01 Requests for Explanation of Adopted Rules. Any interested person may, within 30 days of the final adoption of a rule, request a written explanation of that rule by making a written request to the board including:

(a) The name and address of the individual making the request; or

(b) If the request is that of an organization or other entity, the name and address of such organization or entity and the name and address of the representative authorized by the organization or entity to make the request.

Source. #8315-B, eff 3-26-05, EXPIRED: 3-26-13

Ph 209.02 Contents of Explanation. The board shall, within 90 days of receiving a request in accordance with Ph 209.01, provide a written response which:

(a) Concisely states the meaning of the rule adopted;

(b) Concisely states the principal reasons for and against the adoption of the rule in its final form; and

(c) States, if the board did so, why the board overruled any arguments and considerations presented against the rule.

Source. #8315-B, eff 3-26-05, EXPIRED: 3-26-13
Ph 301.01 Application.

(a) Application form Ph A-1, revised September 2015, for licensure to practice the profession of pharmacy in New Hampshire may be obtained from the board or the board website accessible at www.nh.gov/pharmacy/;

(b) Applicants for licensure shall submit a completed form A-1 application for licensure and file it at the office of the board identified in Ph 103.03 along with:

(1) A copy of the candidate's birth certificate;

(2) A recent, full face photograph of the candidate;

(3) An official final transcript sent directly from the college to the board office; and

(4) The prescribed fee which shall be $265.

(c) An official final transcript shall be mailed directly from the college to the board before either NAPLEX scores or New Hampshire licensure status is released, or, if a foreign graduate, the foreign graduate shall have completed a transcript verification program as provided by the Foreign Pharmacy Graduate Examination Committee (FPGEC) certification.

(d) The photograph required by Ph 301.01 (b)(2) shall be attached to the application form in the presence of a notary public or justice of the peace.

Ph 301.02 Additional Requirements. In addition to any requirements imposed by statute, all candidates for a license to practice pharmacy in New Hampshire shall demonstrate that they possess the following qualifications:

(a) The candidate shall be not less than 18 years of age;

(b) The candidate shall be of good professional character, and not have been convicted of any felony, or of a misdemeanor resulting from a violation of any drug and/or pharmacy-related law or rule;

(c) The candidate shall have graduated with a doctor of pharmacy degree (PharmD) granted by a school of pharmacy, or a college of pharmacy, or a department of a pharmacy of a university;
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(d) To meet the requirements of (c) above, the school, college or department of pharmacy, shall be accredited by the Accreditation Council for Pharmacy Education (ACPE) or the Canadian Council for Accreditation of Pharmacy Programs (CCAPP).

(e) If a foreign graduate, in lieu of (c) and (d) above, the candidate shall have graduated from a foreign college of pharmacy other than Canada and have obtained full certification from the FPGEC including:

1. Passing the FPGEE with a score of at least 75; and
2. Demonstrating proficiency in english by passing the Test Of English as a Foreign Language Internet Based Test (TOEFL iBT).

(f) Prior to the examination date, the candidate shall:

1. Have completed an internship in pharmacy which consists of:
   a. At least 1500 hours, starting no earlier than 4 months prior to the third year of study in a college of pharmacy; and
   b. Work predominantly related to the practice of pharmacy including, but not limited to:
      1. The selling of drugs and medical supplies;
      2. Interpreting, compounding, preparing and dispensing prescription orders;
      3. Preparing pharmaceutical products; and
      4. Keeping records and preparing reports required by federal and state statutes.

2. Have completed the internship record form Ph A-3 revised September 2015 and submitted it to the board.

(g) The candidate shall complete and pass the examinations described in Ph 301.03.

Source. #6181-B, eff 2-5-96; amd by #6933, eff 2-1-99; paragraphs (a)-(d) EXPIRED: 2-5-04; amd by #8316, eff 3-26-05; paragraphs (e)-(g) EXPIRED: 2-1-07; paragraphs (a)-(d) EXPIRED: 3-26-13

New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15

New. #11031, eff 1-29-16

Ph 301.03 Required Examinations. The examinations required for pharmacist licensure in New Hampshire shall be the National Association of Boards of Pharmacy Licensure Examination (NAPLEX) and the New Hampshire Multistate Pharmacy Jurisprudence Examination (NH MPJE) administered the National Association of Boards of Pharmacy (NABP).

Source. #6181-B, eff 2-5-96; ss by #6933, eff 2-1-99, EXPIRED: 2-1-07
Ph 301.04  **Required Examination Score.** To successfully complete the NAPLEX and NH MPJE examinations required by Ph 301.03, the candidate shall, on the initial examination or any subsequent re-examination permitted by Ph 301.05, obtain a score of not less than 75 on each examination.

**Source.** #6181-B, eff 2-5-96; amd by #6933, eff 2-1-99; paragraph (a) and subparagraphs (b)(1) and (b)(3) EXPIRED: 2-5-04; amd by #8316, eff 3-26-05; paragraph (b) and subparagraphs (b)(2) and (b)(4) EXPIRED: 2-1-07; paragraph (a) and subparagraphs (b)(1) and (b)(3) EXPIRED: 3-26-13

New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15

New. #11031, eff 1-29-16

**Ph 301.05**  **Notice and Election of Re-examination.**

(a) Any candidate who fails to obtain the minimum required score on either of the 2 examinations required in Ph 301.03 may elect to retake the examination.

(b) All candidates shall notify the board in writing whether he/she elects to be re-examined. The candidate for re-examination shall register and pay for the re-take examination through the National Association of Boards of Pharmacy online registration website accessible at www.nabp.net.

**Source.** #6181-B, eff 2-5-96; ss by #6933, eff 2-1-99, EXPIRED: 2-1-07

New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15

New. #11031, eff 1-29-16 (from Ph 301.05)

**Ph 301.06**  **Issuance or Denial of Original License.**

(a) If candidate timely files an application, complete in all respects, successfully completes all examinations required by Ph 301 and demonstrates the complete fulfillment of the requirements of these rules, RSA 318, and RSA 318-B, the board shall issue a license to practice pharmacy.

(b) In the event a candidate for an original license to practice pharmacy in New Hampshire fails to meet the requirements of these rules, or RSA 318, or both, the board shall deliver to the applicant a written denial of the application, specifying in detail the requirement which the candidate failed to meet, and how the candidate is deficient.

**Source.** #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

Ph 302.01 Reciprocity.

(a) Instead of retaking the NAPLEX examination required by Ph 301.03, a candidate may transfer the actual score he or she attained on the NAPLEX administered by a state other than New Hampshire, provided that:

(1) The candidate is still duly licensed and is in good standing in that state; and

(2) All other New Hampshire pharmacist licensing requirements have been met.

Source. #6181-B, eff 2-5-96; amd by #6933, eff 2-1-99; subparagraphs (a)(1)-(a)(3) EXPIRED: 2-5-04; amd by #8316, eff 3-26-05; paragraph (a) intro. EXPIRED; 2-1-07; subparagraphs (a)(1)-(a)(3) EXPIRED: 3-26-13

New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15

New. #11031, eff 1-29-16

Ph 302.02 Application.

(a) The preliminary application for reciprocal licensure may be obtained from a link provided on the NH board of pharmacy website or from the National Association of Boards of Pharmacy, 1600 Feehanville Drive, Mount Prospect, Illinois, 60056, telephone number (847) 391-4406, website www.nabp.net. This application shall be filed with the National Association of Boards of Pharmacy.

(b) Following verification of the applicant’s credentials by NABP the applicant shall receive an official NABP license transfer application in the mail.

(c) The candidate shall file a completed NABP license transfer application provided by the National Association of Boards of Pharmacy along with NH form Ph A-1, revised September 2015, application for initial licensure as a pharmacist in NH, and attach the following:

(1) A copy of the candidate's birth certificate, or if born outside of the United States, a copy of the certificate of naturalization or passport showing date of birth;

(2) A recent, full-face photograph of the candidate attached to the application;

(3) An official copy of the candidate's pharmacy college transcript mailed directly from the college to the board, or if a foreign graduate, certification from the FPGEC; and

(4) The application fee of $265.
Ph 302.03 **Requirements.** In addition to any requirements imposed by statute, all candidates for licensure by reciprocity to practice pharmacy in New Hampshire shall demonstrate that they possess the following qualifications:

(a) The candidate shall be not less than 18 years of age;

(b) The candidate shall be of good professional character as evidenced by the absence of conviction of any felony or of a misdemeanor resulting from a violation of any drug and/or pharmacy related law or rule;

(c) The candidate shall possess a professional pharmacy baccalaureate degree or a doctor of pharmacy degree (PharmD) granted by a school of pharmacy, or a college of pharmacy, or a department of pharmacy of a university accredited by the Accreditation Council for Pharmacy Education (ACPE) or the Canadian Council for Accreditation of Pharmacy Programs (CCAPP);

(d) A candidate who is a foreign pharmacy graduate, other than Canadian, in lieu of (c) above, shall provide written documentation that such candidate has:

(1) Obtained full certification from the FPGEC; and

(2) Passed NAPLEX;

(e) The candidate shall be licensed and in good standing in the state from which he or she is seeking licensure transfer; and

(f) The candidate for a reciprocal license shall complete and pass the NH MPJE examination on the current federal and state laws and rules governing the practice of pharmacy in the state of New Hampshire.

Ph 302.04 **Reciprocity Application Time Limitation.** Candidates who fail to complete the MPJE examination, as required by Ph 302.03(f), within one year after the candidate's application is received at the board office shall have their application denied, but fees shall be retained by the board. If a candidate wishes to re-apply for New Hampshire licensure, a new application containing updated information shall be filed with the board.
Ph 302.05  NH MPJE Examination Required Scores and Fees.

(a) To successfully complete the examination required by Ph 302.03(f), the candidate shall, in the initial examination or any subsequent re-examination, obtain a score of not less than 75.

(b) The candidate shall pay the current examination fee to, and as assessed by, NABP.

Ph 302.06  NH MPJE Re-Examination Notice and Election.

(a) Any candidate who has failed to attain the minimum score on the NH MPJE examination as required by Ph 302.05, shall notify the board in writing whether he or she elects to be re-examined.

(b) Any candidate for re-examination of the NH MPJE examination shall register and pay for the re-take examination through the National Association of Boards of Pharmacy online registration website accessible at www.nabp.net.

Ph 302.07  Reciprocity License Issuance or Denial.

(a) If a candidate timely files an application, complete in all respects and meeting the requirements of Ph 302, and demonstrates the fulfillment of the requirements of these rules and RSA 318 and RSA 318-B, the board shall issue a license to practice pharmacy.

(b) In the event a candidate for a reciprocity license to practice pharmacy in New Hampshire fails to meet the requirements of these rules or RSA 318 and RSA 318-B, or both, the board shall deliver to the candidate a written denial of the application, specifying in detail each requirement which the candidate failed to meet, and how the candidate is deficient.
PART Ph 303  PHARMACY PERMIT OPTION

Ph 303.01  Licensing the Entire Store Area.

(a) The pharmacy shall include the prescription department and all other retail sections of the store.

(b) The entire pharmacy shall be equipped with a functional alarm system to prevent entry when the pharmacy is not open to the public, according to Ph 702.04.

(c) The prescription department shall not be closed while the balance of the establishment remains open.

(d) A licensed pharmacist shall be on duty at all times when the pharmacy is open to the public.

Source.  #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8316, eff 3-26-05, EXPIRED: 3-26-13

New.  #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15

New.  #11031, eff 1-29-16

Ph 303.02  Licensing Only the Prescription Department.

(a) The pharmacy shall include only the prescription department where drugs, chemicals, medicines, prescriptions are stored, compounded and dispensed. This area shall not include the other retail sections of the store the principle business of which is not the practice of pharmacy.

(b) The prescription department described in (a), above, shall be equipped with a functional alarm system to prevent entry when the pharmacy is not open to the public according to Ph 702.04.

(c) The prescription department may be closed while the remainder of the business establishment remains open to the public. During such periods, the pharmacy shall comply with Ph 702.04.

(d) A licensed pharmacist shall be on duty at all times when the prescription department is open to the public and during any absences by the pharmacist, the prescription department shall be secured except as is provided in Ph 704.01(b).

(e) Whenever the prescription department is closed, a sign indicating that there is no pharmacist on duty shall be conspicuously displayed in the pharmacy area. Such sign shall be composed of 3" lettering.
(f) Whenever the prescription department is closed, prescriptions may be left via a mail slot which falls directly into the pharmacy area.

(g) The prescription mail slot:

(1) Shall be constructed so as to accept only a written or typed prescription or a notation of the prescription number for refills;

(2) Shall be no larger than 8" X 1" and designed so that prescriptions or notations, once deposited, cannot be retrieved by hand or by mechanical means; and

(3) Shall be constructed so as to deliver these prescriptions or notations directly into the prescription area for access by the pharmacist only so that they are not visible to the general public.

(h) No prescription, new or refill, shall be left with or accepted by pharmacy technicians as defined in RSA 318:1, XI-b or pharmacy interns as provided in RSA 318:42, IX when the prescription department is closed except as is provided in Ph 704.01(c).

(i) No finished prescriptions shall be left outside of the pharmacy area prescription department for pick-up when the prescription department is closed.

(j) No telephone prescriptions, new or refill shall be accepted by pharmacy technicians or pharmacy interns when the prescription department is closed except as is provided in Ph 704.01(c).

(k) All drug order deliveries containing prescription drugs shall be delivered only when the prescription department is open and/or a licensed pharmacist is on the premises in order to secure such drug orders.

(l) A barrier preventing access to the prescription department by the public, shall be erected pursuant to the security requirements of Ph 702.04(c).

(m) The pharmacist-in-charge may designate personnel, in compliance with the provisions of Ph 702.05(b), to have keys, and a list of these individuals shall be communicated to the board of pharmacy in writing whenever changes occur.

(n) All prescription departments licensed under this section shall be so equipped with a physical barrier from floor to ceiling capable of being locked and alarmed, separate from the rest of the store, to be utilized when the prescription department is not opened to the public.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05; amd by #8572, eff 2-23-06; paragraphs (a)-(c), (e)-(g), (i), and (k)-(n) EXPIRED: 3-26-13; paragraphs (d), (h), and (j) EXPIRED: 2-23-14

New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15

New. #11031, eff 1-29-16
PART Ph 304  PHARMACY PERMIT APPLICATION

Ph 304.01 Obtaining and Filing a Permit Application.

(a) Application Ph B-1 revised September 2015 for a permit to operate a pharmacy in New Hampshire may be obtained from the board or board website, and shall be filed at the board office, identified in Ph 103.03;

(b) Form Ph B-1 shall be used for:

(1) Applying for a permit to operate a new pharmacy within the State of New Hampshire;

(2) Changing the location of a currently licensed New Hampshire pharmacy;

(3) Changing the ownership of a currently licensed New Hampshire pharmacy; and


Source.  #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8316, eff 3-26-05, EXPIRED: 3-26-13

New.  #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15

New.  #11031, eff 1-29-16

Ph 304.02 Application Contents.

(a) The applicant for a permit to operate a pharmacy in New Hampshire, shall complete form Ph B-1 revised September 2015.

(b) The applicant shall also submit scale drawings of the pharmacy, detailing usage of all space.

(c) The applicant shall supplement the application with any certificates, affidavits, plans, documents, or other information sufficient to show full compliance with all of the requirements of Ph 304.

(d) The applicant shall submit a certificate from the secretary of state attesting to the documents creating the corporate person and any amendment(s) thereof to the certificate of incorporation, or authorizing it to do business in the state of New Hampshire under the corporate name.

(e) The application shall be filed with the prescribed fee of $250.

Source.  #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New.  #6181-B, eff 2-5-96;amd by #6933, eff 2-1-99; paragraphs (a)-(d) EXPIRED: 2-5-04; amd by #8316, eff 3-26-05; paragraph (e) EXPIRED: 2-1-07; paragraphs (a)-(d) EXPIRED: 3-26-13
PART Ph 305  PHARMACY PERMIT PROCEDURE

Ph 305.01 Pharmacy Permit Conference.

(a) In addition to all requirements set forth in the statutes and elsewhere in this chapter, each applicant applying for a permit to operate a pharmacy in New Hampshire shall appear before the board for an informal conference to review the responsibilities of the pharmacist-in-charge and permit holder.

(b) If the owner is not the pharmacist-in-charge, then the owner or an officer of the corporation, or the district manager, as well as the anticipated pharmacist-in-charge shall appear before the board.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15
New. #11031, eff 1-29-16

Ph 305.02 Site Inspection for Pharmacy Permit.

(a) Following the applicant's conference, the proposed site shall be inspected by one or more board members or compliance inspectors to determine if the premises are secure and suitable, as set forth in the NH pharmacy application information according to the provisions of Ph 702, for the operation of a pharmacy and that the required professional library material, according to Ph 702.07 (c) & (d), is available.

(b) Within the 60 day period after the issuance of the temporary permit as required by Ph 305.03, an inspector or a board member or both shall inspect the pharmacy. The full operation of the pharmacy shall be examined for compliance with federal and state statutes and rules governing the practice of pharmacy to ensure public protection.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15
New. #11031, eff 1-29-16

Ph 305.03 Issuance and Denial of Pharmacy Permit.

(a) Applicants shall file a completed application at least 30 days before consideration will be given for a temporary permit.

(b) Providing that, the premises are suitable, according to Ph 305.02 (a), for the operation of a pharmacy and the applicant has met all other requirements of these rules and RSA 318, the applicant shall be granted a temporary permit which shall expire in 60 days. The temporary permit shall authorize the operation of a pharmacy only in the location and only under the name specified in the permit and shall
authorize the pharmacist-in-charge to buy, possess and dispense prescription drugs, chemicals and pharmaceuticals.

(c) After consideration of the application and the report of the primary site inspection, the board shall notify the applicant in writing of all deficiencies in the application which, in the absence of correction, shall result in the denial of the application. The applicant shall, within 20 days of the date of the notice of deficiency, deliver to the board documents evidencing the correction of those deficiencies. In the absence of
a timely filing of documentation, the application shall, without further action or notice by the board, be
denied effective as of the expiration of 20 days after the date of the notification of deficiency.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15
New. #11031, eff 1-29-16

PART Ph 306 PHARMACY PERMITS - CHANGES IN SUPPORTING DATA

Ph 306.01 Pharmacy Ownership Transfer. A transfer of ownership shall include any of the
following:

(a) The sale of the pharmacy;
(b) The addition or deletion of one or more partners in a partnership;
(c) The death of a singular owner; or
(d) In a publicly traded, multi-tiered corporation, a change in the corporate ownership of the
majority or controlling interest of the lowest tier of the corporate structure doing business as a pharmacy in
the State of New Hampshire.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05; amd by #8572, eff 2-23-06;
itro. paragraph and paragraphs (a)-(c) EXPIRED: 3-26-
13; paragraph (d) EXPIRED: 2-23-14
New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-
15
New. #11031, eff 1-29-16

Ph 306.02 Reporting Changes. The person to whom a permit to operate a pharmacy in New
Hampshire has been issued shall, within 15 days of that person's discovery of a change in any of the data
contained in the application for an original or renewal permit, report that change to the board in writing.
An original new permit application, form Ph B-1 revised September 2015 shall be completed and filed in
addition to the written notice when the name, location, ownership, licensed area or pharmacist in charge of
the pharmacy are changed.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-
15
New. #11031, eff 1-29-16
Ph 306.03  **Change in Pharmacy Name or Location - Prohibited.** No person shall operate a pharmacy under a name, or at a location, different from the name and location contained in the permit issued pursuant to Ph 304.

*Source.* #6181-B, eff 2-5-96, EXPIRED: 2-5-04

*New.* #8316, eff 3-26-05, EXPIRED: 3-26-13

*New.* #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15

*New.* #11031, eff 1-29-16

Ph 306.04  **Renovations.** Plans for any renovation at any time after an original permit is issued shall be filed with the board for review and approval before proceeding with such changes.

*Source.* #6181-B, eff 2-5-96, EXPIRED: 2-5-04

*New.* #8316, eff 3-26-05, EXPIRED: 3-26-13

*New.* #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15

*New.* #11031, eff 1-29-16

Ph 306.05  **Special Permit Provisions for Sudden Termination of Pharmacist-In-Charge (PIC).** Existing pharmacy permit holders who have a sudden loss of the pharmacist-in-charge (PIC), shall be issued a special pharmacy permit valid for 60 days while a new PIC is identified and appears before the board according to Ph 305.01.

*Source.* #6181-B, eff 2-5-96, EXPIRED: 2-5-04

*New.* #8316, eff 3-26-05, EXPIRED: 3-26-13

*New.* #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15

*New.* #11031, eff 1-29-16

**PART Ph 307  RENEWAL AND REPLACEMENT PHARMACY PERMITS**

Ph 307.01  **Renewal Permits Required.** The person to whom a permit to operate a pharmacy in New Hampshire has been issued shall renew that permit by December 31st of each year.

*Source.* #6181-B, eff 2-5-96, EXPIRED: 2-5-04

*New.* #8316, eff 3-26-05, EXPIRED: 3-26-13

*New.* #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15

*New.* #11031, eff 1-29-16
Ph 307.02 Renewal Application Where Obtained and Filed. Applications for the renewal of a permit to operate a pharmacy in New Hampshire may be obtained from, and shall be filed at the board office.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15
New. #11031, eff 1-29-16

Ph 307.03 Renewal Application Contents and When Filed.

(a) Applications for renewal of a permit to operate a pharmacy in New Hampshire shall consist of the prescribed form Ph B-2 revised September 2015 and the prescribed fee of $250.

(b) Renewal applications as required pursuant to Ph 307.01 shall be submitted to the board office identified in Ph 103.03 no later than the 15th day of December of each year.

Source. #6181-B, eff 2-5-96; amd by #6933, eff 2-1-99; paragraph (b) EXPIRED: 2-5-04; amd by #8316, eff 3-26-05; paragraph (a) EXPIRED: 2-1-07; paragraph (b) EXPIRED: 3-26-13
New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15
New. #11031, eff 1-29-16

Ph 307.04 Renewal Application Deficiencies. The board shall notify the applicant in writing as to how the application for renewal is deficient. The applicant may, within 10 days after the date of the notice of deficiency, correct the deficiency or the renewal shall be denied.

Source. #6181-B, eff 2-5-96; amd by #6933, eff 2-1-99; paragraph (b) EXPIRED: 2-5-04; amd by #8316, eff 3-26-05; paragraph (a) EXPIRED: 2-1-07; paragraph (b) EXPIRED: 3-26-13
New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15
New. #11031, eff 1-29-16

Ph 307.05 Issuance or Denial of Renewal Permit.

(a) If an applicant shall timely file an application, complete in all respects, and shall demonstrate the fulfillment of all the requirements of these rules and RSA 318, the board shall issue a renewal permit.

(b) An application which continues to fail to meet the requirements of these rules and RSA 318 shall be denied.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
Ph 307.06 Replacement Permit Application and Contents.

(a) The holder of a current permit to operate a pharmacy in New Hampshire, whose permit has been lost or destroyed shall apply for a replacement permit within 15 days after the date the licensee discovers, or with reasonable diligence, should have discovered, the loss or destruction of the permit. There shall be no form prescribed for an application for a replacement permit.

(b) The request for a replacement permit shall:

1. Be in writing;
2. Contain the number of the current permit held by the applicant, if known;
3. Be accompanied by the remains, if any, of the permit for which a replacement is sought;
4. Be accompanied by the prescribed fee of $25; and
5. Be filed at the board office.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15
New. #11031, eff 1-29-16

PART Ph 308 REVOCATION AND SUSPENSION OF A PHARMACY PERMIT

Ph 308.01 Grounds for Revocation or Suspension. The board may revoke or suspend a permit to operate a pharmacy for grounds which include but are not limited to:

(a) Misconduct as described in RSA 318:29, II; and

(b) Violations of the provisions of RSA 318:29, V.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15
New. #11031, eff 1-29-16

Ph 308.02 Effect of Revocation.

(a) The revocation of a pharmacy permit shall permanently withdraw the authority to operate a pharmacy in New Hampshire.
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(b) A subsequent permit may be obtained only by:

(1) Complying with all of the requirements of RSA 318 and these rules regarding the original licensing of pharmacies;

(2) Paying all penalties assessed in connection with the cause for revocation; and

(3) By demonstrating that the cause for revocation does not exist at the time of the subsequent application.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15
New. #11031, eff 1-29-16 (from Ph 308.01)

Ph 308.03 Effect of Suspension.

(a) The suspension of a pharmacy permit shall temporarily withdraw the authority to operate a pharmacy in New Hampshire until the time specified in the order of suspension.

(b) The authority to operate a pharmacy in New Hampshire shall be recovered only by;

(1) Complying with all of the requirements specified in the order of suspension;

(2) Complying with all of the requirements of RSA 318 and these rules regarding the renewal of a pharmacy permit; and

(3) Paying all penalties assessed in connection with the cause for suspension.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15
New. #11031, eff 1-29-16 (from Ph 308.01)

Ph 308.04 Voluntary Surrender When Permitted.

(a) Any person holding a pharmacy permit may voluntarily return that permit to the board.

(b) The return of such permit shall be accompanied by the licensee's signed, written statement as to why the permit is being voluntarily returned to the board.

(c) The voluntary surrender of a permit to operate a pharmacy in New Hampshire shall serve to withdraw the authority for the licensee to operate that pharmacy in New Hampshire.

(d) Voluntary surrender of a permit to operate a pharmacy in New Hampshire shall not be permitted if there exists, at the time the permit is presented to the board, any cause for involuntary revocation or suspension of the licensee's permit to operate a pharmacy, unless the licensee presenting the
permit shall state in writing that the voluntarily surrendered permit is in lieu of proceedings for the involuntary revocation or suspension of the permit to operate a pharmacy in New Hampshire.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15
New. #11031, eff 1-29-16 (from Ph 308.03)

Ph 308.05 Hearing. Except as authorized by statute or these rules, a permittee to operate a pharmacy in New Hampshire shall not be disciplined except after notice and opportunity for hearing provided by Ph 200.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05; ss by #8572, eff 2-23-06, EXPIRED: 2-23-14
New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15
New. #11031, eff 1-29-16 (from Ph 308.04)

PART Ph 309 STANDARDS OF PRACTICE FOR MANUFACTURERS, WHOLESALERS AND DISTRIBUTORS

Ph 309.01 License Required.

(a) No person shall manufacture or act as a wholesale distributor of prescription drugs or prescription devices without first obtaining a license to do so from the board according to RSA 318:51-a. No license shall be issued or renewed for a manufacturer or wholesale drug distributor unless the same shall be operated in a manner prescribed by law and according to the rules adopted by the board of pharmacy with respect thereto.

(b) Separate licenses shall be required for each manufacturing and distribution site owned or operated by a manufacturer or wholesale distributor. Provided however, that an agent or employee of any licensed manufacturer or wholesale distributor shall not be required to be licensed under this section and may lawfully possess prescription drugs and devices if he is acting in the usual course of his business or employment.

(c) The board shall provide, on an annual basis, a license renewal form to all licensed manufacturers and wholesale distributors of prescription drugs and devices.
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(d) The prescribed fee for original and annual renewal licenses for manufacturers and wholesale distributors of prescription drugs and devices shall be $250.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15
New. #11031, eff 1-29-16

Ph 309.02 Obtaining and Filing a License Application. Applications for licensure of manufacturers, wholesalers and distributors may be obtained from, and shall be filed at, the board office, identified in Ph 103.03.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15
New. #11031, eff 1-29-16

Ph 309.03 Application Contents. The applicant for licensure shall supply, on form Ph A-5, at least the following information:

(a) Name of the company;

(b) The address of the actual location where manufacturing, wholesaling and distribution occurs;

(c) Identification of ownership; and

(d) Name and address of the person responsible for licensing.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15
New. #11031, eff 1-29-16

Ph 309.04 Storage Conditions. All facilities at which prescription drugs are repackaged, wholesaled, stored, held, sold, offered for sale, exposed for sale, or kept for sale shall provide storage areas that ensure proper lighting, ventilation, temperature, sanitation, humidity, equipment, and security conditions. All prescription drugs or chemicals shall be stored at appropriate temperatures per label requirements or in compliance with the latest edition of the official United States Pharmacopeia (USP) compendium requirements to help ensure that the identity, strength, quality, and purity of the products are not affected. If no temperature requirements are listed, prescription drugs may be stored at room temperature in compliance with U.S.P. definition for room temperature. A separate storage section shall be provided for prescription drugs that are deteriorated, outdated, misbranded, or otherwise adulterated.
Ph 309.05 Facilities.

(a) All buildings in which prescription drugs are wholesaled, repackaged, stored, held, sold, offered for sale, exposed for sale, or kept for sale shall be of suitable size, construction, and location to facilitate cleaning and maintenance.

(b) Buildings shall meet all applicable federal, state, and local standards. A facility shall not be located in a residence. All facilities shall be located in an area that is commercially zoned.

(c) A wholesale drug distribution facility shall notify the local police department or other appropriate law enforcement agency that it is a distributor of prescription drug products and controlled substances.

Ph 309.06 Security.

(a) Each wholesale drug distribution center shall be equipped with an internal alarm system to detect entry after hours. The alarm system shall be of the type that transmits a signal directly to a central station protection company, to a local or state police agency that has a legal duty to respond, a 24 hour control station operated by the wholesale drug distributor.

(b) Manufacturers and wholesale drug distributors shall ensure that all access from outside their premises is secure. This shall include, but not be limited to, the installation of adequate lighting at the outside perimeter of the premises.

(c) Internal security policies shall be developed to provide protection against theft by personnel.
Ph 309.07 Recordkeeping.

(a) Inventories and other records of transactions regarding the receipt and disposition of prescription drugs shall be maintained and made available for inspection by the board's inspectors for a period of 2 years.

(b) Records may be kept at a central location rather than at each distribution center, but records shall be made available for inspection within 72 hours of request by the board's inspectors.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15
New. #11031, eff 1-29-16

Ph 309.08 Inspections.

(a) Inspections shall be performed by the board's inspectors and be conducted at the request of the board.

(b) Inspections shall be conducted during normal business hours, and notification of inspections shall be given no less than 48 hours in advance.

(c) Information that is considered to contain trade secrets or which might be proprietary in nature shall be protected from public disclosure.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15
New. #11031, eff 1-29-16

Ph 309.09 Written Policies and Procedures.

(a) Written policies and procedures shall be developed by management personnel to assure that the manufacturer and wholesale drug distributor prepares for, protects against, and handles crisis situations that affect the security or operation of the facility. Such crises may include fires, floods, or other natural disasters, and situations of local, state or national emergency.

(b) Written policies and procedures described in (a) above shall also provide for:

1. The management and correction of all errors or inaccuracies in inventories;

2. The assurance that any outdated stock, or any stock with an expiration date that, in the wholesale drug distributor's view, does not allow sufficient time for repacking or resale, shall be prepared for return to the manufacturer or otherwise destroyed; and

3. The control over the shipping and receiving of all stock within the operation.
(c) A copy of the policies and procedures, or sections thereof, shall be made available to the board upon request.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15
New. #11031, eff 1-29-16

Ph 309.10 Returned Goods. A wholesale operation shall maintain a procedure for the proper handling and disposal of returned goods.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15
New. #11031, eff 1-29-16

Ph 309.11 Handling Recalls.

(a) A wholesale operation shall maintain a written policy for handling recalls and withdrawals for products.

(b) Policies required by (a) above shall cover all recalls and withdrawals of prescription drug products due to:

1. Any voluntary action on the part of the manufacturer;
2. The direction of the Food and Drug Administration, or any other federal, state or local governmental agency; and
3. Replacement of existing merchandise with an improved product or new package design.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15
New. #11031, eff 1-29-16

Ph 309.12 Responsibility for Operation. A wholesale drug distribution operation shall maintain a list of principals and persons in charge including officers, directors, or primary stockholders and their qualifications.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
Ph 309.13 Compliance with State and Federal Law.

(a) All manufacturers, wholesalers and distributors shall comply with all applicable state and federal laws and regulations.

(b) All manufacturers, wholesalers and distributors, doing business in New Hampshire, shall, before shipping or distributing any prescription drug, verify that the recipient is properly licensed to receive and possess such drugs.

(c) All manufacturers, wholesalers and distributors, licensed and doing business in the state of New Hampshire, shall not provide unsolicited controlled drug samples to licensed practitioners.

(d) A manufacturer’s license shall allow for the direct wholesaling or distribution of such drugs to other licensed or authorized recipients.

(e) A duly authorized agent of a manufacturer, wholesaler or distributor licensed in this state, may possess and distribute potent or prescription drugs to individuals who may lawfully possess such drugs as may be necessary to further the licensed activity of the manufacturer, wholesaler or distributor.

(f) Indirect sale or distribution shall include, but not be limited to:

(1) Solicitation, in this state, by manufacturers, wholesalers or distributors sales representatives;

(2) Telephone solicitations to customers located in this state by manufacturers, wholesalers or distributors sales representatives;

(3) Solicitation of customers located in this state by mail or by the use of media advertising which has a significant circulation in the state of New Hampshire.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15
New. #11031, eff 1-29-16

Ph 309.14 Violations.

(a) No manufacturer or wholesaler shall distribute prescription drugs directly to a consumer or a patient, or operate in such a manner as to endanger the public health.

(b) Any person who manufacturers, wholesales, or otherwise distributes prescription drugs, according to RSA 318:51-a and the provisions of Ph 309, shall be subject to disciplinary action as provided in RSA 318:29.
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10702, INTERIM, eff 10-23-14, EXPIRED: 4-21-15

New. #11031, eff 1-29-16
CHAPTER Ph 400  CONTINUED STATUS

PART Ph 401  RENEWAL AND REPLACEMENT LICENSES

Ph 401.01  Obtaining and Filing Renewal Applications.  Application form Ph A-2 for the renewal of a license to practice pharmacy in New Hampshire may be obtained from, and shall be filed at, the board office.

Source.  #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8316, eff 3-26-05, EXPIRED: 3-26-13

New.  #10812, eff 4-18-15

Ph 401.02  Renewal Application Contents and Filing Deadline.

(a) Applications for renewal of a license to practice pharmacy in New Hampshire under RSA 318 shall be completed and filed on a Pharmacist Licensure Renewal Form Ph A-2 (February 2015).

(b) With the exception of authorized immunizing pharmacists per the provisions of Ph 1300, which shall have the combined renewal fee as noted below in (d), the application and the prescribed fee of $125 shall be filed with the board no later than the 15th day of December each year. Each licensee shall obtain and file his or her application for license renewal prior to this date.

(c) The renewal fee for pharmacists who are authorized immunizing pharmacists shall be $135, which includes a fee for the immunization endorsement on their pharmacist license.

(d) Per the provisions of RSA 318:29-a, VI(b), $15 of each pharmacist renewal fee noted in sections (b) and (c) above, shall be used to fund the impaired pharmacist program.

Source.  #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New.  #6181-B, eff 2-5-96; amd by #6933, eff 2-1-99; paragraphs (a) and (b) EXPIRED: 2-5-04; amd by #8316, eff 3-26-05; amd by #9139-B, eff 4-25-08; paragraphs (a) and (b) EXPIRED: 3-26-13; ss by #10842, eff 6-3-15
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

Ph 401.03 Renewal Application Deficiencies. Within 5 days of receipt at the board office, the board shall notify the applicant in writing if the renewal application is deficient. The applicant may then correct the deficiency or file with the board a written request for a hearing before the board.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10812, eff 4-18-15

Ph 401.04 Renewal License Issuance and Denial.

(a) If an applicant timely files an application, complete in all respects, and demonstrates the fulfillment of all the requirements of these rules and RSA 318, the board shall issue a renewal license to practice pharmacy.

(b) Applicants shall register with the New Hampshire Prescription Drug Monitoring Program pursuant to the requirements articulated in RSA 318-B:33, II and Ph 1503.01 (a).

(c) An application failing to meet the requirements of these rules or RSA 318, or both, shall, after the notice and opportunity for hearing, be denied.

(d) Applicants who fail to register for the New Hampshire Prescription Drug Monitoring Program pursuant to RSA 318-B:33, II and Ph 1503.01 (a), shall, after the notice and opportunity for hearing, be denied.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10812, eff 4-18-15

Ph 401.05 Duplicate/Replacement Original Certificate of Licensure or Renewal License - Issuance.

(a) If seeking a duplicate or replacement for an original certificate of licensure the applicant shall:

(1) Submit a written request, signed by the pharmacist, to the board for replacement; and

(2) Provide payment of the prescribed fee which shall be $50.

(b) If seeking a duplicate or replacement for an annual renewal license the applicant shall:

(1) Submit a written request, signed by the pharmacist, to the board for a duplicate or replacement; and
(2) No fee shall be assessed for a duplicate or replacement renewal license.

Source.  #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8316, eff 3-26-05, EXPIRED: 3-26-13

New.  #10812, eff 4-18-15

Ph 401.06 Reinstatement. A pharmacist whose license to practice pharmacy in this state has been suspended, revoked, voluntarily surrendered or allowed to lapse shall be subject to the following requirements:

(a) File a reinstatement application with the board which shall include at least the following:

(1) Name, address and telephone number of the applicant;

(2) Date of birth; and

(3) Current employment information.

(b) Pay the reinstatement fee of $200;

(c) Submit certificates of attendance/participation in accredited/approved continuing pharmaceutical education courses/programs for a minimum of 15 hours, of which at least 5 hours shall be earned in a live setting. All such continuing education shall have been earned in the period 12 months immediately preceding the date of application for reinstatement;

(d) Successfully complete the jurisprudence MPJE examination as specified in Ph 302.07(a);

(e) If the pharmacist has not held a license to practice pharmacy in this state for a period of 2 years or more, the applicant shall provide:

(1) Notarized affidavit(s) documenting the pharmacist's pharmacy experience during the 2 years immediately preceding the date of his/her application for reinstatement; and

(2) Proof of status of licensure in all states that the pharmacist has been licensed in; and
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(f) If the pharmacist has not held a license to practice pharmacy in this state for a period of 5 years or more and has not practiced pharmacy in any other state, the board shall require the completion of a period of pharmacy practice internship prior to reinstatement.

Source.  #2442, eff 9-1-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New.  #6181-B, eff 2-5-96; amd by #6933, eff 2-1-99; intro. paragraph and paragraphs (a)-(d) and (f)-(g) EXPIRED: 2-5-04; amd by #8316, eff 3-26-05; paragraph (e) EXPIRED: 2-1-07; intro. paragraph and paragraphs (a)-(d) and (f)-(g) EXPIRED: 3-26-13

New.  #10812, eff 4-18-15

Ph 401.07  Gold Certificates.

(a) The board of pharmacy shall issue a gold certificate to any pharmacist who has been regularly licensed as a pharmacist in New Hampshire for 50 consecutive years.

(b) Gold certificates shall be distinctive in coloration and text from other pharmacist licenses issued by the board, and shall be designed to appropriately recognize each recipient pharmacist for his/her half-century of professional practice.

(c) A gold certificate shall be a one-time issuance of honorary nature and confer no right to practice pharmacy upon the recipient.

(d) The awarding of gold certificates shall be made by the board of pharmacy without charge to the recipient.

Source.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8316, eff 3-26-05, EXPIRED: 3-26-13

New.  #10812, eff 4-18-15

PART Ph 402  DISCIPLINARY MATTERS

Ph 402.01  Effect of Revocation.

(a) The revocation of a pharmacist license shall permanently withdraw the authority to practice pharmacy in New Hampshire.

(b) A subsequent license may be obtained only by:

(1) Complying with all of the requirements of RSA 318 and these rules regarding the original licensing of pharmacists;

(2) Paying all penalties assessed in connection with the cause for revocation; and
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(3) Demonstrating that the cause for revocation does not exist at the time of the subsequent application.

Source.  #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8316, eff 3-26-05, EXPIRED: 3-26-13

New.  #10812, eff 4-18-15

Ph 402.02 Effect of Suspension.

(a) The suspension of a pharmacist license shall temporarily withdraw the authority to practice pharmacy in New Hampshire until the time specified in the order of suspension.

(b) The authority to practice pharmacy in New Hampshire shall be recovered only by:

(1) Complying with all of the requirements specified in the order of suspension;

(2) Complying with all of the requirements of RSA 318 and these rules regarding the renewal of a license to practice pharmacy in New Hampshire; and

(3) Paying all penalties assessed in connection with the cause for suspension.

Source.  #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8316, eff 3-26-05, EXPIRED: 3-26-13

New.  #10812, eff 4-18-15

Ph 402.03 Voluntary Surrender of License.

(a) Any person holding a pharmacist license may voluntarily surrender that license by returning it to the board accompanied by a signed letter stating that the pharmacist intends to permanently surrender his or her license.

(b) The surrender shall be effective upon acceptance by the board and shall immediately preclude the pharmacist from practicing pharmacy in New Hampshire.

(c) A voluntary license surrender, standing alone, shall not prevent the pharmacist from subsequently reapplying for a license.

(d) The voluntary surrender of a license shall have no effect upon the board's authority to:

(1) Investigate violations of the pharmacy laws or the rules of the board by a person licensed at the time the alleged violation occurred; or

(2) Impose disciplinary sanctions based on past conduct which could affect the ability of the former licensee to reapply for a license at a later date.
(e) A voluntary license surrender during the pendency of a disciplinary proceeding shall be recorded in the board's files as "surrendered during disciplinary proceeding."

(f) Nothing in this section shall prohibit the board and a licensee from entering into a settlement agreement or a consent decree relative to any alleged violation of the pharmacy laws or the rules of the board.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10812, eff 4-18-15

Ph 402.04 Hearing. Except as authorized by statute or these rules, a licensee shall not be disciplined except after notice and opportunity for hearing.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10812, eff 4-18-15

PART Ph 403 CONTINUING EDUCATION REQUIREMENTS

Ph 403.01 Definitions.

(a) "Accredited programs/courses" means continuing education sponsored by providers which are approved by the American Council on Pharmaceutical Education (ACPE) or the Canadian Council on Continuing Education in Pharmacy (CCCEP).

(b) “AMA category I programs” means all programs accepted by the American Medical Association in category I.

(c) "Board approved programs/courses" means continuing education which has been reviewed and recommended by the continuing education advisory council and approved by the board of pharmacy or continuing education programs approved by a Canadian provincial or territorial pharmacy licensing authority.

(d) “Certificate of accredited/approved CEU's” means a document, issued to a particular pharmacist by an accredited or approved provider certifying that the pharmacist has satisfactorily completed a specified number of CEU's. Such certificates include a unique program identification number issued by the accrediting/approving provider.

(e) “Continuing education” means accredited or approved post-licensure pharmacy education designed to maintain professional competence in the practice of pharmacy, improve professional skills, and preserve pharmaceutical standards for the purpose of protecting the health and welfare of the citizens in the
Continuing education includes study in one or more of the general areas of the properties and actions of drugs and dosage forms, etiology, characteristics and therapeutics of the disease state, socio-economic and legal aspects of health care.

(f) “Continuing education advisory council (CEAC)” means a group of individuals appointed by the board of pharmacy to serve in an advisory capacity on continuing education.

(g) “Continuing education unit (CEU)” means 10 contact hours of participation in accredited or board approved continuing education courses/programs.

(h) “In-state approved provider” means an individual, institution, organization, association, corporation or agency located in the state of New Hampshire in no manner affiliated with any manufacturer or distributor of supplies or services used in the practice of pharmacy, who is approved by the board of pharmacy to provide continuing pharmacy education according to Ph 403.12.

Source. #1867, eff 11-22-81; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New. #6181-B, eff 2-5-96; amd by #6933, eff 2-1-99; paragraphs (c)-(h) EXPIRED: 2-5-04; amd by #8316, eff 3-26-05; paragraphs (a) and (b) EXPIRED: 2-1-07; paragraphs (c)-(h) EXPIRED: 3-26-13

New. #10812, eff 4-18-15

Ph 403.02 Renewal Requirements.

(a) The board of pharmacy shall not issue licensure renewals unless the pharmacist indicates on the renewal application, and under penalty of unsworn falsification, that he/she has completed the minimum required hours of accredited/approved continuing pharmaceutical education courses/programs according to Ph 403.02(d). An incomplete renewal application shall be returned to the applicant.

(b) Continuing education shall be required of all licensed, active or inactive pharmacists who apply for license renewal.

(c) Pharmacists submitting applications for the first annual licensure renewal shall be exempt from the continuing education requirements.

(d) All pharmacists licensed in New Hampshire shall acquire 1.5 CEU's during the 12 months immediately preceding the license renewal date of January 1st. At least 0.5 CEU's shall be earned in a live setting.

(e) Continuing education credits shall not be recognized for any repeat program attended or completed. Repeat programs shall be identified as any program, live or correspondence, which carries the same ACPE, CME or any board of pharmacy program identification number.

(f) The pharmacist shall retain all certificates and/or other documented evidence of participation in an approved/accredited continuing education program/course for a period of at least 3 years. Such documentation shall be made available to the board for random audit and/or verification purposes.
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(g) Not less than 10% of the registrants shall be randomly selected each year by the board for determinations of compliance with Ph 403.02.

Source. #1867, eff 11-22-81: ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New. #6181-B, eff 2-5-96; amd by #6933, eff 2-1-99; paragraphs (a)-(f) EXPIRED: 2-5-04; amd by #8316, eff 3-26-05; paragraph (g) EXPIRED: 2-1-07; paragraphs (a)-(f) EXPIRED: 3-26-13

New. #10812, eff 4-18-15

Ph 403.03 Excess CEU's. Excess CEU's earned in one licensure period shall not be carried forward into the new licensure period for the purpose of fulfilling that year's continuing education prerequisite for licensure renewal.

Source. #1867, eff 11-22-81: ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10812, eff 4-18-15

Ph 403.04 CEU's from Other States. The board of pharmacy shall accept comparable continuing education units which have been approved by other boards of pharmacy provided they meet or exceed the requirements as set forth in Ph 403.

Source. #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10812, eff 4-18-15

Ph 403.05 Credit for Instructors of Continuing Education.

(a) Any pharmacist, whose primary responsibility is not the education of health professionals, who leads, instructs or lectures to groups of nurses, physicians, pharmacists or others on pharmacy related topics in organized continuing education or in-service programs, shall be granted continuing education credit for such time expended during actual presentation.

(b) Any pharmacist whose primary responsibility is the education of health professionals shall be granted continuing education credit only for time expended in leading, instructing, or lecturing to groups of physicians, pharmacists, nurses or others on pharmacy-related topics outside his/her formal course responsibilities in a learning institution.

(c) Credit for presentation of in-service training programs or other lectures shall be granted only once for any given program or lecture.
(d) A maximum of 4 hours in this category may be applied toward fulfilling the total continuing education yearly requirements. However, these hours shall not be considered in fulfilling the live requirements as set forth in Ph 403.02(d).

Source. #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96
New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10812, eff 4-18-15

Ph 403.06 Postgraduate Pharmacy Curricula.

(a) A pharmacist who matriculates in a postgraduate pharmacy curriculum or post graduate pharmacy program shall be awarded CEU's for satisfactory completion of each course within said curriculum or program.

(b) The course work for which CEU credit is provided pursuant to (a) above, shall provide instruction in one or more of the following areas of study:

(1) Pharmacy;
(2) Pharmaceutical calculations;
(3) Pharmaceutical chemistry;
(4) Pharmacology;
(5) Therapeutics;
(6) Pharmacy management;
(7) Pharmaceutical jurisprudence; or
(8) Other course work related to the pharmaceutical sciences.

Source. #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96
New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10812, eff 4-18-15

Ph 403.07 Audio/Visual Continuing Education.

(a) Continuing education credit may be claimed for the completion of home study audio and/or video cassette tape programs/courses, provided that such programs require the completion of a written exam by the pharmacist to be scored by the provider of such programs.

(b) Audio/visual continuing education programs, including satellite transmissions, which provide for group discussion and include a facilitator shall, be allowed as live programming.
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(c) Webinars that are ACPE approved and contain an “L” in the program approval number shall be allowed as live programming.

Source.  #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96
New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New.  #8316, eff 3-26-05, EXPIRED: 3-26-13
New.  #10812, eff 4-18-15

Ph 403.08 Waiver. The board shall waive some or all of the continuing education requirements, for a period not to exceed one calendar year, for such hardships as illness or incapacity. Written request for waiver shall be submitted to the board for consideration.

Source.  #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96
New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New.  #8316, eff 3-26-05, EXPIRED: 3-26-13
New.  #10812, eff 4-18-15

Ph 403.09 Military Personnel. Military personnel or spouses shall not be exempt from the continuing education requirements, because correspondence programs/courses are available, but shall be exempt from the live requirement if assignment is in a foreign country.

Source.  #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96
New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New.  #8316, eff 3-26-05, EXPIRED: 3-26-13
New.  #10812, eff 4-18-15

Ph 403.10 Reinstatement. Any pharmacist desiring reinstatement of licensure shall show evidence of completion of at least 1.5 CEU's, according to Ph 403.02(d) and earned in the 12 months immediately preceding the date of application for reinstatement.

Source.  #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96
New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New.  #8316, eff 3-26-05, EXPIRED: 3-26-13
New.  #10812, eff 4-18-15

Ph 403.11 Penalty. Any pharmacist who alters, forges, or intentionally falsifies, or causes to be altered, forged, or falsified any information, documents, or records required to be kept or submitted by this rule shall be subject to disciplinary action under RSA 318:29, II. Falsification of records shall constitute misconduct.
Ph 403.12 In-State Approved Providers of Continuing Pharmacy Education.

(a) An individual, institution, organization, association, corporation or agency located in the state of New Hampshire desiring to be an in-state provider of continuing pharmacy education shall notify the board in writing subject to the criteria set forth in Ph 403.12 (d)(1) - (10).

(b) Approval of in-state providers shall be valid for a period of 2 years from date of approval after which time re-application shall be necessary.

(c) In-state providers who desire to become approved by the board shall provide their educational qualifications and an example of a program to the CEAC committee for review.

(d) In state providers shall comply with the following:

(1) The provider shall designate a responsible person for the administration of the continuing pharmacy education program and liaison with the CEAC and the board;

(2) Providers shall award continuing pharmacy education credit to successful participants in terms of CEU's;

(3) The provider shall maintain a list of successful participants for each program provided for a period of not less than 3 years;

(4) The list required by (3) above shall be made available to the CEAC and the board on request;

(5) The provider shall award to each successful participant a certificate containing at least the following information:
   a. The name of the provider;
   b. The completion date of the continuing education program;
   c. The name of the participant;
   d. The title of the program;
   e. The number of CEU's the program has been assigned; and
   f. The board of pharmacy program identification number.

(6) All programs shall be referenced as "live" or "correspondence" in nature;

(7) Providers shall present their participants with a statement of goals and objectives prior to each continuing pharmacy education program and involve their participants in identifying their own educational needs;
(8) Providers shall develop and employ evaluation techniques that will assess the effectiveness of the continuing pharmacy education offerings and the level of fulfillment of the stated objectives with the goal of continual improvements;

(9) Providers shall utilize an evaluation mechanism for the purpose of allowing each participant to assess his/her achievement of personal objectives; and

(10) Providers shall assign an identification number to every program presented according to the numbering system designated by the board of pharmacy.

(e) Continuing education programs presented by in-state approved providers shall not have to be submitted to the CEAC for review and approval by the board.

(f) In-state approved providers of continuing pharmacy education shall publicize programs and/or coursework by referencing endorsement by the board only as follows: "This program is approved by the New Hampshire Board of Pharmacy for _______ CEU's of continuing pharmacy education". Programs shall also be referenced as "live" or "correspondence" in nature.

(g) Board approval of in-state provider shall be revoked following notice and opportunity to be heard upon a finding that the provider has engaged in fraud or dishonesty or is no longer in compliance with one or more of the criteria of (d) above.

Source. #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10812, eff 4-18-15

Ph 403.13 Continuing Education Advisory Council Membership.

(a) The advisory council shall consist of not less than 6, nor more than 10 members, at least one of whom shall be a member of the board.

(b) The term of appointment shall be for 3 years and shall be served until the expiration date or until a successor has been named. Should a vacancy occur, a successor shall be appointed to serve the unexpired term.

(c) The advisory council shall submit all recommendations to the board for its implementation and/or approval.

(d) It shall be the duty of the advisory council to:

(1) Elect from its membership a chairman and a secretary annually;

(2) Recommend to the board the standards and specifications required of programs/courses which might be acceptable for board approval in fulfilling continuing education requirements;

(3) Recommend programs which meet the standards and specifications adopted;

(4) Recommend the number of CEU's granted for the satisfactory completion of approved programs; and
PART Ph 404 STANDARDS FOR COMPOUNDING AND DISPENSING STERILE AND NON-STERILE PHARMACEUTICALS

Ph 404.01 Purpose and Scope.

(a) The purpose of this part is to provide all compounders with guidance on applying good compounding practices for the preparation of non-sterile and sterile compounded formulations for dispensing and/or administration to humans and animals. Compounding is an integral part of pharmacy practice and is essential to the provision of healthcare.

(b) The board shall require all compounders engaging in compounding in all situations to adhere to and comply with the current edition of the United States Pharmacopeia including but not limited to Chapters 795 (USP 795) and 797 (USP 797), following those guidelines that apply to their practice setting. These chapters shall be reviewed in full and followed by compounders prior to non-sterile or sterile pharmaceutical compounding. These regulations shall apply to non-sterile and sterile compounding of medications.

Ph 404.02 Definitions.

(a) “Active pharmaceutical ingredients” means chemicals, substances, or other components of articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases in humans or animals or for use as nutritional supplements.

(b) “Added substances” means the ingredients necessary to prepare the drug product but are not intended or expected to cause human pharmacological response if administered alone in the amount or concentration contained in a single doses of the compounded preparation. The term “added substances” includes the terms “inactive ingredients”, “excipients”, and “pharmaceutical ingredients.”

(c) “Ante-area” means:
(1) An ISO Class 8 or better area where personnel perform hand hygiene and garbing procedures, staging of components, order enter, CSP labeling, and other high-particulate-generating activities are performed;

(2) A transition area that:
   a. Provides assurance that pressure relationships are constantly maintained so that air flows from clean to dirty areas; and
   b. Reduces the need for the heating, ventilating, and air-conditioning (HVAC) control system to respond to large disturbances.

(d) “Aseptic processing” means a mode of processing pharmaceutical and medical products that involves the separate sterilization of the product and of the package containers, closures or packaging material for medical devices and the transfer of the product into the container and its closure under at least ISO Class 5 conditions.

(e) “Beyond-use date (BUD)” is the date after which a compounded preparation should not to be used; determined from the date the preparation is compounded.

(f) “Biological Safety Cabinet (BSC)” means a ventilated cabinet for CSPs, personnel, product, and environmental protection having an open front with inward airflow for personnel protection, downward high-efficiency particulate air (HEPA)-filtered laminar airflow for product protection, and HEPA-filtered exhausted air for environmental protection.

(g) “Buffer area” means an area where the primary engineering control (PEC) is physically located.

(h) “Clean room” means a room in which the concentration of airborne particles is controlled to meet a specified airborne particulate cleanliness class. Microorganisms in the environment are monitored so that a microbial level for air, surface, and personnel gear are not exceeded for a specified cleanliness class.

(i) “Component” means any ingredient used in the compounding of a drug preparation, including any active ingredient or added substance that is used in its preparation.

(j) “Compounder” means a licensed professional authorized by the appropriate jurisdiction to perform compounding pursuant to a prescription or medication order by a licensed prescriber.

(k) “Compounding” means the preparation, mixing, assembling, altering, packaging, and labeling of a drug, drug-delivery device, or device in accordance with a licensed practitioner's order, or initiative based on the practitioner/patient/pharmacist/compounder relationship in the course of professional practice, and includes the following:

   (1) Preparation of drug dosage forms for both human and animal patients;

   (2) Preparation of drugs or devices in anticipation of prescription drug orders based on routine, regularly observed prescribing patterns;

   (3) Reconstitution or manipulation of commercial products that may require the addition of one or more ingredients;

   (4) Preparation of drugs or devices for the purposes of, or as an incident to research clinical or academic teaching, or chemical analysis; and
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(5) Preparation of drugs and devices on the order of a practitioner, which may be sold to the practitioner for use in his or her office to administer to a specific patient, in limited quantities, but not for resale.

(l) “Compounding Aseptic Containment Isolator (CACI)” means a compounding aseptic isolator (CAI) designed to provide worker protection from exposure to undesirable levels of airborne drug throughout the compounding and material transfer processes and to provide an aseptic environment for compounding sterile preparations.

(m) “Compounding Aseptic Isolator (CAI)” means a form of isolator specifically designed for compounding pharmaceutical ingredients or preparations. It is designed to maintain an aseptic compounding environment within the isolator throughout the compounding and material transfer processes.

(n) “Critical area” means an ISO Class 5 environment.

(o) “Critical site” means a location that includes any component or fluid pathway surfaces such as vial septa, injection ports, beakers or openings such as opened ampules or needle hubs exposed and at risk of direct contact with air including ambient room or HEPA filtered, moisture such as oral and mucosal secretions, or touch contamination. Risk of microbial particulate contamination of the critical site increases with the size of the openings and exposure time.

(p) “Direct Compounding Area (DCA)” means an area within the ISO Class 5 primary engineering control (PEC) where critical sites are exposed to unidirectional HEPA-filtered air, also known as first air.

(q) “Disinfectant” means an agent that frees from infection, usually a chemical agent but sometimes a physical one, and that destroys disease-causing pathogens or other harmful microorganisms but might not kill bacterial and fungal spores. It refers to substances applied to inanimate objects.

(r) “First air” means the air exiting the HEPA filter in a unidirectional air stream that is essentially particle free.

(s) “Hazardous drugs” means any drug which in studies of animals or humans have been classified as carcinogenic, toxic to development or reproduction, or toxic to organs.

(t) “Labeling” means a term that designates all labels and other written, printed, or graphic matter on an immediate container of an article or preparation or on, or in, any package or wrapper in which it is enclosed, except any outer shipping container. The term “label” designates that part of the labeling on the immediate container.

(u) “Limited quantities” means a batch with 50 or less dosage units provided to a hospital or practitioner to administer to their own patient.

(v) “Manufacturing” means the production, preparation, propagation, conversion or processing of a drug or device, either directly or indirectly, by large volume extraction from substances of natural origin, or independently by means of chemical or biological synthesis, and includes any packaging or repackaging of a substance or labeling or relabeling of its container, and the promotion and marketing of such drugs and devices for resale.

(w) “Media-fill test” means a test used to qualify aseptic technique of compounding personnel or processes and to ensure that the processes used are able to produce sterile product without microbial contamination. During this test, a microbiological growth medium such as Soybean–Casein Digest Medium is substituted for the actual drug product to simulate admixture compounding.
(x) “Memorandum of understanding” means a document specific to the preparation(s) provided to a practitioner by a compounder outlining the distinct responsibilities of the compounder and practitioner.

(y) “Multiple-dose container” means a multiple-unit container for articles or preparations intended for parenteral administration only and usually containing antimicrobial preservatives.

(z) “Negative pressure room” means a room that is at a lower pressure than the adjacent spaces and, therefore, the net flow of air is into the room.

(aa) “Pharmacy bulk package” means a container of a sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for infusion or, through a sterile transfer device, for the filling of empty sterile syringes.

(ab) “Positive pressure room” means a room that is at a higher pressure than the adjacent spaces and, therefore, the net airflow is out of the room.

(ac) “Preparation” means a compounded drug dosage form or dietary supplement or a device to which a compounder has introduced a drug.

(ad) “Primary Engineering Control (PEC)” means a device or room that provides an ISO Class 5 environment for the exposure of critical sites when compounding CSPs. Such devices include, but are not limited to, laminar airflow workbenches (LAFWs), BSCs, CAIs, and CACIs.

(ae) “Product” means a commercially manufactured sterile drug or nutrient that has been evaluated for safety and efficacy by the FDA.

(af) “Segregated compounding area” means a designated space, either a demarcated area or room, that is restricted to preparing low-risk level CSPs with 12-hour or less BUD. This area shall contain a device that provides unidirectional airflow of ISO Class 5 air quality for preparation of CSPs and shall be used for activities and materials that are extraneous to sterile compounding.

(ag) “Single-dose container” means a single-unit container for articles or preparations intended for parenteral administration only. It is intended for a single use. A single-dose container is labeled as such. Examples of single-dose containers include prefilled syringes, cartridges, fusion-sealed containers, and closure-sealed containers when so labeled.

(ah) “Sterilization by Filtration” means passage of a fluid or solution through a sterilizing grade membrane to produce a sterile effluent.

(ai) “Sterilizing grade members” means that membranes that are documented to retain 100% of a culture of 107 microorganisms of a strain of Brevundimonas (Psuedomonas) diminuta per square centimeter of membrane surface under a pressure of not less than 30 psi or 2.0 (bar). Such filter membranes are nominally at 0.22-um or 0.2-um nominal pore size, depending on the manufacturer’s practice.

(aj) “Terminal Sterilization” means the application of a lethal process, such as steam under pressure or autoclaving, to sealed containers for the purpose of achieving a predetermined sterility assurance level of usually less than 10-6, or a probability of less than one in one million of a non-sterile unit.

(ak) “Unidirectional flow” means the airflow moving in a single direction in a robust and uniform manner and at a sufficient speed to reproducibly sweep particles away from the critical processing or testing area.
Ph 404.03 Non-Sterile Pharmaceutical Compounding.

(a) Compliance with USP 795 and all applicable USP chapters related to non-sterile compounding shall be followed.

(b) There are 3 general categories of non-sterile compounding described in this section that require different levels of experience, training and physical facilities. The 3 categories shall be:

1. Simple compounding which includes reconstituting or manipulating a commercial product that might require the addition of one or more ingredients as directed by the manufacturer or preparing a product that has a USP compounding monograph or appears in a peer reviewed article that contains the quantities for all components, procedures and equipment with the exception of pre-measured compounding kits;

2. Moderate compounding which includes making a preparation that requires complex calculation or procedures to determine quantities of components per preparation or per individualized dosage units, making a preparation for which stability data for that specific formulation is not available and mixing 2 or more manufactured creams when the stability of the mixture is unknown; and

3. Complex compounding which includes making a preparation that requires specialized training, environment, facilities, equipment, and procedures such as transdermal dosage forms and modified-release preparations.

(c) Responsibilities of the compounder shall include:

1. Compounding preparations of accepted strength, quality, and purity and in accordance with the prescription or medication order;

2. Dispensing the finished preparation, with appropriate packaging and labeling, and in compliance with RSA 318:47-a, federal law, and other regulatory agencies where appropriate;

3. Maintaining proficiency in drug or dietary supplement compounding;

4. Ensuring the quality of compounded preparation by adhering to the general principles listed in USP 795 and all applicable compounding laws, guidelines and standards including but not limited to:
   a. Training of all the personnel shall be current and documentation of such kept on site;
   b. Compounding ingredients shall be purchased from reliable sources and be properly stored;
c. Bulk component containers shall be properly labeled and SDS sheets available;

d. Equipment used shall be clean, properly used and maintained;

e. Environment shall be suitable to prevent cross contamination including the use of powder containment systems if API’s are used or powder is created through manipulation of solid dosage forms or emptying of powder containing vials;

f. Compounding personnel shall wear appropriate and clean clothing. Protective apparel such as lab coats gowns, gloves, shoes, or masks shall be worn as necessary to protect personnel from chemical exposure and/or contamination;

g. Only authorized personnel shall be allowed in the compounding area;

h. Compounding conditions and procedures shall be such to prevent errors;

i. There shall be assurance that processes are always carried out as intended or specified and are reproducible;

j. All aspects of compounding shall be properly documented;

k. Procedures and records exist for investigating and correcting failures or problems in compounding and testing; and

l. A valid and reproducible recall policy and procedure.

(5) The compounder shall be responsible for ensuring that each individual incidence of the compounding process meets the criteria in USP 795.

(d) The compounding area shall adhere to the general principles listed in USP 795 guidelines including but not limited to:

(1) Adequate space specifically designated for compounding and storage of equipment and materials;

(2) Be clean, orderly, and properly maintained;

(3) Easily accessible hand washing, hot and cold water, soap or detergent, and an air-drier or single-use towels must be present;

(4) Be located in a separate area from sterile compounding area;

(5) Purified water shall be used for compounding non-sterile drug preparations when formulations indicate the inclusion of water;

(6) Disposal of all hazardous drug wastes shall comply with applicable federal and state regulations; and

(7) All personnel who perform routine custodial waste removal and cleaning activities in storage and preparation areas for hazardous drugs shall be trained in appropriate procedures to protect themselves and prevent contamination including spill clean ups.

(e) All equipment and utensils used in compounding shall comply with the following:

(1) Be of appropriate design and capacity for the required task;
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(2) Automatic, mechanical, electronic, or other equipment used in compounding shall be routinely inspected, calibrated, or checked according to the manufacturer’s recommendations to ensure proper performance; and

(3) Equipment shall be stored to protect it from contamination. It shall be located in an area to facilitate its use, cleaning and maintenance.

(f) Component Selection, Handling and Storage shall be subject to the following requirements:

(1) A United States Pharmacopeia (USP), National Formulary (NF), or Food Chemicals Codex (FCC) substance shall be the recommended source of ingredients for compounding all preparations.

(2) If ingredients are from a non-FDA registered facility the professional judgment of the compounder shall be used in selecting an acceptable and reliable source and shall establish purity and safety including obtaining a certificate of analysis from the manufacturer or qualified third party;

(3) Components for compounding shall be properly labeled with lot numbers and expiration dates. If a component is transferred from the original container to a new container, the new container shall be labeled with the component name, original supplier, lot or control number, transfer date, and expiration date and shall provide integrity that it is equal to or better than the original container;

(4) For components that do not have expiration dates assigned by the manufacturer or supplier the compounder shall label the container with the date of receipt and assign a conservative expiration date not to exceed 3 years after receipt;

(5) Written control procedures shall be established to monitor the output and to validate the performance of those compounding processes that might be responsible for causing variability in the final drug product, including but not limited to, the following:

   a. Capsule weight variation;
   b. Adequacy of mixing to insure uniformity and homogeneity;
   c. Clarity, completeness, or pH of solutions; and
   d. Observation of instability;

(6) When compounding with manufactured drug products, the compounder shall consider all ingredients, including excipients, present in the drug product relative to the intended use of the compounded preparation and the effect of manipulating the drug product on the therapeutic appropriateness and stability of the components;

(7) All components used in compounding shall be stored as directed by the manufacturer, or according to USP or NF requirements, in a clean, dry area under appropriate temperature conditions. All components shall be stored off the floor, handled and stored to prevent contamination, and rotated so that the oldest stock is used first. All containers shall be properly labeled; and

(8) Use of pre-measured compounding kits shall adhere to all USP 795 standards, including the level of non-sterile compounding and utilizing a master formulation record and a compounding record.
(g) The following provisions of USP 795 shall be followed when determining stability and beyond use dating:

(1) Compounders shall consult and apply drug-specific and general stability information and literature when available;

(2) Compounders shall consider the following when determining BUDs:
   a. Nature of the drug and degradation mechanism;
   b. Dosage form and its components;
   c. Potential for microbial proliferation in the preparation;
   d. Container when it is packaged;
   e. Intended duration of therapy; and
   f. Expected storage conditions;

(3) When using manufactured solid dosage forms to prepare a solution or aqueous suspension, the compounding shall also consider factors such as hydrolysis, oxidation, and the freeze-thaw property of the final preparation;

(4) When a manufactured product is used as the source of the active pharmaceutical ingredient for a non-sterile compounded preparation, the product expiration date shall not be used to assign a BUD for the compounded preparation. Instead the compounding shall refer to the manufacturer for stability information and to the literature for applicable information on stability, compatibility, and degradation of ingredients. All data shall be carefully interpreted in relation to the actual compounded formulation;

(5) Susceptible preparations should contain suitable antimicrobial agents to protect against bacteria, yeast, and mold contamination inadvertently introduced during or after the compounding process. When antimicrobials are contraindicated, storage of the preparation at controlled cold temperature shall be necessary to retard microbial growth. Appropriate patient or caregiver instruction regarding storage and handling shall be essential;

(6) In the absence of reliable stability information or published date the following general guidelines for maximum BUD shall be:
   a. A maximum of 6 months for non-aqueous formulations;
   b. A maximum of 14 days under refrigeration for water-containing oral formulations; and
   c. A maximum of 30 days for water containing topical, dermal and mucosal liquid and semisolid formulations.

(7) The BUD shall not exceed the expiration date of the API or any other component.

(h) The compounding shall ensure that the containers and closures used in packaging compounded preparations meet the following USP requirements:
(1) The containers and closures shall be made of clean material in order not to alter the quality, strength, or purity of the compounded preparation;

(2) Container-drug interaction shall be considered for substances that have sorptive or leaching properties; and

(3) Containers and closures shall be handled and stored in such a way as to prevent contamination.

(i) Compounders shall comply with the following requirements regarding compound documentation;

(1) Documentation, written or electronic, shall be kept for 4 years;

(2) Documentation shall comply with state and federal laws;

(3) Documentation shall not be required when preparing a compounded preparation according to the manufacturer’s labeled instructions;

(4) The record may be a copy of the prescription in written or machine-readable form and shall include a master formula record and a compound record;

(5) Information contained in the master formulation record shall include the following:

   a. Official or assigned name, strength, and dosage form of the preparation;

   b. Calculations needed to determine and verify quantities of components and doses of active pharmaceutical ingredients;

   c. Description of all ingredients and their quantities;

   d. Compatibility and stability information, including references when available;

   e. Equipment needed;

   f. Mixing instructions;

   g. Order of mixing;

   h. Mixing temperature or other controls;

   i. Duration of mixing;

   j. Any other pertinent instruction;

   k. Labeling information in addition to legally required information found in RSA 318:47-a including:

      1. Name and quantity or concentration of each active ingredient;

      2. Assigned BUD;

      3. Storage conditions; and

      4. Prescription number;

   l. Container used in dispensing;
m. Packaging and storage requirements;

n. Description of final preparation; and

o. Quality control procedures and expected results; and

(6) The compound record shall contain at least the following:

   a. Official or assigned name, strength, and dosage of the preparation;

   b. Master formulation record reference for the preparation;

   c. Names and quantities of all components;

   d. Sources, lot numbers, and expiration dates of components;

   e. Total quantity compounded;

   f. Name of the person who prepared the compound, who performed the quality control procedures, and approved the preparation;

   g. Date of the preparation;

   h. Assigned controlled or prescription number;

   i. Assigned BUD;

   j. Description of final preparation;

   k. Results of quality control procedures such as weight range of filled capsules, pH record; and

   l. Documentation of any QC issues and any ADRs reported by patient or caregiver;

(j) All significant procedures performed in the compounding area shall be covered by written standard operating procedures (SOPs) including:

   (1) Facility maintenance, workflow, and cleaning;

   (2) Equipment use and maintenance;

   (3) Personnel;

   (4) Training;

   (5) Preparation;

   (6) Packaging;

   (7) Storage of compounded preparations;

   (8) Quality assurance;

   (9) Safety;

   (10) Uniformity;
(11) Continuous quality improvement; and

(12) Maintain updated SDS library.

(k) The compounder shall perform the following to ensure quality control;

(1) Review calculation, ingredients, measurements and procedures; and

(2) Observe the finished preparation to ensure that it appears as expected and investigate any discrepancies and take appropriate corrective action before the prescription is dispensed to the patient.

(l) The compounder shall ensure the following compounding controls are followed:

(1) There are written procedures for the compounding of drug preparations to ensure that the finished preparations have the identity, strength, quality, and purity that they purport to have. These procedures shall be available in either written form or electronically stored;

(2) The written procedures shall be followed in execution of the compounding process;

(3) Check and document each weight and measurement;

(4) Document the identity of the person(s) actually performing the compounding;

(5) Document the name of compounder;

(6) Establish written procedures that will describe quality assurance tests or examinations to be conducted on the compounded preparation to ensure uniformity and integrity;

(7) To monitor the output and to validate the performance of those compounding processes and equipment that could be responsible for causing variability in the final compounded preparation; and

(8) Records shall be maintained with compounding records for 10 years.

(m) At the time of dispensing, the patient or the patient’s agent shall be counseled about proper use, storage, handling, and disposal of the compounded preparation. The patient or the patient’s agent shall also be instructed to observe and report to the compounder any changes in the physical characteristics of the compounded preparation. Counseling may be in written, oral, electronic, or other formats. The compounding pharmacist shall investigate any reported problem with a compounded preparation and take corrective action.

(n) It shall be the responsibility of the compounder to ensure that a training program has been implemented and that it is ongoing. Compounding personnel shall be trained initially and the training shall be documented.

(o) Steps in the training procedure shall include the following:

(1) All employees involved in pharmaceutical compounding shall read and become familiar with USP Chapter 795. They shall also be familiar with other relevant publications including how to read and interpret SDSs;

(2) All employees shall read and become familiar with each of the procedures related to compounding including those involving the facility, equipment, personnel, actual compounding, evaluation, packaging, storage and dispensing;
(3) All personnel who compound hazardous drugs shall be fully trained in the storage, handling and disposal of these drugs. This training shall occur before preparing or handling hazardous drugs;

(4) All training activities shall be documented. The compounder shall meet with employees to review their work and answer any questions the employee may have concerning compounding procedures;

(5) The compounder shall demonstrate the procedures for the employee and shall observe and guide the employee throughout the training process. The employee shall then repeat the procedure without any assistance from, but under the supervision of the compounder;

(6) When the employee has demonstrated to the compounder a verbal and functional knowledge of the procedure, then and only then shall the employee be permitted to perform the procedure without direct supervision. However the compounder shall be physically present and shall approve all ingredients and their quantities and the final preparation;

(7) When the compounder is satisfied with the employee’s knowledge and proficiency, the compounder shall sign the documentation records to show that the employee was appropriately trained;

(8) The compounder shall continually monitor the work of the employee and ensure that the employee’s calculations and work are accurate and adequately performed; and

(9) The compounder shall be solely responsible for the finished preparation.

(p) The following requirements shall be met when compounding for animal patients:

(1) Intended use on any animal patient, such as companion, performance or food, shall be determined before compounding for that patient. Because humans can consume animals as food, care shall be taken to prevent drug residue from entering the human food chain;

(2) Compounders who compound for animals shall possess knowledge of drug regulation, uses, dosing and disposition in animal patients to properly determine appropriateness of therapy; and

(3) The compounding pharmacist shall be knowledgeable about the individual species limitations in physiology and metabolic capacity that can result in toxicity when certain drugs or excipients are used in compounded preparations. For this reason, pharmacists compounding for animals shall use when possible, formulations developed specifically for animal patients. If such formulations are not available, the compounding pharmacist shall conduct a literature review to determine whether a specific component of the formula is toxic to the target species. Compounded preparations shall not to be dispensed or sold to veterinary offices for resale.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10812, eff 4-18-15
Ph 404.04  Regulatory Requirements for Sterile Compounding.

(a) A compounding shall have and maintain a permit issued by the board that allows for the compounding of sterile products as defined by the board.

(b) When a compounding prepares more than 50 dosage units for non-patient specific preparations the compounding shall be registered as a drug manufacturer or 503B with the FDA.

(c) Compounders supplying limited quantities, less than 50 dosage units, to providers for administration use shall have an MOU with the provider for each compounded product they supply to the provider. When a compounding provides a practitioner a non-patient specific preparation, the compounding shall provide the practitioner a copy of the test result for each lot provided to the practitioner.

(d) Each batch of a high risk CSP shall be assigned a unique lot number and shall be tested by an independent lab for sterility, potency, and endotoxins. Only a batch that has passed all 3 tests shall be made available to provide to a hospital or practitioner.

(e) A compounding shall not compound a sterile product of an FDA-approved product when the product is commercially available.

(f) When no commercial source of a sterile product exists, such as being listed on the FDA backorder list, the compounding shall only use USP or other USP recognized grades such as BP, JP, EP, bulk ingredients obtained from a good manufacturing practice compliant supplier. The compounding shall obtain and keep on file for at least 3 years a certificate of analysis and potency testing of all bulk ingredients used to compound each and every compounded product made with a bulk, non-sterile ingredient.

(g) A compounding who uses hazardous products shall meet state and federal requirements for handling of hazardous agents.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10812, eff 4-18-15

Ph 404.05  Sterile Quality Requirements.

(a) Each compounding shall maintain documentation that confirms staff training and competency related to proper garbing and hand hygiene, aseptic technique and related practices, and cleaning and disinfection procedures prior to compounding of any actual sterile product preparation.

(b) Each compounding shall maintain documentation that confirms that the compounding tests aseptic techniques of all staff that compounds sterile products by preparing media fill units per USP standards.

(c) Each compounding shall maintain documentation that confirms all staff that compounds sterile products are pre-qualified using media fills before compounding of actual drug preparations.

(d) When a positive media fill occurs, compounding shall perform a comprehensive investigation to identify root cause, and document the finding.

(e) When a positive media fill occurs, compounding shall institute corrective and preventive action, and document the corrective action.
(f) Each compounder shall verify that all personnel who compound sterile products are complying with gowning, gloving, and glove-tip processes consistent with USP standards by meeting the following requirements:

1. Three glove fingertip tests shall be performed initially then annually for low and medium risk compounding;
2. Three glove fingertip tests shall be performed initially then every 6 months for high risk compounding; and
3. Media fill tests shall be performed every 6 months for high risk compounding.

(g) Each compounder shall perform routine surface microbiological and fungal environmental monitoring to minimize contamination at least every 6 months, or in accordance with facilities policies.

(h) Each compounder shall perform comprehensive investigations of out-of-limit findings, as recommended by USP standards to determine root cause, followed by corrective and preventative actions at least weekly. Each compounder shall maintain all documentation of its findings.

(i) Each compounder shall perform, at least semi-annually, viable particle testing in primary engineering controls, such as laminar flow workbench, biological safety cabinet and room air according to USP standards.

(j) Each compounder shall ensure that all compounded sterile products that require refrigeration are stored in appropriate refrigeration at all times.

(k) When a compounder assigns a BUD for a sterile product that exceeds BUD limits established in USP standards, a compounder shall have laboratory testing results that support extended expiration dating for compounded sterile preparations to any patient or organization that request such documentation.

(l) Each compounder shall perform studies to determine extended expiration dates, using evidence-based and validated stability testing procedures, for compounded sterile preparations for which no extended expiration evidence exists.

(m) Each compounder shall have a policy that requires validation of new or changed facilities, equipment, processes, container types, for sterility, and repeatability.

(n) Each compounder shall have a quality assurance program to promptly address equipment problems.

(o) Each compounder shall have a quality assurance program for compounding that includes at least the following separate, but integrated, components:

1. Training;
2. Standard operating procedures;
3. Documentation;
4. Verification;
5. Testing;
6. Cleaning and disinfecting;
(7) Containers, packaging and repackaging; and

(8) Storage.

(p) Personnel involved in the compounding, evaluation, packaging and dispensing of compounded preparations shall be properly trained and evaluated to include:

(1) Three glove fingertip tests shall be performed initially then annually for low and medium risk compounding; and

(2) Three glove fingertip tests shall be performed initially then every 6 months for high risk compounding.

(q) Personnel shall undergo re-qualification using media fills and glove fingertip tests annually for low and medium risk sterile compounding and every 6 months thereafter for high risk sterile compounding.

(r) Each compounder shall have an action plan and alert limits for environmental monitoring.

(s) Each compounder shall develop and implement methods for improving quality based on analyzed data found in its environmental monitoring.

(t) Each compounder shall evaluate and continuously monitor the methods used for the packaging, handling, and transport of CSPs.

(u) Each compounder shall evaluate and continuously monitor the storage of CSPs to ensure compliance with appropriate storage conditions.

(v) Each compounder shall ensure drug storage refrigerators, freezers and medication storage areas have daily monitoring and documentation of temperatures.

(w) Compounder personnel shall inspect all drug storage areas routinely to ensure drugs are stored separately from food.

(x) Each compounder shall ensure all solutions, medications, equipment, and supplies located in all areas are stored according to the manufacturer or USP requirements and are inspected monthly for proper conditions of light, temperature, moisture, and ventilation.

(y) Each compounder shall ensure all outdated and unused CSPs are segregated in a separate area for return and disposal.

(z) Each compounder shall ensure only pharmacists training in sterile compounding determine whether a CSP not administered as originally intended can be used for an alternate patient or under alternate conditions.

(aa) Each compounder shall have an environmental sampling plan based on the compounding activities performed, locations to be monitored, the device used to monitor, the frequency of collection, and procedures if readings exceed established thresholds.

(ab) The 2 types of monitoring that shall be used are:

(1) Non-viable monitoring which includes particle counts, monitoring pressure or velocity difference between the buffer area, ante area and non-classified area and shall be done at least every 6 months; and
(2) Viable monitoring which detects microbial or fungal contaminants in the compounding area and shall be done using a volumetric collection method.

(ac) Monitoring, sampling, and testing for surface contamination from hazardous drugs is conducted at least every month or earlier in cases of contamination from fluid or solid dosage form spills.

(ad) Compounder shall ensure certification of its PEC complies with the requirements of USP Standards. Certification shall be done by an independent entity certified to perform the test. Each certifying entity shall leave a signed copy of the test with the compounder who shall retain the document for at least 4 years.

(ae) Each compounder shall ensure the PEC is certified every 6 months or sooner if recommended by the manufacturer.

(af) Each compounder shall ensure viable and non-viable airborne sampling occurs minimally every 6 months. Monitoring shall include all areas at risk of contamination including but not limited to inside of PEC, counters, anteroom, areas near doorways, and any pass-through, counters, storage areas, shelves, shipping and receiving areas, and employee work areas.

(ag) Each compounder shall ensure sampling data is base-lined, evaluated and documented on a routine basis as defined by USP standards.

(ah) Each compounder shall have a written plan and schedule for environmental monitoring.

(ai) Each compounder shall have a written environmental plan that adequately evaluates the various controlled air environment areas including the PEC, buffer area, and anteroom.

(aj) Compounder facility personnel, or external personnel, who complete the environmental monitoring shall be appropriately trained and certified by a national certification entity.

Source.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New.  #8316, eff 3-26-05, EXPIRED: 3-26-13
New.  #10812, eff 4-18-15

Ph 404.06 Compounding Environment

(a) Each compounder shall ensure there is sufficient space for the type and amount of compounding done.

(b) Each compounder shall ensure there is appropriate space for orderly placement of equipment and materials to prevent mix-ups between ingredients, containers, labels, in-process materials and finished preparations.

(c) Each compounder shall ensure it has procedures to prevent cross-contamination.

(d) Each compounder shall ensure areas used for sterile preparation are separate and distinct from areas used for non-sterile preparation.

(e) Each compounder shall have a well-lighted compounding environment.

(f) Each compounder shall ensure all heating, ventilation and air conditioning systems are controlled to maintain a constant temperature 24 hours per day, 7 days per week.
(g) Each compounder shall maintain a bulk storage area that is adequately arranged and proper
temperature and humidity maintained.

(h) Each compounder shall supply hot and cold potable water for hand and equipment washing in
the compounding area, and soap or detergent and single-use towels or driers shall be readily available.

(i) Each compounder shall ensure all compounding areas are maintained in a clean and sanitary
condition.

(j) When compounder uses hard-wall construction, the finished surface shall provide a non-porous,
durable and washable surface.

(k) The compound area shall meet the following requirements:

   (1) All ceilings shall be smooth, impervious, free from cracks and non-shedding, such as
       plastic covered clean room grade ceiling tiles, and all tiles shall be sealed;

   (2) All floors shall be smooth, impervious, free from cracks and non-shedding, and the floor
       must be of seamless vinyl;

   (3) All fixtures shall be smooth, impervious, free from cracks and non-shedding. All fixtures
       shall be mounted to wall in a way that seals any space between wall and fixture;

   (4) All shelving shall be smooth, impervious, free from cracks and non-shedding;

   (5) Counters shall be smooth, impervious, free from cracks and non-shedding;

   (6) All cabinets shall be smooth, impervious, free from cracks and non-shedding;

   (7) Ceiling to wall junctures shall be covered or caulked to avoid cracks;

   (8) Inlaid ceiling panels shall be impervious and hydrophobic;

   (9) Ceiling panels shall be caulked around the perimeter to seal them to frame;

   (10) Floors shall be overlaid with wide sheet vinyl flooring with heat welded seams and
        coving to the sidewall;

   (11) There shall be no dust-collecting overhangs;

   (12) There shall be no windowsills;

   (13) Exterior lens surface of ceiling light fixtures shall be smooth, mounted flush, and sealed;

   (14) There shall be no sinks in primary and secondary compounding areas;

   (15) There shall be no floor drains in primary and secondary compounding areas;

   (16) Carts shall be made of stainless steel wire or sheet metal with cleanable casters;

   (17) Carts shall be mobile;

   (18) All surfaces shall be designed to provide effective cleaning;

   (19) All surfaces shall be resistant to damage by cleaning agents;

   (20) There shall be no cardboard containers in buffer area at any time;
(21) There shall be no computers, printers, radios and refrigerators in the buffer area at any time;

(22) The bulk storage area shall be maintained in a clean and sanitary condition;

(23) Trash shall be disposed of in a safe, sanitary and timely manner; and

(24) All components, containers and equipment shall be stored off the floor in a manner to prevent contamination and permit inspection and cleaning of the compounding and storage area.

(l) Each compounder shall ensure equipment is of appropriate design and size for the compounding that is performed.

(m) Each compounder shall ensure that all equipment is of appropriate design such that the surface that contact pharmaceutical components, in-process materials or finished preparations is not reactive, additive or adsorptive.

(n) Each compounder shall ensure that all equipment is thoroughly cleaned immediately after use to avoid cross-contamination.

(o) Each compounder shall ensure all equipment is stored to prevent it from contamination and is located to facilitate its use, maintenance, and cleaning.

(p) Each compounder shall ensure all equipment used for allergenic ingredients is appropriately handled, cleaned and stored immediately after use.

(q) Each compounder shall ensure all work surfaces are cleaned of loose materials and residue from spills before compounding.

(r) Each compounder shall ensure all floors in the buffer area and ante area are mopped daily with a cleaning and disinfecting agent at a time when no aseptic compounding is in progress.

(s) Each compounder shall approve all cleansing and sanitizing agents considering compatibilities, effectiveness, and presence of inappropriate or toxic residues.

(t) Each compounder shall ensure the following requirements are met:

(1) Mops, wipes, sponges, and other cleaning materials shall be non-shedding and dedicated for use only in the sterile compounding area;

(2) Cleaning tools shall be replaced as soon as they are identified as unsuitable for use;

(3) All cleaning materials shall be disposable and discarded after one use;

(4) All trash shall be collected in suitable plastic bags and removed on a daily basis with minimal agitation;

(5) Workspaces shall be cleaned and sanitized daily including all buffer room carts, equipment, workbenches, work surfaces, and floors, and document the activity;

(6) Storage shelving in buffer and ante areas shall be emptied of all supplies, cleaned, and sanitized at planned intervals at least monthly;

(7) Walls and ceilings in buffer and ante areas shall be cleaned at least monthly; and
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(8) All equipment shall be clean, properly maintained, validated and documented at appropriate intervals as defined by USP Standards.

Source: #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10812, eff 4-18-15

Ph 404.07 Engineering Controls.

(a) Each compounder shall ensure the PEC, LAFW and BSCs provide ISO Class 5 air quality;

(b) Each compounder shall ensure the buffer room maintains a minimum of an ISO Class 7 air quality;

(c) Each compounder shall ensure the buffer room is designed to reduce the risk of contaminants being blown into the primary compounding area, or PCA. To be considered a clean room, buffer area must meet specific air quality, HEPA filtration, air changes per hour, and room pressure differentiation criteria to provide at least ISO Class 7 air quality.

(d) Each compounder shall ensure that within the buffer area, the PEC should be kept away from excess traffic, doors, air vents, or anything that could introduce contaminants into the workbench.

(e) Each compounder shall ensure that the anteroom is separate from buffer area.

(f) Each compounder shall ensure that the anteroom provides ISO Class 8 air quality, or ISO Class 7 air quality, depending on the connecting buffer area.

(g) Each compounder shall ensure the anteroom area should store an adequate amount of gowning supplies but should not be part of high traffic area or corridor.

(h) Each compounder shall ensure the anteroom is used to un-carton and sanitize all supplies to be taken into buffer area.

(i) Each compounder shall ensure sure the anteroom contains:

   (1) Hand sanitizing equipment;
   (2) Proper gowning equipment and space to accommodate gowning activities;
   (3) Faucet handles that shall be designed to be hands-free; and
   (4) That the buffer area can be accessed without the use of hands.

(j) Each compounder that only compounds low and/or medium risk preparations, the ante room may be in the same area as the buffer room, separated by a line of demarcation. However, a separate ante room shall be the preferred method.

(k) Each compounder that compounds high risk preparations, the buffer room and the ante room shall be 2 separate rooms.

(l) Each compounder shall ensure all supplies brought into the buffer area are non-permeable, non-shedding, and resistant to disinfectants.
(m) Each compounder shall ensure all materials exposed to patient care areas are kept out of the buffer area.

(n) Each compounder shall ensure the PECs are cleaned and disinfected at the beginning of each shift, before each batch, at least every 30 minutes during compounding, when surfaces are visibly soiled, and when surface contamination is known or even suspected.

(o) Each compounder shall ensure all interior working surfaces are cleaned and disinfected of LAFW from top to bottom, back to front, away from the HEPA filter. Cleaning shall be performed with purified water, and disinfecting with sterile 70% isopropyl alcohol or similar antimicrobial, residue-free sanitizing agent.

(p) Each compounder shall ensure nothing shall be permitted to come in contact with the HEPA filter. This includes cleaning solutions, aspirate from syringes, or glass from ampules, which shall not be broken towards the filter.

(q) Each compounder shall ensure air exchange with the surrounding environment shall not occur unless the air is first passed through a microbial retentive filter such as a HEPA system capable of containing airborne concentrations of the physical size and state of the drug being compounded. Where volatile hazardous drugs are prepared, the exhaust air from the isolator shall be appropriately removed by properly designed building ventilation.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10812, eff 4-18-15
New. #10812, eff 4-18-15

Ph 404.08 Compounding Procedures.

(a) Each compounder shall ensure that all personnel adhere to the following when they are in the LAFW or buffer areas:

1. No smoking, food, drink, or chewing gum shall be allowed in the buffer area at any time;
2. No jewelry shall be worn on the hands or wrists and there shall be no visible piercings;
3. No make-up shall be worn in the buffer area as it can shed particles;
4. Before putting on gloves, the nails shall be cleaned, and the hands, wrists, and forearms shall be washed thoroughly for at least 30 seconds with warm water and antimicrobial skin cleanser;
5. Personnel shall appropriately utilize gowns, masks, gloves, hair covers, and shoe covers;
6. No paper, pens, labels, or trays shall be placed in the workbench; and
7. No objects that shed particles shall be brought into the buffer area such as cardboard cartons, paper towels, and cotton items.

(b) Each compounder shall ensure when cleaning and disinfecting the interior work surfaces of the LAFW it is done from top to bottom, back to front, away for the HEPA filter.
(c) Each compounder shall ensure personnel check the quality, purity, amount, and identity of all ingredients.

(d) Each compounder shall ensure all personnel use the correct compounding procedures when compounding sterile products, and periodically disinfect gloves with sterile 70% isopropyl alcohol and allow them to dry thoroughly before continuing.

(e) Each compounder shall ensure that open and partially used containers are properly labeled and stored.

(f) Each compounder shall ensure the following:

1. CSP has an appropriate BUD that is identified on all product labels;
2. When the BUD exceeds USP standards, it is based on scientific criteria;
3. Packaging is appropriate for sterility and stability;
4. Product labels are appropriate and complete for safe use; and
5. Products are visually inspected for physical integrity during and after compounding, and a final check of the CSP is performed.

(g) Each compounder shall ensure any deficiencies in compounding procedures can be rapidly identified and corrected.

(h) Each compounder shall ensure that finished compounded products are maintained in a separate area away from the active compounding area, and that no more than 2 entries into any one sterile container or sterile administration device.

(i) Each compounder shall ensure all compounding activity only involves closed or sealed packaging systems.

(j) In the absence of stability and sterility testing of any CSP the compounder shall use BUD based on USP standards as defined for the following CSPs:

1. Low risk compounded product storage shall not exceed 48 hours at room temperature, 14 days at cold temperature or 45 days in a frozen state if the stability of the product allows;
2. Medium risk compounded product storage shall not exceed 30 hours at controlled room temperature, 9 days at cold temperature or 45 days in a frozen state;
3. High risk compounded product storage shall not exceed 24 hours at room temperature, 3 days at cold temperature or 45 days in a frozen state.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10812, eff 4-18-15

Ph 404.09 Records Management.

(a) Compounder shall maintain the following records related to compounding of sterile products for at least 4 years:
(1) PEC certification records;
(2) GAP analyses; and
(3) Detailed formulation record of each sterile compounded preparation that includes:
   a. Name of preparation, strength and dosage form;
   b. All ingredients and their quantities;
   c. Equipment used for the preparation;
   d. Add mixing instructions to include order of mixing, temperatures, duration of mixing and other pertinent factors;
   e. Assigned beyond-use date;
   f. Container used;
   g. Storage requirements; and
   h. Quality control procedures.

(b) Each compounding shall have procedures developed for the facility, equipment, personnel, preparation, packaging and storage of compounded preparation to ensure accountability, accuracy, quality, safety, and uniformity in compounding.

(c) Each compounding shall have a procedure for recalls. The recall file shall be maintained with information concerning any applicable recalled products affecting the pharmacy.

(d) Each compounding shall perform and maintain a quality control history and quality assurance trend reports on a quarterly basis and upon request.

(e) Each compounding shall maintain documentation that confirms that sterile media used is certified by the manufacturer to be sterile and guaranteed to promote growth.

(f) Each compounding shall maintain detailed reports on the incidence of positive media test results and the follow-up retests after corrective action is completed.

(g) Each compounding shall provide a guaranteed shelf life upon delivery. This date shall be based on USP Standards, or based on established scientific criteria.

(h) Each compounding shall document processes and procedures including shipping validation studies to ensure that preparations leaving the site retain their integrity and stability through the shipping cycle.

(i) Each compounding shall ensure that all personnel annually receive live training and visual process validation including written documentation of both processes.
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(j) Each compounder shall maintain documentation that it’s cleaning methods and agents are effective in preventing contamination of the sterile preparations area.

Source.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New.  #8316, eff 3-26-05, EXPIRED: 3-26-13
New.  #10812, eff 4-18-15

PART Ph 405 STANDARDS OF PRACTICE FOR NUCLEAR/RADIOLOGIC PHARMACY

Ph 405.01 Purpose. The practice of nuclear pharmacy is hereby recognized as a specialty of pharmacy practice, regulated by the state board of pharmacy. As such, the following rules are included to address those areas specific or unique to this specialty practice.

Source.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New.  #8316, eff 3-26-05, EXPIRED: 3-26-13
New.  #10812, eff 4-18-15

Ph 405.02 Definitions.

(a) "Authentication of product history" means identifying the purchasing source, the ultimate fate, and any intermediate handling of any component of a radiopharmaceutical or other drug.

(b) "Nuclear pharmacy" means a pharmacy which provides radiopharmaceutical services.

(c) "Practice of nuclear pharmacy" means a patient-oriented service that embodies the scientific knowledge and professional judgment required to improve and promote health through the assurance of the safe and efficacious use of radiopharmaceuticals and other drugs.

(d) "Quality assurance procedures" means all activities necessary to guarantee the integrity of the process used to provide radiopharmaceutical services, including authentication of product history and maintenance of all records as required by the department of health and human services, bureau of radiological health.

(e) "Quality control testing" means the performance of chemical, biological and physical tests on compounded radiopharmaceuticals and the interpretation of the resulting data to determine their suitability for use in humans and animals.

(f) "Radiopharmaceutical" means any drug which exhibits spontaneous disintegration of unstable nuclei with the emission of nuclear particles or photons. The term includes any nonradioactive reagent kit or nuclide generator which is intended to be used in the preparation of any such substance, but does not include drugs such as carbon-containing compounds or potassium-containing salts which contain trace quantities of naturally occurring radionuclides. The term also includes any biological product which is labeled with a radionuclide or intended solely to be labeled with a radionuclide.
(g) "Radiopharmaceutical service" means the procurement, storage, handling, compounding, preparation, labeling, quality control testing, dispensing, distribution, transfer, record keeping and disposal of radiochemicals, radiopharmaceuticals and ancillary drugs.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10812, eff 4-18-15

Ph 405.03 General Requirements for Pharmacies Providing Radiopharmaceutical Services.

(a) A permit to operate a pharmacy which provides radiopharmaceutical services shall only be issued to a person who is, or who employs, a qualified nuclear pharmacist. All personnel performing tasks in the preparation and distribution of radiopharmaceuticals and ancillary drugs shall be under the direct supervision of a qualified nuclear pharmacist, who shall be in personal attendance when the pharmacy is open for business. The pharmacist-in-charge shall be responsible for all operations of the pharmacy.

(b) The nuclear pharmacist who licenses the pharmacy shall hold a current license issued by the board, and be either certified as a nuclear pharmacist by the board of pharmaceutical specialties or satisfy each of the following requirements:

(1) Meets minimal standards of training for status as authorized user of radioactive material, as specified by the department of health and human services, bureau of radiological health;

(2) Has successfully completed a minimum of 200 contact hours of instruction in nuclear pharmacy and the safe handling and use of radioactive materials from a nationally accredited college of pharmacy, or other training program recognized by the department of health and human services, bureau of radiological health;

(3) The 200 hours of instruction referenced in (2) above shall be apportioned as follows:

a. Radiation physics and instrumentation, 85 hours;
b. Radiation protection, 45 hours;
c. Mathematics pertaining to the use and measurement of radioactivity, 20 hours;
d. Radiation biology, 20 hours; and
e. Radiopharmaceutical chemistry, 30 hours;

(4) Has attained a minimum of 500 hours of clinical/practical nuclear pharmacy training under the supervision of a qualified nuclear pharmacist in, but not limited to, the following areas:

a. Procuring radioactive materials;
b. Compounding radiopharmaceuticals;
c. Performing routine quality control procedures;
d. Dispensing radiopharmaceuticals;
e. Distributing radiopharmaceuticals;
f. Implementing basic radiation protection procedures; and

g. Consulting and educating the nuclear medicine community, patients, pharmacists, other health professionals, and the general public; and

(5) Has submitted an affidavit of experience and training to the board.

(c) The permit to operate a nuclear pharmacy shall be effective only so long as the pharmacy also holds a current license issued by the department of health and human services, bureau of radiological health. Copies of the bureau of radiological health inspection reports shall be available at the pharmacy for board inspection.

(d) Nuclear pharmacies shall have adequate space and equipment, commensurate with the scope of services required and provided and meeting minimal space requirements established for all pharmacies in the state.

(e) All pharmacies handling radiopharmaceuticals shall include, but not be limited to, the following areas:

(1) Radiopharmaceutical preparation/dispensing area;
(2) Radioactive material shipping/receiving area;
(3) Radioactive material storage area; and
(4) Radioactive waste decay area.

(f) The application for a permit to operate a nuclear pharmacy shall be the same as in Ph 304.01 and Ph 304.02.

(g) The nuclear pharmacy professional service area shall be secured from unauthorized personnel and shall be totally enclosed and lockable.

(h) Nuclear pharmacies shall maintain records of acquisition, inventory and disposition of all radioactive drugs and other radioactive materials in accordance with the board and the department of health and human services, bureau of radiological health statutes and rules.

(i) A radiopharmaceutical shall be dispensed only to a licensed practitioner authorized by the department of health and human services, bureau of radiological health to possess, use and administer such drug. A radiopharmaceutical shall be dispensed only upon receipt of a prescription or medication order from such licensed practitioner. Otherwise, a radiopharmaceutical may be transferred to a person who is authorized to possess and use such drug for non-clinical applications.

(j) A nuclear pharmacy, upon receiving an oral prescription order for a radiopharmaceutical, shall immediately have the prescription order reduced to writing, or recorded in a data processing system.

(k) The writing or record required by (i) above shall contain at least the following:

(1) The name of the institution and prescriber, or prescribers' agent;
(2) The date of dispensing and the calibration time of the radiopharmaceutical;
(3) The name of the procedure;
(4) The name of the radiopharmaceutical;
(5) The dose or quantity of the radiopharmaceutical;
(6) The serial number assigned to the order for the radiopharmaceutical;
(7) Any specific instructions;
(8) The initials of the person who received the order; and
(9) The initials of the person who dispensed the order.

(l) Whenever an order is for a therapeutic or blood-product radiopharmaceutical, the patient's name shall be obtained and recorded prior to dispensing.

(m) The immediate outer container shield of a radiopharmaceutical to be dispensed shall be labeled with:

(1) The name and address of the pharmacy;
(2) The name of the prescriber;
(3) The date of dispensing;
(4) The serial number assigned to the order for the radiopharmaceutical;
(5) The standard radiation symbol;
(6) The words "Caution Radioactive Material";
(7) The name of the procedure;
(8) The radionuclide and chemical form;
(9) The amount of radioactivity and the calibration date and time;
(10) If a liquid, the volume;
(11) If a solid, the number of items or weight;
(12) If a gas, the number of ampules or vials;
(13) Molybdenum 99 content to USP limits; and
(14) The name of the patient or the words "Physician's Use Only" in the absence of a patient name.

(n) When the prescription is for a therapeutic or blood-product radiopharmaceutical, the patient name shall appear on the label. The requirements of this paragraph shall be met when the name of the patient is readily retrievable from the physician upon demand.

(o) The immediate inner container label of a radiopharmaceutical to be dispensed shall be labeled with:

(1) The name of the pharmacy;
(2) The standard radiation symbol;
(3) The words "Caution Radioactive Material";

(4) The identity of the radionuclide;

(5) The chemical form;

(6) The name of the procedure; and

(7) Serial number of the radiopharmaceutical.

(p) When a radiopharmaceutical is dispensed under the authority of an investigational new drug application (IND), the nuclear pharmacy records shall include an investigator's protocol for the preparation of the radiopharmaceutical, and a letter from the manufacturer or sponsor indicating that the physician requesting the radiopharmaceutical is a qualified investigator.

(q) Each nuclear pharmacy shall have a current copy of the United States Pharmacopeia/National Formulary (USP/NF), USP-DI, and a current copy of state and federal rules and regulations governing the safe storage, handling, use, dispensing, transport and disposal of radiopharmaceuticals.

Source.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8316, eff 3-26-05, EXPIRED: 3-26-13

New.  #10812, eff 4-18-15

Ph 405.04 Minimum Equipment. The pharmacy shall have at least the following equipment:

(a) A radionuclide dose calibrator;

(b) A refrigerator;

(c) A single or multiple channel scintillation counter with well-type NaI (Tl) or Ge (Li) detector;

(d) A radiochemical fume hood and filter system with air sampling equipment;

(e) An area survey meter;

(f) At least 2 Geiger Mueller survey meters including one high-range meter;

(g) A microscope and hemacytometer;

(h) A laminar air flow hood and appropriate supplies to ensure sterile practices for parenteral solutions;

(i) Syringe and vial radiation shields;

(j) A lead-shielded drawing station;

(k) Decontamination supplies;

(l) Supplies to perform quality assurance testing;

(m) Lead transport shields for syringes and vials; and

(n) United States Department of Transportation approved USA Type A - 7A transport containers and other labels and supplies for shipping radioactive materials.
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

Source.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8316, eff 3-26-05, EXPIRED: 3-26-13

New.  #10812, eff 4-18-15
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

CHAPTER Ph 500 ETHICAL STANDARDS

PART Ph 501 CODE OF ETHICS

Ph 501.01 Standards of Conduct.

(a) The ethical standards set forth in this part shall bind all licensees, and violation of any such standard shall be a basis for the imposition of disciplinary sanctions.

(b) A licensed pharmacist shall:

(1) Hold the health and safety of patients to be of first consideration and render to each patient the full measure of his/her ability as an essential health practitioner;

(2) Never condone the dispensing, promoting or distributing of drugs or medical devices, or assist therein, which are not of good quality, which do not meet standards required by law or which lack therapeutic value for the patient;

(3) Always strive to perfect and enlarge his/her professional knowledge;

(4) Utilize and make available his/her knowledge as might be required in accordance with his/her best professional judgment;

(5) Observe the law, uphold the dignity and honor of the profession, and accept its ethical principles;

(6) Not engage in any activity that will bring discredit to the profession and shall expose, without fear or favor, illegal or unethical conduct in the profession;

(7) Seek at all times only fair and reasonable remuneration for services rendered;

(8) Never agree to or participate in transactions with practitioners of other health professions or any other person under which fees are divided or which might cause financial or other exploitation in connection with the rendering of their professional services;

(9) Respect the confidential and personal nature of professional records, except in emergency situations where the best interest of the patient requires or the law demands, and shall not disclose such information to anyone without patient authorization;

(10) Not agree to practice under terms or conditions which tend to interfere with or impair the proper exercise of professional judgment and skill, which could cause a deterioration of the quality of his/her service or which require him/her to consent to unethical conduct;

(11) Refrain from advertising professional services in a manner which is misleading to the public or which conveys by implication that the services of fellow pharmacists are unethical or inferior;

(12) Maintain a sanitary and orderly prescription department which is fully equipped and stocked to meet the needs of the community; and
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(13) Fulfill all professional obligations conscientiously and with due respect for the physical and well-being of the community, and, uphold at all times the standards of the profession of pharmacy.

Source. #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05; ss by #10455, eff 11-1-13
CHAPTER Ph 600  LIMITED RETAIL DRUG DISTRIBUTOR

Statutory Authority: RSA 318:51-b

PART Ph 601  LICENSING OF LIMITED RETAIL DRUG DISTRIBUTORS

Ph 601.01 License Required.

(a) EXPIRED

(b) EXPIRED

(c) EXPIRED

(d) EXPIRED

(e) The prescribed fee for annual and renewal licenses for limited retail drug distributors shall be:

(1) For clinics under contract with the department of health and human services (DHHS), $150; and

(2) For methadone maintenance/detoxification treatment centers, $250.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New. #8572, eff 2-23-06; amd by #9139-B, eff 4-25-08; paragraphs (a)-(d) EXPIRED: 2-23-14

Ph 601.02 Obtaining and Filing a License Application.

Source. #8572, eff 2-23-06, EXPIRED: 2-23-14

Ph 601.03 Application Contents.

Source. #8572, eff 2-23-06, EXPIRED: 2-23-14

Ph 601.04 Consultant Pharmacist.

Source. #8572, eff 2-23-06, EXPIRED: 2-23-14

Ph 601.05 Changes in Supporting Information. The applicant shall notify the board, immediately, of any changes of information from that which was submitted on the original application pursuant to Ph 601.03. Failure to report changes shall result in the imposition of a $25 administrative fee. No license shall be issued until all fees are paid in full.

Source. #8572, eff 2-23-06; ss by #9139-B, eff 4-25-08

Ph 601.06 Renewal Applications.

Source. #8572, eff 2-23-06, EXPIRED: 2-23-14

Ph 601.07 Temperature.

Source. #8572, eff 2-23-06, EXPIRED: 2-23-14
Ph 601.08 Quarantine.

Source. #8572, eff 2-23-06, EXPIRED: 2-23-14

Ph 601.09 Space.

Source. #8572, eff 2-23-06, EXPIRED: 2-23-14

Ph 601.10 Security.

(a) - (g) EXPIRED

(h) The consultant pharmacist shall develop a distribution system, which shall prevent the illegal diversion of drugs. Where applicable, the inventory of all schedule II controlled substances and other controlled drugs as required by federal law stored in any area of the facility, shall be checked by 2 persons at least every 24 hours and accountability records shall be completed by the nursing or medical staff and maintained on-site for inspection by the consultant pharmacist, except:

(1) In situations at the methadone maintenance/detoxification facilities that result in only one staff member being present, the inventory shall be counted, signed, dated and shall be “cosigned” immediately upon the presence of a second staff member.

(2) At no time shall there lapse more than 72 hours before this inventory verification by a second party.

Source. #8572, eff 2-23-06; amd by #9139-B, eff 4-25-08; paragraphs (a)-(g) EXPIRED: 2-23-14

Ph 601.11 Dispensing Practices.

(a) Drugs shall be dispensed only by or in the presence of and under the supervision of a pharmacist, physician, advanced registered nurse practitioner, physician assistant, or registered nurse, as identified in RSA 318:42,VII (a), in compliance with state and federal pharmacy-related laws and rules.

(b) In the case of methadone maintenance/detoxification facilities and according to the provisions of RSA 318:42, VII(a), the dispensing of narcotics is extended to employees of the clinic, authorized in writing according to the provisions of 21 CFR 1301.74(i) of the federal law.

(c) EXPIRED

(d) EXPIRED

Source. #8572, eff 2-23-06; amd by #9139-B, eff 4-25-08; paragraphs (c) and (d) EXPIRED: 2-23-14

Ph 601.12 Deliveries.

Source. #8572, eff 2-23-06, EXPIRED: 2-23-14

Ph 601.13 Access to Drug Supply.

(a) Only the pharmacist, physician, advanced registered nurse practitioner, physician assistant or registered nurse, as identified in RSA 318:42,VII (a), shall have access to the drug supply.
(b) In the case of methadone maintenance/detoxification facilities, access to the drug storage area may also be extended to licensed practical nurses provided such authorization is granted, in writing, according to the provisions of 21 CFR 1301.72(d) of the federal law.

(c) Methadone maintenance/detoxification facilities shall supply the board with a list of all individuals that have been granted access to the drug supply, and, should this list change, the board shall be notified, in writing, within 72 hours of such changes.

Source. #8572, eff 2-23-06; ss by #9139-B, eff 4-25-08

Ph 601.14 Dispensing Records.

(a) EXPIRED

(b) EXPIRED

(c) Methadone maintenance/detoxification facilities shall maintain a dispensing log, completed by the nursing or medical staff, containing the following information:

(1) - (4) EXPIRED

(5) Patient identification number;

(6) - (8) EXPIRED

(d) EXPIRED

Source. #8572, eff 2-23-06; amd by #9139-B, eff 4-25-08; paragraphs (a)-(c)(4), (c)(6)-(7), and (d) EXPIRED: 2-23-14

Ph 601.15 Prescription Labels.

Source. #8572, eff 2-23-06, EXPIRED: 2-23-14

Ph 601.16 Labeling Exemption.

Source. #8572, eff 2-23-06, EXPIRED: 2-23-14

Ph 601.17 Violations.

Source. #8572, eff 2-23-06, EXPIRED: 2-23-14
Chapter 700 Standards of Practice

Part 701 References and Definitions

Ph 701.01 Applicability. The provisions of this chapter shall apply to, and impose duties upon, all pharmacists, pharmacies, manufacturers, wholesalers and distributors holding licenses issued by the board.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10903, eff 8-5-15

Ph 701.02 Definitions. Except where the context makes another meaning manifest, the following words mean:

(a) "Adulterated drug" means any drug:

(1) That is contaminated, decomposed, deteriorated, sub-potent, super-potent, or otherwise unsafe for administration to man or other animals;

(2) Which has been manufactured, composed, prepared, stored, or dispensed in such a manner which may cause it to be contaminated, decomposed, deteriorated, sub-potent, super-potent, or otherwise unsafe for administration to man or other animals; and

(3) Which can be defined as an adulterated drug under the provisions of RSA 146:4 or federal law.

(b) "Device" means an instrument, apparatus, implement, machine, contrivance, implant, or other similar or related article, including any component part or accessory, which is required under federal law to bear the label, "Caution: Federal or State law requires dispensing by or on the order of a physician" or "Rx only".

(c) "Distributor" means a person or persons who supplies or facilitates the supply of prescription drugs or devices to someone other than the patient, including, but not limited to, manufacturers, repackagers, brokers and wholesale drug distributors.

(d) "Drug outlet" means all pharmacies, limited retail drug distributors, durable medical equipment providers, dispensing practitioners, hospitals, drug abuse treatment centers, retail stores, penal institutions, infirmaries, clinics and federal or state facilities that are engaged in delivery or distribution of drugs.

(e) "Drug room" or "medication room" means that room or area in an institution used to store prescription drugs.

(f) "Electronic prescription" means transmission of information in electronic form, modem to modem, by way of electronic equipment.

(g) "Facsimile prescription" means the transmission of the exact visual image of a document by way of electronic equipment.

(h) "Institution" means a health care facility which provides inpatient care and includes:
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(1) Hospitals;

(2) Nursing homes;

(3) Extended care facilities;

(4) Residential care facilities;

(5) Infirmary;

(6) Correctional facilities; and

(7) Clinics.

(i) "Institutional pharmacy" means an area in an institution where drugs are stored, manufactured, compounded, dispensed, or issued to other areas or departments of the institution.

(j) "Misbranded drug" means a drug:

(1) Whose label misrepresents the contents or is misleading;

(2) If dispensed by prescription, a drug whose label does not comply with the provisions of RSA 318 or RSA 318-B; and

(3) Which can be defined as a misbranded drug under the provisions of RSA 146 or federal law.

(k) "NH Pharmacy Law Book" means a publication of the board which contains RSA 318, RSA 318-B and Ph 100 through Ph 1700 and any future chapters.

(l) "Prescriber" means a practitioner, duly authorized by statute, who issues a drug order or prescription.

(m) "Principal" means an officer, director, or primary stockholder of a business entity or corporation.

(n) "Professional corporation" as used in these rules means a corporation organized under RSA 294-A for the purpose of providing professional services in the field of medicine, dentistry, veterinary, podiatry, or any other profession in which individual practitioners can lawfully possess, dispense, or distribute prescription drugs.

(o) “Signature” means:

(1) The handwritten name of an individual affixed by the hand of that individual to a document;

(2) An electronic sound, symbol, or process attached to or logically associated with a record and executed or adopted by a person with the intent to sign a document or record; or

(3) An electronic signature.

(p) "Traditional physician-pharmacist-patient relationship" means a situation whereby the pharmacist knows either the physician, the patient, or both, and/or can readily and easily check on factors concerning the prescription.
(q) "Unit-dose" means a single-unit container that is designed to hold a quantity of drug product intended for administration as a single dose and labeled with the identity, quantity and/or strength, name of the manufacturer, lot number and expiration date of the drug product.

(r) "Unprofessional conduct" means conduct and practices which are hostile to the protection of public health, safety and welfare and includes:

1. Knowingly engaging in any activity which violates state and federal statutes, regulations and rules governing the practice of pharmacy;
2. Knowingly dispensing an outdated product;
3. Knowingly charging for more dosage units than are actually dispensed;
4. Knowingly altering prescriptions or other records which the law requires the pharmacy or pharmacist to maintain;
5. Knowingly dispensing medication without proper authorization or prescription;
6. Defrauding any persons or government agency receiving pharmacy services; or
7. Placing a signature on any affidavit pertaining to any phase of the practice of pharmacy which the pharmacist knows to contain false information.

(s) "USP" means the United States Pharmacopeia, published by and issued under the authority of the Pharmacopeial Convention, which provides recognized standards and specifications for all drug entities in the U.S.

(t) "Wholesale drug distribution" means distribution of prescription drugs other than to the patient, including, but not limited to distribution by manufacturers, repackers, own label distributors, jobbers, and wholesale drug distributors.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New. #6181-B, eff 2-5-96; amd by #6933, eff 2-1-99; amd by #7535, eff 8-1-01; paragraph (a) EXPIRED: 2-5-04; amd by #8316, eff 3-26-05; amd by #8572, eff 2-23-06; paragraphs (b), (d)-(m), and (p)-(s) EXPIRED: 2-1-07; paragraph (o) EXPIRED: 8-1-09; paragraph (a) EXPIRED: 3-26-13; paragraphs (c) and (n) EXPIRED: 2-23-14

New. #10903, eff 8-5-15

Ph 701.03 References. Persons subject to these rules shall comply with the following regulations and statutes as cited:

(a) RSA 146, Purity and Branding of Foods and Drugs;
(b) RSA 318, Pharmacists and Pharmacies;
(c) RSA 318-B, the New Hampshire Controlled Drug Act;
(d) 21 USC Sections 300 through 369, the Federal Food, Drug, and Cosmetic Act;
(e) 21 CFR 1300 to end; and

(f) The United States Pharmacopeia.

Source.  #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by 
#2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-
B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8316, eff 3-26-05, EXPIRED: 3-26-13

New.  #10903, eff 8-5-15

PART Ph 702 PHARMACY FACILITIES AND EQUIPMENT

Ph 702.01 Area, Space and Fixtures.

(a) Pharmaceuticals, library and equipment shall be housed in a well-lit and ventilated room or
department with clean and sanitary surroundings devoted primarily to the preparation and dispensing of
prescriptions. This portion of a pharmacy shall have an area of not less than 200 square feet. No area shall
be included in the calculation of the minimum area required by this section unless that area is used
exclusively for the storage, manufacture, preparation and dispensing of drugs.

(b) The space primarily devoted to the preparation of prescriptions shall be equipped with:

(1) Necessary counters and storage cabinets;

(2) A sink with hot and cold running water with plumbing that meets all applicable state and
local building codes; and

(3) Temperature controlled storage equipment used exclusively for drugs.

Source.  #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by 
#2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-
B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8316, eff 3-26-05; amd by #8572, eff 2-23-06; 
paragraphs (a)-(b)(2) and (c) EXPIRED: 3-26-13; 
paragraph (b)(3) EXPIRED: 2-23-14

New.  #10903, eff 8-5-15
Ph 702.02 Temperature. The temperature in any area wherein drugs are stored, manufactured, prepared or dispensed, shall be monitored and at all times be in compliance with the standards established by the manufacturer.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10903, eff 8-5-15

Ph 702.03 Quarantine. Any drug which is expired, adulterated or misbranded shall be removed from routine stock and held in a specifically designated area of the pharmacy pending proper and safe disposition.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10903, eff 8-5-15

Ph 702.04 Security.

(a) That portion of a pharmacy wherein drugs are stored, manufactured, prepared or dispensed, shall, when the pharmacy is open, be so designed and constructed as to prevent entry into that area by any person or persons without the knowledge of the pharmacist then on duty, or when the pharmacy is not open to the public, by the activation of an alarm.

(b) The pharmacy shall be equipped with an alarm system which, when activated, shall emit a signal which is:

(1) Audible to the average person situated outside the building in which the pharmacy is located, at least 100 feet from any point of that building, or the public highway closest to that building, whichever is greater; or

(2) Observable by a law enforcement or security officer situated in a station of the law enforcement organization having jurisdiction over the area in which the pharmacy is located, an office of a security organization serving the area in which the pharmacy is located or an alarm monitoring company.
(c) In order to be adequately designed and constructed, within the meaning of this section, a pharmacy shall be equipped with a door or doors capable of being locked.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10903, eff 8-5-15

Ph 702.05 Limitations on Access.

(a) Except as provided in Ph 704.01(b), no pharmacy shall be open unless a pharmacist is on duty. At all times during which a pharmacist is not on duty in the pharmacy, all entry to the licensed pharmacy area shall be barred by locked doors.

(b) The keys to the locked doors of a pharmacy shall be possessed only by:

(1) The pharmacist-in-charge;

(2) Pharmacists in the employ of the pharmacy;

(3) A non-pharmacist owner or owners of the pharmacy; or

(4) Store management and security personnel when secured in a locked safe in the building and kept separate from the alarm code needed to access the secured area.

(c) A non-pharmacist owner or owners may be on the premises of a pharmacy which he or she owns in the absence of a pharmacist employed by that pharmacy, provided that the pharmacy is not open and no drugs are prepared, dispensed or sold.

(a) Except as provided in Ph 704.01(b), no pharmacy shall be open unless a pharmacist is on duty in the pharmacy. At all times during which a pharmacist is not on duty in the pharmacy, all entry to the pharmacy shall be barred by locked doors.

(b) The keys to the locked doors of a pharmacy shall be possessed only by:

(1) The pharmacist-in-charge;

(2) Pharmacists in the employ of the pharmacy;

(3) A non-pharmacist owner or owners of the pharmacy;

(4) Qualified security personnel as shall be designated by the pharmacist-in-charge and a list of such personnel shall be filed with the board by the pharmacist-in-charge; or

(5) If an institutional pharmacy, administrators of the institution and those nurses designated to enter the pharmacy to obtain medications in emergency situations.

(c) A non-pharmacist owner or owners may be on the premises of a pharmacy which he or she owns in the absence of a pharmacist employed by that pharmacy, provided that the pharmacy is not open and no drugs are compounded, dispensed or sold.
(d) The pharmacy permit shall be issued to the pharmacy in the name of the pharmacist-in-charge, who shall have sole control and responsibility for the operation of the pharmacy in accordance with all laws and rules pertaining to the practice of pharmacy in this state and always in the best interest of public health and safety.

Source.  #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New.  #6181-B, eff 2-5-96; amd by #6933, eff 2-1-99; paragraphs (a)-(c) EXPIRED: 2-5-04; amd by #8316, eff 3-26-05; amd by #8572, eff 2-23-06; para. (d) EXPIRED: 2-1-07; ss by #10456, eff 11-1-13; ss by #10903, eff 8-5-15


Source.  #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8316, eff 3-26-05, EXPIRED: 3-26-13

New.  #10903, eff 8-5-15

Ph 702.07 Minimum Standard of Technical Equipment and Stock.

(a) Permit holders shall provide that every pharmacy shall have contained therein, at all times, the following:

1. Prescription labels showing the name, address, telephone number and DEA number of the pharmacy;

2. All equipment, supplies and drugs that are relevant to the practice and meet all state and federal standards;

3. An assortment of auxiliary labels or the software to produce them;

4. A current reference library, or the ability to access references on line, as determined by the pharmacist-in-charge to meet the needs of the practice, and specialties, of that pharmacy and the patients it serves; and
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(5) A current copy, with supplements, or the ability to access online within the licensed area the New Hampshire Pharmacy Law Book.

Source.  #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New.  #6181-B, eff 2-5-96; ss by #6933, eff 2-1-99, EXPIRED: 2-1-07

New.  #10102, eff 3-30-12; ss by #10903, eff 8-5-15

PART Ph 703 RECORDS AND REPORTS

Ph 703.01 Recordkeeping Requirements.

(a) The requirements of Ph 703 shall be in addition to all record keeping and reporting requirements contained in all federal and state rules and regulations.

(b) Hard copies of prescription records and reports shall not be required to be maintained if they can be reproduced on demand with the exception of Schedule II – V controlled substance prescriptions not presented in electronic format.

(c) Hardcopy prescriptions for Schedule II – V controlled substances shall be kept on file for 4 years.

Source.  #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8316, eff 3-26-05, EXPIRED: 3-26-13

New.  #10903, eff 8-5-15

Ph 703.02 Prepackaging of Drugs.

(a) Drugs shall be prepackaged in quantities suitable for internal distribution only by a pharmacist or by supportive personnel under the direct supervision of a pharmacist.

(b) The label of a prepackaged unit shall indicate the:

(1) Brand name and strength of the drug, or if no brand name, the generic name, strength, and name of the manufacturer or distributor;

(2) Assigned in-house, quality control lot number;

(3) Expiration date; and

(4) Quantity of the drug, if the quantity is greater than one.

(c) The pharmacist who prepackages or supervises prepackaging shall maintain a written or electronic record that contains at least the following information:

(1) Name of the drug, strength, and dosage form;
(2) Assigned in-house, quality control lot number;

(3) Manufacturer or distributor;

(4) Manufacturer's lot number;

(5) Expiration date;

(6) Quantity per prepackaged unit;

(7) Number of prepackaged units;

(8) Date packaged;

(9) Identifier of the prepacker; and

(10) Signature of the responsible pharmacist.

(d) Stock packages, repackaged units, and control records shall be quarantined together until checked/released by the pharmacist.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10903, eff 8-5-15 (from Ph 703.03)

Ph 703.03 Controlled Drug Losses.

(a) The pharmacist-in-charge or pharmacist on duty shall report to the board in writing, any theft or significant loss of controlled substances within one business day. The pharmacist-in-charge shall complete a New Hampshire Drug Loss Form (revised 5/2015) or DEA 106 Form and mail or fax to the board as soon as the investigation into the loss is complete or within 30 days of the discovery of the loss.

(b) All instances of diversion shall be reported.

(c) A pharmacy shall keep a perpetual inventory for all Schedule II drugs and actual counts shall be verified monthly. The inventory reports shall be maintained for a minimum of 2 years.

(d) A pharmacy shall consider a controlled drug loss to be significant when:

(1) The percentage of dosage units of a specific drug exceeds 2% of monthly dispensing volume; or

(2) Fifteen or more dosage units are not accounted for.

(e) The written report referenced in (a) shall contain at least the following:

(1) Date of discovery;

(2) The identity of the person making the discovery;

(3) The name and location of the pharmacy from which the drug is missing;
(4) Name, strength, dosage form, NDC and quantity of the missing drug(s); and

(5) The cause of the controlled drug loss as determined by the investigation.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10903, eff 8-5-15 (from Ph 703.04)

Ph 703.04 Automated Data Processing Systems. All pharmacies shall have an automated data processing system to be used for the storage of original, faxed or written prescriptions and the retrieval of refill information for all prescription orders including, but not limited to, controlled substances in schedules II, III, IV, and V, as defined in 21 CFR 1308.11-1308.15 subject to the following conditions:

(a) The system shall provide security against improper manipulation or alteration of stored records. Individual access codes shall be unique to each licensed location and shall not be available to any other location;

(b) A pharmacy shall make arrangements with the supplier of data processing services or materials to assure that the pharmacy continues to have access to the complete prescription and dispensing records if the relationship with such supplier terminates for any reason. A pharmacy shall assure continuity in the maintenance of records for the protection of public health;

(c) Any computerized system shall provide on-line retrieval, via electronic display or hard-copy printout, of all prescription records processed at that licensed location;

(d) The information required by (c) above shall include:

(1) The original prescription number;

(2) The date of issuance of the original prescription order by the practitioner;

(3) The full name and address of the patient;

(4) The name, address, and DEA registration number of the practitioner, when applicable;

(5) The name, strength, dosage form, quantity prescribed, and quantity dispensed if different from the quantity prescribed, and the total number of refills authorized by the prescribing practitioner, if any; and

(6) The date each fill is dispensed.

(e) Any computerized system shall also provide on-line retrieval, via electronic display or hard-copy printout, of the current refill history of all prescription orders including controlled substances in schedules III, IV, and V;

(f) This refill history shall include:

(1) The name of the drug;

(2) The date of refill;
(3) The quantity dispensed;

(4) The identification code, or name or initials of the dispensing pharmacist for each refill; and

(5) The total number of refills dispensed to date for that prescription order;

(g) Documentation of the fact that the refill information entered into the computer each time a pharmacist refills an original prescription order, including refill orders for a schedule III, IV, or V controlled substances is correct shall be provided by:

1. A hard-copy printout of each day's controlled substance prescription order refill data which shall be verified, dated, and signed by each pharmacist who refilled such prescription orders; or

2. In lieu of such a printout, the pharmacy shall maintain a bound log book, or separate file, in which each individual pharmacist involved in such dispensing shall sign a statement each day, attesting to the fact that the refill information entered into the computer that day has been reviewed by him and is correct as shown;

(h) The hard-copy printout or log book referenced in (g) above shall be kept at the pharmacy, in a separate file, for a period of 4 years from the dispensing date;

(i) The computerized system shall have the capability of producing a printout of all refill data and shall include:

1. A refill-by-refill audit trail for any specified strength and dosage form of any controlled substance;

2. Name of the prescribing practitioner;

3. Name and address of the patient;

4. Quantity dispensed on each refill;

5. Date of the dispensing for each refill;

6. Name or identification code of the dispensing pharmacist; and

7. The number of the original prescription order;

(j) In any computerized system employed by a user pharmacy, the central recordkeeping location shall be capable of sending the printout to the pharmacy within 48 hours;

(k) Each pharmacy using an automated data processing system shall maintain on file a hard copy of all controlled substance prescriptions in schedules II, III, IV and V, excluding electronic, preserving all information contained on the original written or oral prescription. Any computer generated material shall be affixed to the rear of the prescription, leaving the face of the prescription intact; and
Computer-produced prescription container labels shall comply with RSA 318:47-a, RSA 318:47-b and RSA 318-B:13, II.

Source. #2118, eff 8-12-82: ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10903, eff 8-5-15 (from Ph 703.05)

Ph 703.05 Federal DEA #222 Order Forms. All used DEA #222 order forms or any successor forms shall be maintained on the premises to which the forms and the corresponding DEA permit number were issued. In the case of on-line ordering of CII drugs, all records of such shall be maintained on said premises and be readily retrievable. Such records shall meet the requirements of federal laws and regulations and shall be maintained for a period of not less than 2 years.

Source. #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New. #6181-B, eff 2-5-96; ss by #6933, eff 2-1-99, EXPIRED: 2-1-07

New. #10066, eff 12-28-11; ss by #10903, eff 8-5-15 (from Ph 703.06)

Ph 703.06 Inspection Report. The current compliance inspection report of the licensed location, conducted by the board, shall be kept on file in the prescription department.

Source. #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10903, eff 8-5-15 (from Ph 703.07)

PART Ph 704 DISPENSING OF DRUGS AND DEVICES

Ph 704.01 Presence of Pharmacists.

(a) Prescription drugs and devices shall be dispensed only in the presence of and under the immediate supervision of a pharmacist except as provided in (b).

(b) Whenever the pharmacy is staffed by a single pharmacist, the pharmacist may take a lunch/rest break for a period of up to 30 minutes without closing the pharmacy.

(c) Pharmacy technicians, NH certified pharmacy technicians and pharmacy interns may remain in the pharmacy if the pharmacist on duty reasonably believes that the security of the prescription drugs will be maintained in his or her absence and in accordance with the following:
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(1) Lunch breaks shall be scheduled as close as possible to the same time each day in order for the patients to become familiar with the approximate times of lunch breaks;

(2) The pharmacist shall remain on the store premises, within the building, during the lunch break and be available for emergencies. Emergencies shall be defined by the pharmacist.

(3) Whenever the pharmacist temporarily leaves the prescription department for a lunch break, a sign indicating that there is no pharmacist on duty shall be conspicuously displayed in full view of patients approaching the prescription department service area. The signage shall also indicate the time when the pharmacist is to return;

(4) Only pharmacy technicians or pharmacy interns authorized by the pharmacist on duty may remain in the pharmacy while the pharmacist is on lunch break;

(5) During such times that the pharmacist is temporarily absent from the pharmacy, only pharmacy technicians or pharmacy interns duly authorized by the pharmacist on duty may continue to perform non-discretionary duties as delineated by the pharmacist. However, all duties performed by the technicians or interns shall be reviewed by the pharmacist upon his or her return from break;

(6) When a pharmacist is not in the pharmacy, there shall be no dispensing or sale of new prescriptions that the pharmacist has checked and are waiting to be picked up nor shall counseling be provided by the pharmacy technician or pharmacy intern;

(7) New, written prescriptions, presented in person by the patient or his agent, may be accepted by the pharmacy technician or pharmacy intern and the processing of that prescription, up to the final check, may occur during the absence of the pharmacist. However, no new prescriptions may be dispensed or sold until the final check is completed by the pharmacist on his or her return;

(8) New prescriptions conveyed by telephone shall be accepted by a NH certified pharmacy technician or pharmacy intern or when authorized by the pharmacist or the caller shall be instructed to call back or a telephone number obtained for the pharmacist to call upon his or her return;

(9) During the pharmacist’s absence, prescription refills which have been previously prepared and checked by a pharmacist may be picked up by the patient or his agent. If the patient has no questions, the sale may proceed as normal with the patient signing a statement indicating the refusal of counseling by the pharmacist. If the patient desires counseling, he or she shall be asked to wait for the pharmacist to return from break or, alternatively, asked to leave a telephone number for the pharmacist to call later that day; and

(10) Telephone refill orders as well as refill requests presented, in person, by the patient or his agent, may be accepted by the pharmacy technician or intern and such refill orders may be processed by the technician or intern up to the final check. However, no such refill orders shall be dispensed or sold until the final check is completed by the pharmacist on his or her return from break.

(d) A pharmacist who takes a lunch break in compliance with this section shall continue to be responsible for the operation and security of the pharmacy department. Therefore if in the professional judgment of the pharmacist, for reasons of security or otherwise, the pharmacist determines that the pharmacy should close during his or her absence, then the pharmacist shall close the pharmacy. All pharmacy technicians, NH certified pharmacy technicians and pharmacy interns shall leave the pharmacy department.
during his or her absence. A sign informing the public of the pharmacist’s return shall be conspicuously posted.

(e) Pharmacists shall follow company protocols in leaving the pharmacy department unattended for any reason, such as but not limited to counselling patients, giving immunizations, or rest room breaks.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New. #6181-B, eff 2-5-96; ss by #6933, eff 2-1-99; ss by #8572, eff 2-23-06; ss by#10459, eff 11-1-13; ss by #10903, eff 8-5-15

Ph 704.02 Pre-signed Prescription Blanks. No person shall possess, and no pharmacy shall have within it, any document signed by a prescriber which, if completed, would be usable as a prescription.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10903, eff 8-5-15

Ph 704.03 Transmission of Prescription Drug Order by Prescriber.

(a) A prescription drug order may be transmitted to a pharmacy by an authorized prescriber or his designated agent in writing, orally, by facsimile or electronically.

(b) A facsimile or electronically transmitted prescription drug or device order shall:

(1) Be sent to the pharmacy of the patient's choice;

(2) For a non-controlled substance prescription drug or device order, include:

a. The name of the patient;

b. The name, strength, and quantity of the drug prescribed;

c. Any directions specified by the prescribing practitioner;

d. The name and address of the prescribing practitioner which shall be printed or typewritten;

e. The prescribing practitioner’s phone number for verbal confirmation; and

f. The date the prescription was ordered;

(3) For a schedule III through V controlled substance prescription drug order, as defined in RSA 318-B:1-b and transmitted by facsimile or as an electronic prescription, shall include:

a. The name and address of the patient;
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

b. The name, strength, and quantity of the drug prescribed;

c. Any directions specified by the prescribing practitioner;

d. The full name of the prescribing practitioner which shall be printed, rubber stamped, or typewritten above or below his or her handwritten signature;

e. The address of the prescribing practitioner;

f. The federal drug enforcement administration (DEA) number assigned to the prescribing practitioner; and

g. The date the prescription was ordered;

(4) A facsimile prescription for a schedule II controlled substance shall not be accepted as an original written prescription except in circumstances when:

a. A prescription prepared in accordance with RSA 318-B:9, III and IV, and issued for a schedule II substance, as defined in RSA 318-B:1-b, to be compounded for the direct administration to a patient in a private residence, long-term care facility, or hospice setting, by parenteral, intravenous, intramuscular, subcutaneous or intraspinal infusion may be electronically transmitted, by the practitioner or the practitioner’s designated agent to the dispensing pharmacy. The printed copy of the transmission shall serve as the original written prescription and shall be maintained in accordance with the provisions of RSA 318-B:9, I;

b. A prescription prepared in accordance with RSA 318-B:9, III and IV, and issued for a schedule II substance, as defined in RSA 318-B:1-b, for a resident of a long-term care facility may be electronically transmitted by the practitioner or the practitioner’s designated agent to the dispensing pharmacy. The printed copy of the transmission shall serve as the original written prescription and shall be maintained in accordance with the provisions of RSA 318-B:9, I; and

c. A prescription prepared in accordance with RSA 318-B:9, III and IV, and issued for a schedule II substance, as defined in RSA 318-B:1-b, for a patient enrolled in a hospice care program, may be electronically transmitted by the practitioner or the practitioner’s designated agent to the dispensing pharmacy. The practitioner or the practitioner’s designated agent shall note on the prescription that the patient is a hospice patient. The printed copy of the transmission shall serve as the original written prescription and shall be maintained in accordance with the provisions of RSA 318-B:9, I;

(5) The pharmacist shall exercise professional judgment regarding the accuracy and authenticity of the electronically transmitted prescription drug order which shall be consistent with existing federal or state laws and rules;

(6) For controlled substances in schedules II, III, IV or V, as defined in RSA 318-B:1-b, a pharmacy may receive an electronically transmitted drug order from the prescriber for filling provided that it is transmitted in accordance with federal law with an electronic signature meeting security requirements required by the Drug Enforcement Agency (DEA) for electronic prescriptions; and

(7) The devices used for the receipt of facsimile or electronically transmitted prescription drug orders shall be located in the prescription department of the pharmacy in order to protect patient confidentiality and to assure security.
Ph 704.04 Transfer of Prescriptions. Original prescription drug order information for drugs may be transferred between pharmacies for the purpose of refill dispensing subject to the following:

(a) The transfer of controlled drug prescriptions shall be communicated between 2 licensed pharmacists;

(b) The transfer of non-controlled prescriptions shall be communicated between 2 licensed pharmacists, NH certified pharmacy technicians or pharmacy interns; and

(c) The transferring pharmacist, NH certified pharmacy technician or pharmacy intern shall notate in the computer record the following:

1. That a copy has been issued, the date of transfer, and the name of the pharmacist transferring the prescription; and

2. The name, address, phone number and DEA number of the pharmacy to which the prescription was transferred and the name of the pharmacist receiving the prescription information.

(d) When a prescription is transferred, no further refills shall be issued by the transferring pharmacy.

(e) The pharmacist receiving the transferred prescription information shall:

1. Include the word "transfer" on the face of the transferred prescription; and

2. Provide all information required to be on the prescription including the:

   a. Patient's name and address;
   b. Doctor's name and address;
   c. Date of issuance of the original prescription and date of transfer;
   d. Number of valid refills remaining and date of last refill;
   e. Pharmacy name, address, and original prescription number from which the prescription information was transferred;
   f. Full name of the transferor pharmacist, NH certified pharmacy technician or pharmacy intern; and
   g. DEA registration number of the transferor pharmacy for controlled substances.

(f) The pharmacist shall maintain both the original and transferred prescription as if they were original prescriptions.
(g) A transferred prescription may be refilled, without limitation, up to the number of remaining refills, as originally authorized, or up to one year from the date of original issue, whichever shall occur first.

(h) The transfer of original prescription drug order information for controlled substances listed in Schedule III, IV or V shall conform to the requirements of 21 CFR 1306.26 and shall be permissible between pharmacies on a one-time basis and shall not be further transferred.

(i) For non-controlled drugs, 2 or more pharmacies may establish and use a common electronic file to maintain required dispensing information. Pharmacies using such a common electronic file shall not be required to physically transfer prescriptions or information for dispensing purposes between or among pharmacies participating in the same common prescription file, except that any such common file shall contain complete and adequate records of such prescription and the date and location of each refill dispensed and provisions shall be made to assure that the number of authorized refills shall not be exceeded.

(j) New or on-hold prescription orders for prescription orders other than control substances may be transferred to another pharmacy provided that a copy of the original prescription or electronic transmission is provided to the pharmacy accepting the transfer.

(k) New or on-hold prescription orders for controlled substances shall not be transferred to another pharmacy.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96
New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05; amd by #8572, eff 2-23-06; ss by #10458, eff 11-1-13; ss by #10903, eff 8-5-15

Ph 704.05 Schedule V Controlled Substances. All cough syrups containing codeine shall not be dispensed without a prescription.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96
New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10903, eff 8-5-15

Ph 704.06 Drug Product Selection.

(a) Unless instructed otherwise by the person receiving the drug pursuant to the prescription, a pharmacist filling a prescription for a drug product prescribed by its trade or brand name may select a therapeutically equivalent drug product with the same established name, active ingredient, strength, quantity and dosage form as the drug product identified in the prescription.

(b) Therapeutically equivalent drugs shall include only those drug products listed in "Approved Prescription Drug Products with Therapeutic Equivalence Evaluations" Published by the United States
Department of Health and Human Services, according to RSA 146-B:2, I, or any written notification or confirmation from the federal Food and Drug Administration (FDA) that a drug product is a therapeutically equivalent drug product.

(c) The pharmacist shall not select an equivalent drug product:

(1) If the prescriber handwrites “medically necessary” on the written prescription;

(2) If when ordering a prescription orally, the prescriber specifies that the prescribed drug is medically necessary; or

(3) If the prescription is electronically transmitted, the prescriber includes a statement on the face of the prescription indicating medically necessary.

(d) The pharmacist shall not select an equivalent drug product unless its price to the purchaser is less than the price of the prescribed drug product.

(e) Unless the prescriber instructs otherwise, the label for every drug product dispensed shall include the product's trade or brand name, if any, or its established generic name and the name of the manufacturer, packer or distributor, using abbreviations such as the National Drug Code (NDC) number if necessary. In the interest of public health and safety, the pharmacist may, when dispensing a generic drug, include the brand name on the prescription label following the generic name. The brand name, however, shall be preceded or followed with the word "sub", indicating substituted for, or "I.C.", indicating interchanged for or “generic for”.

(f) The pharmacy file copy or computer record of every dispensing of a prescription shall include the trade or brand name, the name of the manufacturer, and the packer or distributor of the drug product dispensed.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05; amd by #8572, eff 2-23-06; paragraphs (a), (d), (e), & (g) EXPIRED: 3-26-13; paragraphs (b), (c), and (f) EXPIRED: 2-23-14

New. #10903, eff 8-5-15

Ph 704.07 Return of Drugs and Devices.

(a) Except as provided in Ph 704.07(b), no drug, prescription, device, sickroom supply or item of personal hygiene which has left control of the pharmacist or pharmacy and is returned to the pharmacy shall be resold or re-dispensed after such item has been taken from the premises by the patient or the patient’s representative, subject to the pharmacist’s professional judgement.

(b) Exceptions to Ph 704.07 (a) shall include:

(1) Orthopedic appliances;

(2) Crutches;

(3) Canes;
(4) Wheelchairs;
(5) Hospital beds;
(6) Bed rails;
(7) Trapezes;
(8) Other durable equipment that can be properly sanitized; and
(9) Medications dispensed in unit-dose packaging to institutionalized patients.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New. #6181-B, eff 2-5-96; amd by #6933, eff 2-1-99; paragraph (b) EXPIRED: 2-5-04; amd by #8316, eff 3-26-05; paragraph (a) EXPIRED: 2-1-07; paragraph (b) EXPIRED: 3-26-13

New. #10903, eff 8-5-15

Ph 704.08 Prescription Pick-up and Delivery.

(a) No person licensed under the provisions of RSA 318, shall enter into or participate in any arrangement or agreement whereby prescriptions may be left at, picked up from, accepted by, or delivered to any store, shop or location not licensed as a pharmacy.

(b) This section shall not prohibit a licensee from picking up prescriptions or delivering prescribed medications at the residence of the patient, or directly to the patient at his/her workplace, or at the institution in which the patient is confined, by means of an employee or by use of a common carrier.

(c) In situations where it is in the best interest of the patient due to behavioral health issues or homelessness a licensee may deliver the prescriptions to an authorized party for distribution to the patient.

(d) Drugs with special handling or storage requirements that will be administered by the practitioner may be delivered directly to the practitioner’s office such as radio pharmaceuticals or frozen Immunizations.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10903, eff 8-5-15

Ph 704.09 Dispensing Adulterated or Misbranded Drugs. A pharmacist shall not dispense or sell to the public any drug which is adulterated or misbranded. After notice and opportunity for a hearing, a
pharmacist who is found by the board to have knowingly dispensed or otherwise sold for consumption an adulterated or misbranded drug, shall be subject to disciplinary action according to RSA 318:29.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10903, eff 8-5-15

Ph 704.10 Out-of-State Prescriptions. Prescriptions written by physicians in a state other than New Hampshire may be dispensed to a patient only when the traditional physician-pharmacist-patient relationship exists.

Source. #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10903, eff 8-5-15

Ph 704.11 Pharmacist-in-Charge/Corporate Entity Requirements/Duties.

(a) Pharmacists looking to serve as a Pharmacist-in-Charge (PIC) shall:

(1) Have worked as a pharmacist for a minimum of 2 years post-graduation;

(2) Complete and pass with a minimum of 80% an exam designed by the board to assess the knowledge of the candidate in regard to their responsibilities as PIC; and

(3) Work a minimum of 20 hours per week at the location where he/she serves as PIC except when absent due to scheduled vacation or other authorized leave.

(b) Pharmacist in charge duties shall include:

(1) Responsibility for the control of all drugs issued or dispensed in the pharmacy where he/she practices;

(2) Ensuring written policies and procedures for the procurement, storage, compounding and dispensing of drugs are in place;

(3) Ensuring that all staff pharmacists are familiar with and in compliance with the established policies and procedures;

(4) Establishing and supervising the recordkeeping system for the purchase, sale, possession, storage, and repackaging of drugs;

(5) Maintaining the security of the prescription department and its contents;
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(6) Determining who will have keys and access to the pharmacy with the exception of security personnel;

(7) Establishing quality assurance guidelines to ensure the medication dispensed is in conformance with the prescription received;

(8) Prohibiting the presence of adulterated or misbranded drugs in the pharmacy;

(9) Ensuring compliance with the provisions of RSA 318 and RSA 318-B and any other state or federal pharmacy-related laws or rules;

(10) Supervising personnel in the prescription department; and

(11) Ensuring all personnel involved in the preparation and dispensing of prescriptions are properly licensed or registered with the board.

(c) Pharmacists may serve as a pharmacist-in-charge for a maximum of 2 pharmacies, providing that one of these pharmacies shall be in an institution requiring the services of a pharmacist only on a part-time basis.

(d) The corporate entity or permit holder shall be responsible for the following:

(1) Written policies and procedures for the procurement, storage, compounding and dispensing of drugs;

(2) Ensuring that all staff pharmacists are familiar with and in compliance with the established policies and procedures;

(3) Determining which security personnel will have keys and access to the pharmacy and inform the pharmacist in charge;

(4) Establishing procedures and policies to ensure the security of the pharmacy department when a pharmacist is working alone and needs to leave the licensed area for counseling, immunizations, lunch or rest room breaks;

(5) Providing online access to the New Hampshire law book, medical reference material and other state and local sites for reference by their pharmacists;

(6) Assuming all the responsibilities of the pharmacist in charge in an interim period when the pharmacist in charge has been vacated unexpectedly; and

(7) Supplying adequate staffing to assist the board of pharmacy during scheduled routine inspections to assist with the retrieval of records when hard copy records are not maintained.

Source. #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05; ss by #10457, eff 11-1-13; ss by #10903, eff 8-5-15

Ph 704.12 Termination of Pharmacist-in-Charge Notice. Whenever a pharmacist-in-charge shall cease performing that function, that pharmacist-in-charge shall notify the board in writing of the date upon which the cessation of that function is effective. That pharmacist-in-charge shall remain responsible for
compliance, in the pharmacy in which he or she was the pharmacist-in-charge, with all pharmacy related statutes and rules until the effective date of termination.

Source.  #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New.  #8316, eff 3-26-05, EXPIRED: 3-26-13
New.  #10903, eff 8-5-15

Ph 704.13 Termination of Pharmacist-in-Charge - Inventory. Whenever a pharmacist-in-charge shall cease performing that function in a pharmacy, the new pharmacist-in-charge shall, within 3 days, cause to be completed a written inventory of all controlled substances located in that pharmacy. The record of that inventory shall be retained in the pharmacy for a minimum of 2 years.

Source.  #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New.  #8316, eff 3-26-05, EXPIRED: 3-26-13
New.  #10903, eff 8-5-15

Ph 704.14 Prescription Refill Limitations.

(a) Prescriptions bearing "PRN", "Ad lib", or other similar prescription refill designation permitting the pharmacist to refill the prescription as needed by the patient, shall be refilled only in keeping with the number of doses ordered and according to the directions for use, and in no instance shall such prescription be refilled beyond one year from the date of issue. If additional medication is needed thereafter, the original prescription shall be voided and a new prescription obtained.

(b) No prescription containing either specific or "PRN" refill authorization shall be refilled when the pharmacist has knowledge that the prescribing practitioner ceases to practice due to:

(1) License suspension or revocation;

(2) No longer maintaining a valid license;

(3) Prescribing limitations placed on a practitioner's license by any state or federal licensing agency which impact on certain previously refillable prescriptions; or

(4) Death.
(c) Notwithstanding (a) and (b) above, the pharmacist may dispense an additional refill supply according to the provisions of Ph 704.15.

Source. #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New. #6181-B, eff 2-5-96; amd by #6933, eff 2-1-99; paragraphs (a) and (b) EXPIRED: 2-5-04; amd by #8316, eff 3-26-05; paragraph (c) EXPIRED: 2-1-07; paragraphs (a) and (b) EXPIRED: 3-26-13

New. #10685, EMERGENCY, eff 10-6-14, EXPIRED: 4-6-15

New. #10903, eff 8-5-15

Ph 704.15 Prescription Refill - Interim Supply. A pharmacist may refill a prescription drug order, including controlled substances listed in Schedules III, IV and V, without the authorization of the prescribing practitioner, provided that:

(a) A failure to refill the prescription might result in an interruption of a therapeutic regimen or create patient suffering;

(b) The pharmacist is unable to contact the practitioner due to:

   (1) A natural or man-made disaster has occurred which prohibits the pharmacist from being able to contact the practitioner; or

   (2) The practitioner’s office being closed without a practitioner on call;

(c) The quantity of prescription drug dispensed does not exceed a 30 day supply for maintenance medications;

(d) The pharmacist informs the patient or the patient's agent at the time of dispensing that the interim supply shall be final and that authorization by the practitioner shall be required for future refills;

(e) The pharmacist shall inform the prescribing practitioner of the limited emergency supply, provided to the patient, at the earliest reasonable time; and

(f) The pharmacists exercises professional judgement in refilling the prescription drug order.

Source. #6181-B, eff 2-5-96; amd by #6933, eff 2-1-99; paragraphs (a), (b), (d), and (e) EXPIRED: 2-5-04; amd by #8316, eff 3-26-05; intro. paragraph and (c) EXPIRED: 2-1-07; paragraphs (a), (b), (d), and (e) EXPIRED: 3-26-13

New. #10903, eff 8-5-15
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

Ph 704.16 Acts Prohibited. Splitting fees, making rebates, or sharing money received for pharmaceutical services, or the donation of and/or the use of equipment with other health practitioners or with health institutions providing patient care shall be deemed by the board to be contrary to the best interests of the patient, and shall therefore be prohibited.

Source. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10903, eff 8-5-15

PART Ph 705 STORAGE OF DRUGS

Ph 705.01 Prescription Drugs. All prescription drugs shall be stored in an area which is under the immediate control of a pharmacist and not accessible to unauthorized persons.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96
New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10903, eff 8-15-15 (from Ph 705.02)

Ph 705.02 Emergency Drug Kits for Long Term Care Facilities/Specialized Care Facilities.

(a) "Emergency drug kit" means a select supply of drugs and/or biologicals located at the licensed institution for the immediate administration to patients/residents upon the order of a practitioner as set forth in rules adopted under RSA 151.

(b) “Automated electronic emergency drug kit” means an automated medication storage system for the immediate administration to patients/residents upon the order of a practitioner as set forth in rules adopted under RSA 151.

(c) “Automated medication dispensing system” means a computerized drug storage device or cabinet designed for use in long term care facilities and other health care institutions.

(d) The placement of controlled substances in emergency drug kits in non-federally registered long term care facilities/specialized care facilities shall be deemed to be in compliance with the Comprehensive Drug Abuse Prevention and Control Act of 1970 provided that:

(1) Controlled substances shall be stored in the emergency drug kit as deemed necessary and jointly approved by the pharmacist in charge and the consultant pharmacist, medical director and the director of nursing services;

(2) The source from which controlled substances for emergency drug kits are obtained shall be a DEA registered hospital, clinic, pharmacy or practitioner;

(3) Controlled substances in emergency drug kits shall be limited to a maximum of 16 separate drug entities with not more than 8 single use containers of each drug entity;

(4) The emergency drug kit containing controlled substances shall be closed with a tamper proof seal and kept in a locked medication room, cart or closet;
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(5) Only the director of nursing services, registered nurse on duty, licensed practical nurse on duty, pharmacist or practitioner shall have access to controlled substances stored in an emergency drug kit;

(6) Controlled substances in emergency drug kits shall be administered to patients only by authorized personnel and only as expressly authorized by an individual practitioner and in compliance with the provisions of 21 CFR 1306.11 and 1306.21;

(7) A usage record shall be contained in the emergency drug kit for each separate drug included which shall be completed by the nursing staff when using any controlled substance or substances from the kit;

(8) The pharmacist shall receive and file for 2 years a copy of all completed usage records;

(9) When the emergency drug kit is opened:
   a. The pharmacist shall be notified by the facility within 24 hours; and
   b. Shift counts shall be done by the nursing staff on all controlled substances until resealed by the consultant pharmacist;

(10) Shift counts of the controlled substances contained in the emergency kit shall not be required when the kit is sealed;

(11) The pharmacist shall check the controlled substances in the emergency drug kit at least monthly and so document inside the kit; and

(12) The placement of controlled substances in emergency drug kits shall be only upon the written authorization of the board of pharmacy.

(e) Automated electronic emergency drug kits shall meet the following conditions:

(1) Real time electronic communication to the provider pharmacy;

(2) For access, employ at least but not limited to:
   a. Bio-Identification; and
   b. Unique individualized password protections assigned by the provider pharmacy;

(3) Automatically generate notice to the provider pharmacy whenever the kit is accessed and provide at least the following information:
   a. Name of individual accessing the kit;
   b. Date and time the kit was accessed;
   c. Name, strength and quantity of drug removed; and
   d. Name of patient for whom the drug was administered; and

(4) Upon restocking the automated electronic emergency drug kit the following conditions shall be met:
a. The filling/restocking of an automated electronic emergency drug kit shall be performed by a licensed pharmacist, physician, physician assistant, advanced practice nurse, registered nurse and registered pharmacy technician.

(5) “Automated medication dispensing system” means a computerized drug storage device or cabinet designed for use in long term care facilities and other health care institutions. An automated medication dispensing system may be used as an electronic emergency drug kit provided the system performs operations or activities relative to the storage, packaging, dispensing and distribution of medications, and which tracks and maintains a record of transaction information;

(6) Automated emergency drug kits shall be allowed as set forth in rules adopted under RSA 151;

(7) Non-controlled legend drugs may be stored in the emergency drug kit in quantities deemed necessary and jointly approved by the pharmacist in charge of the provider pharmacy, consultant pharmacist, medical director and the director of nursing services; and

(8) The placement of controlled substances in automated electronic emergency drug kits in non-federally registered long term care facilities and other health care institutions shall be deemed to be in compliance with the Comprehensive Drug Abuse Prevention and Control Act of 1970 provided that:

   a. Controlled substances shall be selected and stored in the automated electronic emergency drug kits in quantities deemed necessary and jointly approved by the pharmacist in charge and the consultant pharmacist, medical director and the director of nursing services;

   b. Only the director of nursing services, registered nurse on duty, licensed practical nurse on duty, pharmacist, registered pharmacy technician or practitioner shall have access to controlled substances stored in an automated electronic emergency drug kit;

   c. Controlled substances in automated electronic emergency drug kits shall be administered to patients only by authorized personnel and only as expressly authorized by an individual practitioner and in compliance with the provisions of 21 CFR 1306.11 and 1306.21; and

   d. When an automated electronic emergency drug kit is utilized, notification of usage shall be reported in accordance with Ph705.02 (e) (3).

Source.  #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8316, eff 3-26-05, EXPIRED: 3-26-13

New.  #10903, eff 8-15-15 (formerly Ph 705.03)
PART Ph 706  PHARMACEUTICAL CARE STANDARDS

Ph 706.01  Patient Records.

(a) A patient record system shall be maintained by all pharmacies for patients for whom prescriptions are dispensed. The patient record system shall provide for the immediate retrieval of information necessary for the dispensing pharmacist to identify previously dispensed drugs at the time a prescription is presented for dispensing.

(b) The pharmacist or supportive personnel shall make a reasonable effort to obtain, record, and maintain the following information:

(1) The full name of the patient for whom the drug is intended;

(2) The address and telephone number of the patient;

(3) The patient's age or date of birth;

(4) The patient's gender;

(5) A list of all prescription drug orders obtained by the patient at the pharmacy maintaining the patient record during the 12 months immediately preceding the most recent entry showing:

   a. The name of the drug or device;

   b. The prescription number;

   c. The name and strength of the drug;

   d. The quantity and date received; and

   e. The name of the prescriber; and

(6) Pharmacist comments relevant to the individual's drug therapy, including any other information peculiar to the specific patient or drug.

(c) The pharmacist shall make a reasonable effort to obtain from the patient or the patient's agent, and record, any known:

(1) Allergies;

(2) Drug reactions;

(3) Idiosyncrasies; and

(4) Usage of other drugs, including over-the-counter drugs, or medical devices currently being used by the patient.
(d) A patient record shall be maintained for a period of not less than 12 months from the date of the last entry in the profile record. This record shall be a hard copy or a computerized form.

Ph 706.02 Prospective Drug Review.

(a) A pharmacist shall review the patient record and each prescription presented for dispensing for purposes of identifying:

(1) Over-utilization or under-utilization;
(2) Therapeutic duplication;
(3) Drug-disease contraindication;
(4) Drug-drug interactions;
(5) Incorrect drug dosage or duration of drug treatment;
(6) Drug-allergy interactions; and
(7) Clinical abuse or misuse.

(b) Upon recognizing any of the above, the pharmacist shall take appropriate steps to avoid or resolve the problem which might include consultation with the prescriber.

Ph 706.03 Patient Counseling.

(a) Pharmacists shall be required to make a reasonable attempt to counsel the patient or patient’s caregiver in person or by telephone when dispensing the first fill of a new prescription in the following situations:

(1) Prescriptions for patients under the age of 13;
(2) Concentrated medications;
(3) Anticoagulant/antiplatelet medications;
(4) Endocrine medications; and
(5) Anti-infective medications.

(b) Pharmacists, pharmacy interns or New Hampshire certified technicians shall document that counselling was given.

(c) In situations where there is no direct contact with the patient or caregiver including but not limited to nursing homes, assisted living or prisons, supplemental printed information shall be provided.

(d) Upon receipt or delivery of a new prescription, where mandatory counseling is not required, and following a review of the patient's record, a pharmacist or his/her designee, shall orally offer to discuss matters which will enhance or optimize drug therapy with each patient or caregiver of such patient.

(e) Patient counseling shall:

(1) Be by the pharmacist or pharmacy intern and in person, whenever practicable, or by telephone; and

(2) Include appropriate elements of patient counseling, such as the following:
   a. The name and description of the drug;
   b. The dosage form, dose, route of administration, and duration of drug therapy;
   c. Intended use of the drug and expected action;
   d. Special directions and precautions for preparation, administration, and use by the patient;
   e. Common side or adverse effects or interactions and therapeutic contraindications that might be encountered, including their avoidance, and the action required if they occur;
   f. Techniques for self-monitoring drug therapy;
   g. Proper storage;
   h. Prescription refill information;
   i. Action to be taken in the event of a missed dose; and
   j. Pharmacist comments relevant to the individual's drug therapy, including any other information peculiar to the specific patient or drug.

(f) Alternative forms of patient information may be used to supplement patient counseling. Examples shall include written information leaflets, pictogram labels, or video programs.

(g) Patient counseling, as described above shall not be required for inpatients of penal institutions or inpatients of a hospital or long term care facility where other licensed health care professionals are authorized to administer the drugs and drug therapy reviews are conducted on a routine basis.
(h) A pharmacist shall not be required to counsel a patient or agent when the patient or agent refuses such consultation. However, failure to document the patient's refusal of counseling shall imply that counseling was provided.

Source. #5552 INTERIM eff 1-8-93, EXPIRES 5-8-93; ss by #5622, eff 5-8-93; ss by #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10903, eff 8-5-15

PART Ph 707 DISPOSAL AND DESTRUCTION OF CONTROLLED DRUGS

Ph 707.01 Controlled Drug Destruction. Any person authorized to possess controlled drugs and desiring to dispose of such drugs may request destruction of the drugs by the board or request an authorization from the board to destroy such drugs.

Source. #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05; ss by #8572, eff 2-23-06, EXPIRED: 2-23-14

New. #10903, eff 8-5-15

Ph 707.02 Request for Destruction.

(a) A request to destroy controlled drugs shall be in writing and signed by a duly authorized person as defined in (b) below. The itemized written request shall be conveyed to the board office and the destruction process shall not proceed until the authorization is received by the person who made the request.

(b) Personnel authorized to sign a request for controlled drug destruction shall include:

(1) Pharmacist-in-charge, as defined in RSA 318:1, X, practitioners or their designated agents;
(2) Administrators of health care institutions or their designated agent or agents;
(3) Agents of the superior court;
(4) County attorneys;
(5) Director, New Hampshire state police;
(6) Chiefs of local police departments; and
(7) Director, New Hampshire division of public health services or his/her designated agent(s).
(c) The written request shall not be required when a consultant pharmacist, acting as an agent of the pharmacy board, destroys controlled drugs in a licensed long-term care or specialized care facility.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New. #6181-B, eff 2-5-96; amd by #6933, eff 2-1-99; paragraph (a), paragraph (b) intro., subparagraphs (b)(2)-(b)(7), and paragraph (c) EXPIRED: 2-5-04; amd by #8316, eff 3-26-05; amd by #8572, eff 2-23-06; paragraphs (b)(2)-(b)(6) EXPIRED: 3-26-13; paragraphs (a), (b) intro., (b)(1), (b)(7), and (c) EXPIRED: 2-23-14

New. #10903, eff 8-5-15

Ph 707.03 Board Authorized Controlled Drug Destruction.

(a) A consultant pharmacist to a nursing home, group home or assisted living facility shall be designated an agent of the pharmacy board for the sole purpose of destroying controlled drugs at the licensed home or homes for which he or she serves as consultant by filing a written request at the board office, identified in Ph 103.03. The written request shall be on the facility’s letterhead, shall identify the pharmacist as the home's consultant pharmacist, and shall be signed by both the administrator of the facility and the consultant pharmacist.

(b) Once authorization is obtained:

(1) A record of the controlled drugs destroyed shall be made on form # Ph 558 (revised 7/2015) obtained at the board office, identified in Ph 103.03; and

(2) Copies of form # Ph 558 (revised 7/2015) shall be distributed as follows:

   a. The original shall be sent to the board office;

   b. A copy shall be maintained on the premises where the destruction occurred for a period of 4 years; and

   c. A copy shall be retained by the consultant pharmacist/agent making the destruction.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New. #6181-B, eff 2-5-96; amd by #6933, eff 2-1-99; paragraphs (c) and (d) EXPIRED: 2-5-04; amd by #8316, eff 3-26-05; amd by #8572, eff 2-23-06; paragraph (a) EXPIRED: 2-1-07; paragraph (b)-(f) EXPIRED: 2-23-14

New. #10903, eff 8-5-15

Ph 707.04 Controlled Drug Destruction by the Board of Pharmacy.

(a) The destruction of controlled drugs by the board shall occur on the premises of the practitioner, institution or agency requesting the destruction. Destruction shall be carried out by any person so
designated as the authorized agent of the board provided that such agent as well as the person requesting destruction or his or her designee are present during the entire destruction process.

(b) The practitioner or person requesting destruction or their designee shall also be present and shall witness destruction of the controlled drugs.

(c) Witnesses may include:

(1) The practitioner or practitioner’s agent, including a pharmacist;

(2) The administrator or assistant administrator; and

(3) The director of nursing, nursing supervisor or charge nurse.

Source.  #1639, eff 11-1-80; ss by #2260, eff 1-5-83;; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8316, eff 3-26-05, EXPIRED: 3-26-13

New.  #10903, eff 8-5-15

Ph 707.05  Record of Controlled Drug Destruction.

(a) A record of the drugs destroyed shall be made on federal form DEA-41, "Registrant's Inventory of Drugs Surrendered" in accordance with 21 CFR 1307.21, 22. This form may be obtained from the board office, identified in Ph 103.03, or from an office of the Drug Enforcement Administration.

(b) The data recorded on form DEA-41 shall include at least the:

(1) Name, strength, and quantity of the drugs destroyed;

(2) Date, time and place of destruction;

(3) Manner of destruction; and

(4) Signature and title of persons destroying and witnessing destruction of the controlled drugs.

(c) Copies of the form designated in Ph 707.05(a) shall be distributed as follows:

(1) The original shall be maintained at the board office, identified in Ph 103.03; and

(2) A copy shall be retained on the premises of the practitioner, agency, court, or person requesting the destruction.
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(d) A copy of the record of those drugs destroyed shall be maintained on the premises where the destruction occurred for a period of 4 years.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New. #6181-B, eff 2-5-96; amd by #6933, eff 2-1-99; paragraphs (a), (b), and (d) EXPIRED: 2-5-04; amd by #8316, eff 3-26-05; paragraph (c) EXPIRED: 2-1-07; paragraphs (a), (b), and (d) EXPIRED: 3-26-13

New. #10903, eff 8-5-15

Ph 707.06 Exemption. Nothing contained in part Ph 707 shall require the board to destroy any drug if the board determines that to do so would impair law enforcement efforts or the health or safety of any person.

Source. #1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10903, eff 8-5-15

PART Ph 708 TERMINATION OF A PHARMACY OPERATION

Ph 708.01 Notification of Closing.

(a) Written notification to the board shall be filed at least 15 days prior to the date of the anticipated closing. This notice shall indicate the date of closing and the planned disposition of legend drugs including controlled substances and all records thereof.

(b) Written notification to DEA shall be filed at least 15 days prior to the date of the anticipated closing. Compliance with DEA instructions relative to closing procedures shall be required.

(c) At least 5 days prior to the anticipated closing a notice shall be conspicuously posted at the pharmacy indicating the date of closing and the future location of the prescription files. This notice shall be posted for a period of at least 30 days unless removed by the landlord or a new tenant.

Source. #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10903, eff 8-5-15
Ph 708.02 Disposition of Drugs/Records.

(a) Security of the pharmacy shall be maintained while there is a supply of legend drugs including controlled substances on the pharmacy premises. Stable, unopened containers of legend drugs including controlled drugs may be returned by the pharmacy to the wholesaler/manufacturer.

(b) At the time of closing, the remaining supply of controlled substances may be sold or given to another pharmacy provided that:

1. The transfer of schedule II substances shall comply with 21 CFR 1307.14 and 21 CFR 1305.06 by means of a properly executed federal DEA #222 Form;
2. The transfer of schedules III, IV, and V are made by invoice with copies to each party and the board; and
3. Prescription files, executed DEA #222 forms, biennial DEA inventories, applicable invoices, the balance of stock of all controlled substances, and the final printouts required by Ph 703.05(r)(2), shall be transferred as a package.

(c) At the time of closing, in addition to the electronic file transfer of the prescription records the closing pharmacy shall:

1. Provide an up-to-date hard-copy printout of all non-controlled drug prescriptions stored in the automated system and a printout of all controlled drug prescriptions for the current 2 year period as part of the final records of that pharmacy;
2. In lieu of such printout, an electronic back-up of the prescription records for the last 2 year may be provided on electronic media; and
3. In the event that the pharmacy files are not sold to another pharmacy, the closing pharmacy shall make provision for these records to be available to any nearby pharmacy.

(d) If, in the interest of public health and safety, the board determines that after closure of the pharmacy a lack in the security, according to Ph 702.04, of the prescription drugs including controlled substances exists, the licensee shall immediately surrender to the board all prescription drugs including controlled substances and forms and invoices thereof. The drugs so held shall be inventoried, packaged, sealed and stored at the expense of the licensee in a place determined by the board to be appropriately secure. The licensee shall have 60 days after the effective date of the closing to make arrangements for the lawful sale or other disposition of these drugs. Lawful sale and/or disposition of these drugs shall be to a duly licensed person authorized to possess and store prescription drugs including controlled substances. Failing compliance within this 60-day period, such drugs shall then be surrendered to the board for destruction.
(e) Before disposing of any merchandise in the pharmacy, the owner and pharmacist-in-charge shall submit the licensed premises to an inspection by a representative of the board to certify that all prescription drugs including controlled substances have been secured.

Source. #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New. #6181-B, eff 2-5-96; amd by #6933, eff 2-1-99; paragraphs (a), (b), (c) intro., (c)(1)-(2), and (e) EXPIRED: 2-5-04; amd by #8316, eff 3-26-05; paragraphs (c)(3) and (d) EXPIRED: 2-1-07; paragraphs (a), (b), (c) intro., (c)(1)-(2), and (e) EXPIRED: 3-26-13

New. #10903, eff 8-5-15

Ph 708.03 Final Written Report. No later than 20 days after a pharmacy closing, the licensee shall:

(a) Return the pharmacy permit to the board;

(b) Notify the board that all signs and symbols indicating the presence of a pharmacy have been removed;

(c) Notify the board that all labels and blank prescriptions have been destroyed;

(d) Notify the board that the DEA license and all blank DEA #222 forms have been returned to the regional director of the DEA;

(e) File with the board, a copy of the dated inventory of all controlled substances transferred including the name and address of the person(s) to whom these drugs and applicable records were transferred; and

(f) In the case of an involuntary closing, file with the board the final disposition of the drugs as soon as possible after the transfer is made.

Source. #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05, EXPIRED: 3-26-13

New. #10903, eff 8-5-15

PART Ph 709 INSTITUTIONAL PRACTICES

Ph 709.01 Definitions.

(a) “Automated medication supply system” means an electronically controlled system that performs operations or activities relative to the storage and distribution of medications for administration and which collects, controls, and maintains all transaction information.
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(b) “Electronic identifier”, for purposes of paragraph (a) above, means a unique security code or other identifier which specifically identifies the person entering information into a data processing system.

Source. #2260, eff 01-05-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05; ss by #8572, eff 2-23-06; ss by #10225, eff 11-7-12; ss by #10903, eff 8-5-15

Ph 709.02 Licensing and Practice Standards.

(a) A pharmacy permit shall be required for each institution with an on-premise pharmacy. Such permit shall be issued to a pharmacist-in-charge, who shall be licensed in the state of New Hampshire. When an institution procures prescription drugs for its patients only on individual prescriptions for specific patients from an off-premise licensed pharmacy, the institution shall not be required to obtain a pharmacy permit.

(b) If an institution does not have a pharmacy on its premises, it may enter into an agreement with a pharmacy licensed to provide such services. Such agreement shall be in writing and shall state the policy and procedures as required by Ph 709. A copy of the agreement shall be made available by the consultant pharmacist to the board upon request. The consultant pharmacist shall be responsible for the maintenance of all records and the compliance with state and federal laws and rules governing the practice of pharmacy.

(c) An institutional license shall permit the pharmacy to dispense medications to in-patients of the institution, staff or employees of the institution, interim supplies of medication to outpatients in emergency situations and home infusion therapy to contractual patients not requiring hospitalization. If a pharmacist is on the premises, outpatient prescription services may be provided by the pharmacy, on a one-time, no-refill basis, to an ambulatory care patient and any patient who is being discharged with medications related to the patient's hospitalization. Labeling for all outpatient prescriptions shall be according to RSA 318:47-a and RSA 318-B: 11.

(d) Members of the board and/or their agents shall inspect the pharmacy, drug room/medication room and all areas or departments of the facility where drugs are stored, manufactured, compounded, dispensed or distributed to ensure:

(1) That adequate drug security and storage requirements are met;

(2) That proper records are maintained; and

(3) That the facility is in compliance with all local, state and federal drug and pharmacy laws and rules.

(e) Those facilities obtaining prescription drugs only on individual prescriptions for specific patients from an off-premise licensed pharmacy shall not be exempt from inspection.

(f) Each institution shall have a pharmacy and therapeutics committee or a comparable committee of its medical staff. This committee shall be composed of representatives of the medical staff and the pharmacist-in-charge, or a licensed staff pharmacist designated by the pharmacist-in-charge, and representatives of the administrative and nursing departments. The pharmacy representative shall be a voting member of the committee and the committee shall meet at least twice a year. The major functions
of this committee shall be to establish the written policies and procedures governing the practice of pharmacy, use of drugs, drug specifications and drug distribution.

(g) An institutional pharmacy may dispense a generic or therapeutic equivalent that has been approved by the pharmacy and therapeutics committee or its equivalent only to in-patients of the institution, staff or employees of the institution and their dependents, or interim supplies of medication to outpatients in emergency situations.

(h) When applicable, the corporate officer, or the officer’s replacement, who signs the pharmacy permit shall be held accountable, along with the pharmacist-in-charge, regarding compliance to federal, state, and local laws related to the practice of pharmacy. Both individuals shall be held accountable regarding compliance as required by the New Hampshire board of pharmacy or other governmental agency regarding the practice of pharmacy.

(i) When applicable, the corporate officer, or the officer’s replacement, who signs the pharmacy permit, and the pharmacist-in-charge, shall comply with federal, state and local laws related to the practice of pharmacy.

Source. #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New. #6181-B, eff 2-5-96; amd by #6933, eff 2-1-99; paragraphs (a), (b), (d), (e), and (f) EXPIRED: 2-5-04; amd by #8316, eff 3-26-05; amd by #8572, eff 2-23-06; paragraphs (c) & (h) EXPIRED: 2-1-07; ss by #10225, eff 11-7-12; ss by #10903, eff 8-5-15

Ph 709.03 Environment.

(a) The institutional pharmacy shall be enclosed, lockable and alarmed.

(b) The institutional pharmacy shall have adequate space necessary for the storage, compounding, labeling, dispensing and sterile preparation of drugs prepared in the pharmacy.

(c) The institutional pharmacy shall be arranged in an orderly fashion and shall be kept clean.

(d) A sink with hot and cold running water shall be available to all pharmacy personnel.

(e) The institutional pharmacy shall have locked storage for schedule II controlled substances and other controlled drugs requiring additional security.

(f) The institutional pharmacy shall have designated areas for the storage of flammable and caustic materials. Such areas shall meet the requirements set by local and state fire laws.

(g) The institutional pharmacy shall have a designated area for the preparation of sterile products.

Source. #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05; ss by #10225, eff 11-7-12; ss by #10903, eff 8-5-15; ss by #10903, eff 8-5-15
Ph 709.04  **Drug Security.**

(a) Drugs stored in any area or department of the facility shall be plainly labeled and kept in a specifically designated, well-illuminated cabinet, closet or storage area and shall be accessible only to authorized personnel.

(b) When controlled drugs are stored in authorized areas other than in the pharmacy, special locked storage for all controlled substances requiring additional security shall be used.

(c) When using an automated medication supply system, the pharmacist-in-charge or designee shall have the responsibility for developing a secure system to assign, discontinue or change personnel access codes.

(d) A pharmacist or registered pharmacy technician under the direction of a pharmacist shall visit and create a retrievable record, at least monthly, all areas or departments of the institution where drugs, biologicals, pharmaceutical chemicals or other pharmaceutical preparations are stored to ensure that they are properly labeled, have not reached their expiration date and show no signs of deterioration. Any substance not conforming to these standards shall be removed from stock.

(e) A retrievable record of each monthly inspection specified in (d) above shall be maintained in the pharmacy for at least 2 years and shall be available to the board upon request.

(f) The pharmacist-in-charge shall ensure that the areas specified in (d) above are in compliance with federal and state drug laws relative to security, drug distribution and product tampering.

(g) The pharmacist-in-charge shall develop a distribution system which shall prevent the illicit diversion of drugs.

(h) Discrepancies shall be reported to the pharmacy within 24 hours and resolved within 72 hours. Missing or unaccounted controlled drugs shall be reported to the NH board and Drug Enforcement Agency (DEA) as specified by 21 CFR § 1301.76-b.

(i) When an emergency drug kit other than regulated by Ph 705.03, containing controlled substances is opened, shift counts shall be done by the nursing staff on all controlled substances until resealed by a pharmacist.

Source: #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New: #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New: #8316, eff 3-26-05; amd by #8572, eff 2-23-06; ss by #10225, eff 11-7-12; ss by #10903, eff 8-5-15

Ph 709.05  **Dispensing Practices.**

(a) Drugs shall be dispensed only by or in the presence of and under the supervision of a pharmacist, or prescriber in compliance with local, state and federal pharmacy-related laws and rules. Upon the written order of a prescriber a nurse may leave a properly labeled container of any non-controlled drug at the patient's bedside. A licensed nurse shall not dispense or compound drugs except as permitted by RSA 318:42.
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(b) The pharmacy shall dispense medications pursuant of an order from a prescriber. Drugs shall be provided to patients in institutions only on the order of a practitioner legally authorized to write prescriptions. No change in the order for drugs shall be made without the approval of a practitioner qualified to write prescriptions.

(c) Each order pursuant to (b) above shall include at least the:

1. Patient's name and location;
2. Date of the order;
3. Name and dosage of the drug;
4. Directions; and
5. Signature of the prescriber or licensed health care professional receiving the order.

(d) Written policies and procedures shall be adopted which establish the method utilized in the procurement, storage and distribution of drugs in all areas or departments of the facility, and which are consistent with state and federal pharmacy laws and rules.

Source. #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New. #8316, eff 3-26-05; amd by #8572, eff 2-23-06; ss by #10225, eff 11-7-12; ss by #10903, eff 8-5-15

Ph 709.06 Access to the Pharmacy.

(a) Only a pharmacist shall open and close the pharmacy. The pharmacist-in-charge of each institutional pharmacy shall establish written policies identifying specific situations when pharmacy technicians may be present in the pharmacy in the absence of a licensed pharmacist.

(b) In the absence of a pharmacist and in accordance with RSA 318:38,1 licensed nurses, designated for this purpose by the pharmacist-in-charge, may obtain from the pharmacy or night cabinet such drugs as needed in an emergency when these drugs are not available in floor stock supplies.

(c) The authorized nurse may enter the pharmacy area and remove the following:

1. A drug in its original container or a drug prepackaged for use within the facility subject to these rules; or
2. An emergency supply of a drug from the original container to be administered to a specific patient.

(d) The authorized nurse shall leave a copy of the physician's order in the pharmacy or night cabinet and on a suitable form record the following:

1. Name and strength of the drug taken;
2. Dosage form taken;
3. Quantity taken;
Ph 709.07 Drug Control in Ambulatory Patient Treatment Areas.

(a) In the ambulatory patient treatment areas, a medical practitioner may dispense drugs for the immediate needs of the patient, not in excess of a 72-hour supply, except that, for Schedule II controlled substances, a maximum of 48-hour supply shall be allowed, if permitted by the institution. The drug container shall be properly labeled.

(b) If a licensed pharmacist is on the premises, that pharmacist may fill one time, full amount, non-refillable prescriptions for patients for medications related to the ambulatory patient treatment visit.

(c) A readily retrievable record shall be made of all administrations and dispensing of controlled drugs in the ambulatory patient area.

(d) This record shall include:

(1) Name and address of the patient;
(2) Name of the medical practitioner;
(3) Name, strength and quantity of the drug(s);
(4) Date of administration or dispensing; and
(5) Signature or electronic identifier, as defined in Ph 709.01(b), of the agent removing the drug(s) from the inventory.
Ph 709.08  **Investigational Drugs.** Investigational drugs for research shall be used only under the supervision of the principal investigator and shall be approved by an appropriate medical staff committee. Such drugs shall be controlled by the pharmacy and shall be properly labeled. A central unit, which may be the pharmacy, shall be established where essential information on investigational drugs is maintained. Nurses shall be given basic pharmacologic information about the drug before administering.

Source.  #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8316, eff 3-26-05; ss by #8572, eff 2-23-06 ss by #10225, eff 11-7-12; ss by #10903, eff 8-5-15

Ph 709.09  **Purchase of Drugs.**

(a) The pharmacist-in-charge, with the consent of the institution's pharmacy and therapeutics committee or comparable committee of its medical staff shall be responsible for the quality of all drugs, biologicals and pharmaceutical chemicals.

(b) Purchasing of drugs, pharmaceuticals, biologicals, intravenous and irrigation fluids shall be subject to approval of the pharmacist-in-charge with the consent of the institution's pharmacy and therapeutic committee or comparable committee of its medical staff.

(c) Radiopharmaceuticals, blood products, radiopaque media and medical devices may be exempted from the approval and/or control of the pharmacist-in-charge by the institution's pharmacy and therapeutics committee.

Source.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8316, eff 3-26-05; ss by #10225, eff 11-7-12; ss by #10903, eff 8-5-15

PART Ph 710  ADMINISTRATIVE FINES

Ph 710.01  **Liability for Administrative Fines.** Persons subject to the disciplinary authority of the board and other persons subject to administrative fines or penalties under RSA 318:29, IV shall, at the discretion of the board, after notice and an opportunity to be heard, be assessed fines and/or penalties as authorized under RSA 318:29, IV.

Source.  #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96

New.  #6181-B, eff 2-5-96, EXPIRED: 2-5-04

New.  #8316, eff 3-26-05, EXPIRED: 3-26-13; ss by #10903, eff 8-5-15

Ph 710.02  **Severity of Fine.**

(a) The decision to impose a fine and the amount of such fine shall depend on:

1. The severity of harm to the public posed by the violation(s);

2. The number of concurrent and/or repeated violations; and
(3) The frequency of violations committed by the particular licensee, permit holder, or other person.

(b) When no violation of the same type has occurred within the 5 years preceding the board's notice to the respondent, the fine assessed shall not exceed $1,000 per violation upon the licensee and/or $2,000 per violation upon the permit holder.

(c) When a single disciplinary infraction of the same type has occurred within the 5 years preceding the board's notice to the licensee, the fine assessed shall not exceed $2,000 per violation upon the licensee and/or $3,000 per violation upon the permit holder.

(d) When more than one disciplinary infraction of the same type has occurred within the 5 years preceding the board's notice to the licensee, the fine assessed shall not exceed $3,000 per violation upon the licensee and/or $5,000 per violation upon the permit holder.

(e) In the case of continuing violations, a separate fine shall be assessed for each day the violation continues, but the total amount of the fine and the licensee's promptness and cooperativeness in ceasing the prohibited conduct in question shall be considered in assessing the daily fines.

(f) In all cases, the board shall consider:

(1) The nature of the offense;
(2) The purpose of the rule or statute violated;
(3) The licensee's state of mind at the time the offense occurred;
(4) The potential harm to the public health;
(5) The deterrent effect upon other practitioners;
(6) The licensee's willingness to cooperate with the board;
(7) The cost to the board of any formal disciplinary hearings which were necessary;
(8) The licensee's acknowledgment of his or her wrongdoing; and
(9) The nature of any other disciplinary sanctions imposed as a result of the offense in question.

Source. #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED: 1-19-96
New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05, EXPIRED: 3-26-13
New. #10903, eff 8-5-15
CHAPTER Ph 800 PHARMACY TECHNICIANS

Statutory Authority: RSA 318:5-a, X, XI

PART Ph 801 PURPOSE AND SCOPE

Ph 801.01 Purpose and Scope. The provisions of this chapter shall apply to, and impose duties upon, all pharmacy technicians holding registrations issued by the board.

Source. #7535, eff 7-25-01, EXPIRED: 7-25-09
New. #10720, eff 11-22-14

PART Ph 802 DEFINITIONS

Ph 802.01 Definitions. Except where the context makes another meaning manifest, the following definitions shall apply:

(a) “Registered pharmacy technician” means a person employed by a pharmacy who can assist in performing, under the supervision of a licensed pharmacist, manipulative, nondiscretionary functions associated with the practice of pharmacy and other such duties and subject to such restrictions as the board has specified; and

(b) Certified pharmacy technician” means a registered pharmacy technician who has become and who maintains national certification by taking and passing an exam recognized by the board for the purpose of certifying technicians.

Source. #7535, eff 7-25-01, EXPIRED: 7-25-09
New. #10720, eff 11-22-14

PART Ph 803 REGISTRATION

Ph 803.01 Application.

(a) No person shall perform the functions or duties of a pharmacy technician unless such person is registered by the board.

(b) Application form PT-1 for registration of pharmacy technicians in New Hampshire may be obtained from and shall be filed at the office of the board, identified in Ph 103.03.

(c) An applicant for registration as a registered pharmacy technician shall meet the following requirements:

(1) Be at least 16 years of age and either have a high school or equivalent diploma, or be working to achieve a high school or equivalent diploma;

(2) Be of good moral character;

(3) Shall not have been convicted of a drug related felony or admitted to sufficient facts to warrant such findings; and

(4) Shall have 80 hours of on the job training and be registered with the board within 15 days.

(d) Training shall be documented by the pharmacist in charge and be retrievable upon inspection.
(e) A registered pharmacy technician applying for registration as a registered certified pharmacy technician shall meet the following additional requirements:

(1) A registered pharmacy technician shall become eligible to attain certified pharmacy technician status after a minimum of 600 hours of training under the direction of a pharmacist and by passing a nationally recognized certification exam recognized by the board; and

(2) A registered pharmacy technician with duties involving sterile and non-sterile compounding shall complete a board approved training program before applying for certified pharmacy technician status.

(f) Applicants for registration shall submit an application form PT-1 for registration to the board that contains the following:

(1) Name, residence address, home telephone number and social security number of the applicant;

(2) Date and place of birth of the applicant;

(3) Name of current employer and address of employment site; and

(4) Applicant's signature and date.

(g) Shall truthfully answer questions on the form regarding any previous felony convictions or convictions for any drug-related offenses.

(h) Submit with application PT-1 the prescribed fee of $50.

(i) No registered pharmacy technician shall act as a certified pharmacy technician unless their certification is current and in good standing. Anyone who does not maintain certification shall notify the board and the pharmacist in charge within 15 days of the lapse of certification. The person shall immediately become a registered pharmacy technician and shall no longer perform the additional duties of a certified pharmacy technician.

(j) Pharmacy technician applicants with previous out of state experience shall meet the requirements set by the board before obtaining certification status.
(3) Registrant’s registration number;
(4) Name of the pharmacy where employed including former and current, if applicable;
(5) Certification status, if applicable; and
(6) All new violations of law, convictions, fines, disciplines or any registration/certification/license revocations for violation of pharmacy-related drug laws/regulations in this or any other state.

Source. #7535, eff 7-25-01, EXPIRED: 7-25-09
New. #10720, eff 11-22-14

PART Ph 805 REVOCATION AND DENIAL

Ph 805.01 Effect of Revocation and Denial.

(a) The board shall refuse to issue a registration or, after notice and hearing, shall revoke a registration whenever the board finds by the preponderance of the evidence any of the following:

(1) That the applicant does not possess good moral character;
(2) That the applicant, or registrant, has willfully violated any of the provisions of RSA 318, RSA 318-B or the board’s administrative rules;
(3) That the applicant has been convicted of a felony or a misdemeanor resulting from a violation of any federal, state, or local drug or pharmacy-related law, rule or regulation;
(4) That the applicant has attempted to obtain a pharmacy technician registration by fraudulent means;
(5) That the applicant is unable to engage in the performance of pharmacy technician functions with reasonable skill and safety by reason of illness, inebriation, misuse of drugs, narcotics, alcohol, chemicals or any other substance, or as a result of any mental or physical condition;
(6) The suspension, revocation, or probation by another state of the applicant’s license, permit, or registration to practice as a pharmacy technician;
(7) That the applicant refused to appear before the board after having been ordered to do so in writing; or
(8) That the applicant made any fraudulent or untrue statement to the board.

(b) The pharmacist-in-charge shall notify the board, in writing, within 7 calendar days after becoming aware that a pharmacy technician has adulterated, abused, stolen or diverted drugs.

(c) The board shall reinstate a registration after review, provided that the reason for revocation no longer exists, or it is determined that there is no longer a threat to public safety.

Source. #7535, eff 7-25-01, EXPIRED: 7-25-09
New. #10720, eff 11-22-14
PART Ph 806 RENEWAL OF REGISTRATIONS

Ph 806.01 Renewal Registrations Required. All pharmacy technician registrations shall expire annually on March 31.

Source. #7535, eff 7-25-01, EXPIRED: 7-25-09
New. #10720, eff 11-22-14

Ph 806.02 Renewal Application Where Obtained and Filed. Applications for the renewal of a registration for a pharmacy technician may be obtained from, and shall be filed at the office of the board, identified in Ph 103.03.

Source. #7535, eff 7-25-01, EXPIRED: 7-25-09
New. #10720, eff 11-22-14

Ph 806.03 Renewal Application Contents and When Filed. Renewal applications shall be filed with the board in accordance with the following:

(a) Applications for renewal of a registration of a pharmacy technician shall be completed by the technician and the pharmacist in charge on Pharmacy Technician Renewal Form PT-2 last revised September 2014.

(b) The application and the prescribed fee of $50.00 shall be filed with the board by the certified pharmacy technician no later than March 31.

Source. #7535, eff 7-25-01, EXPIRED: 7-25-09
New. #10720, eff 11-22-14

Ph 806.04 Continuing Education Requirements for Certified Pharmacy Technicians.

(a) The board of pharmacy shall not issue registration renewals unless the certified pharmacy technician indicates on the renewal application, and under unsworn falsification, that he/she has completed the minimum required hours of accredited/approved continuing pharmaceutical education courses/programs according to Ph806.04. Incomplete renewal application shall be returned to the applicant.

(b) Continuing education shall be required of all registered active or inactive certified pharmacy technicians who apply for registration renewal.

(c) All certified pharmacy technicians registered in New Hampshire shall acquire 1.0 APCET, AMA Category 1 and 2, or board approved CEU’s during the 12 months immediately preceding the license renewal date of April 1st of which:

(1) At least 0.1 live CEU’s shall be earned in a didactic setting;
(2) At least 0.1 CEU’s shall be earned in error prevention or patient safety; and
(3) Certified pharmacy technicians with duties involving sterile and non-sterile compounding shall complete a minimum of 0.2 CEU’s in the area of compounding or other competencies determined by the board.
(d) Continuing education credits shall not be recognized for any repeat program attended or completed. Repeat programs shall be identified as any program didactic or correspondence which carries the same ACPET, CME or any board of pharmacy program identification number.

(e) The certified pharmacy technician shall retain all certificates and/or other documented evidence of participation in an approved/accredited continuing education program/course for a period of 3 years. Such documentation shall be made available to the board for random audit and/or verification.

(f) Not less than 10% of the registrants shall be randomly selected each year by the board for determinations of compliance with Ph806.04.

Source. #10720, eff 11-22-14

Ph 806.05 Penalty. Any certified pharmacy technician who alters, forges, or intentionally falsifies or causes to be altered, forged or falsified any information, documents, or records required to be kept or submitted by this rule shall be subject to disciplinary action under RSA 318:29, II. Falsification of records shall constitute misconduct.

Source. #10720, eff 11-22-14

Ph 806.06 Excess CEU’s. Excess CEU’s earned in one licensure period shall not be carried forward into the new licensure period for the purpose of fulfilling that year’s continuing education prerequisite for licensure renewal.

Source. #10720, eff 11-22-14

Ph 806.07 CEU’s from Other States. The board of pharmacy shall accept comparable continuing education units which have been approved by other boards of pharmacy provided they meet or exceed the requirements as set forth in Ph 806.

Source. #10720, eff 11-22-14

PART Ph 807 PHARMACY TECHNICIANS – STANDARDS OF PRACTICE

Ph 807.01 Responsibilities and Duties. Persons subject to these rules shall comply with the following:

(a) It shall be the responsibility of the pharmacist-in-charge to identify pharmacy technicians and to assure that such persons are registered with the board as pharmacy technicians within 30 days of employment.

(b) All pharmacy technicians shall wear a name tag, identifying them as a “Registered Pharmacy Technician or “Certified Pharmacy Technician” while on duty, whichever is applicable.

(c) The pharmacist in charge shall determine the duties of each pharmacy technician based upon the needs of the pharmacy. Pharmacy technicians shall be limited to performing tasks in the preparation of prescription and non-prescription drugs and devices and to provide nonjudgmental technical support services, within their respective level.

(d) The pharmacist on duty or the supervising pharmacist may further limit the duties of a pharmacy technician.
(e) The pharmacist shall verify and confirm the correctness, exactness, accuracy and completeness of the acts, tasks, and functions undertaken by the pharmacy technician who assists the pharmacist in the practice of pharmacy.

Source. #7535, eff 7-25-01; amd by #8572, eff 2-23-06; para (d) EXPIRED: 7-25-09; paras. (a)-(c) and (e) EXPIRED: 2-23-14

New. #10720, eff 11-22-14

Ph 807.02 Registered Pharmacy Technician Duties. Registered pharmacy technician duties shall include:

(a) The processing of refill request orders;

(b) The retrieval of prescription files, patient files and profiles and other such records pertaining to the practice of pharmacy;

(c) The counting, weighing, measuring, pouring and reconstitution of prescription medication or stock legend drugs and controlled substances; and

(d) The data entry of prescription orders without supervision providing they annually complete a board approved data entry module.

Source. #10720, eff 11-22-14

Ph 807.03 Certified Pharmacy Technician Duties. Registered certified pharmacy technician duties shall include:

(a) Accepting a new oral telephone order;

(b) Accepting an oral refill authorization from a provider;

(c) Communicating a prescription transfer for a non-control medication to or from another pharmacy that does not maintain a common database;

(d) Communicating orally or in writing, any medical, therapeutic, clinical, or drug information, or any information recorded on a patient profile that does not require professional judgment;

(e) Performing the data entry of a prescription or medication order into the computer without supervision;

(f) The task of reducing to writing a prescription left on a recording or message line. Prescription order can only be deleted by pharmacist on duty;

(g) Preparing or compounding sterile and non-sterile compounds after completing board approved compound training;
(h) Stocking or replenishing of an automated dispensing machine or other stock location. A certified pharmacy technician may check the medications pulled by a pharmacy technician or certified pharmacy technician against the delivery report prior to the refill of the automated dispensing machine or other stock location. A licensed health professional shall check the medication before administering to the patient. The facility shall employ bar coding, radio frequency identification (RFID), or another form of electronic bedside verification.

Source. #10720, eff 11-22-14
CHAPTER Ph 900 MAIL-ORDER PHARMACY

Statutory Authority: RSA 318:37, II

PART Ph 901 PURPOSE AND SCOPE

Ph 901.01 Scope. The provisions of this chapter shall apply to, and impose duties upon, all mail-order pharmacies holding registrations issued by the board.

Source. #7474, eff 4-5-01; ss by #9341, eff 12-4-08; ss by #10663, eff 9-3-14

PART Ph 902 DEFINITIONS

Ph 902.01 “Mail-order pharmacy” means “mail-order pharmacy” as defined in RSA 318:1, VII-b, namely, “a pharmacy that is located in a state of the United States, other than this state, whose primary business is to dispense a prescription drug or device under a prescription drug order and to deliver the drug or device to a patient, including a patient in this state, by the United States mail, a common carrier, or a delivery service. Mail-order pharmacies include, but are not limited to, pharmacies that do business via the Internet or other electronic media.”

Source. #7474, eff 4-5-01; ss by #9341, eff 12-4-08; ss by #10663, eff 9-3-14

PART Ph 903 REGISTRATION

Ph 903.01 Application.

(a) No person shall conduct or operate a mail-order pharmacy located outside of this state by delivering in any manner prescription drugs or prescription devices into this state unless such pharmacy is registered in New Hampshire and a permit has been issued by the New Hampshire board of pharmacy.

(b) Application form MO-1, “Registration of Mail-order Pharmacy,” may be obtained from and shall be filed at the office of the board, identified in Ph 103.03.

(c) Applicants for registration as a mail-order pharmacy shall submit a completed MO-1 that contains the following information:

(1) Name, address, telephone number and Internet address, if applicable, of the pharmacy;

(2) The names, addresses and titles of all principal corporate officers, if incorporated and if unincorporated, partners or owners of the pharmacy;

(3) If a corporation, a certificate of incorporation from the state in which incorporated;

(4) If a limited liability company, partnership or sole proprietorship, a tax ID number;

(5) The name and home-state pharmacist license number of the pharmacist-in-charge of the location listed in number (1) above;

(6) A copy of the pharmacy’s current license, permit, or registration certificate used by the regulatory or licensing agency of the state in which the pharmacy is located, as well as a copy of the current DEA registration, if applicable;
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(7) A copy of the most recent inspection report conducted by the state in which the pharmacy is located;

(8) A list of any and all Internet websites from which the mail-order pharmacy solicits business; and

(9) Signature of the pharmacist-in-charge and date.

(f) As attachments to the completed MO-1, the applicant shall provide the following:

(1) One of the following:

   a. Verified Internet Pharmacy Practice Sites™ accreditation from the National Association of Boards of Pharmacy®; or

   b. The following materials:

      1. At least 2 photographs of the actual existing exterior, including the pharmacy signage, of the building in which the pharmacy will be or is currently located;

      2. At least 2 photographs of the prescription department as viewed by an approaching patron;

      3. At least 4 photographs of the prescription department as viewed from the interior, showing the prescription compounding area, refrigerator, water facilities and pharmaceutical inventory storage area; and

      4. Scaled drawings of the pharmacy and drug storage area.

(2) A prescription label, containing the name, address and phone number of the pharmacy, that would be used on finished prescription products mailed to NH residents;

(3) A sample copy of a printed patient medication profile that shall include the following information:

   a. Name and address of the patient;

   b. Name, address and DEA registration number of the prescriber;

   c. Name, strength and quantity of drug dispensed;

   d. Assigned prescription number;

   e. Date of original filling; and

   f. Date of refill(s); and

(4) Copies of the following documents:

   a. A copy of an inspection report, created within the last 12 to 18 months, which documents compliance with the State of New Hampshire board of pharmacy rules regarding sterile compounding of injectable drugs and non-sterile compounding in compliance with the United States Pharmacopeia Chapter 797 and Chapter 795 pursuant to RSA 318:14-a performed by:

      1. Your home state’s board of pharmacy;
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

2. Other responsible state or national regulatory agency; or

3. New Hampshire board of pharmacy approved third party entity.

b. A signed attestation by the pharmacist-in-charge stating there is a policy and procedures manual available showing compliance with USP 795 and 797; and

c. A hood certification inspection report completed under dynamic conditions, not at rest, within the last 6 months; and

(5) The prescribed fee which shall be $1,000.

(g) Failure to comply with any of the provisions of Ph 903 shall result in denial of a permit.

(h) Any person or pharmacy whose pharmacy business fits the definition of a mail-order pharmacy and delivers prescription drugs or prescription devices to New Hampshire residents from more than one out-of-state pharmacy shall register each such pharmacy separately.

Source.  #7474, eff 4-5-01; amd by #9139-B, eff 4-25-08; ss by #9341, eff 12-4-08; ss by #10663, eff 9-3-14

PART Ph 904 REGISTRATIONS – CHANGES IN SUPPORTING DATA

Ph 904.01 Reporting Changes.

(a) The mail-order pharmacy to which a registration has been issued shall within 30-days of any change of information supplied in the original application, notify the board.

(b) The notice required pursuant to (a) above shall contain:

(1) Current New Hampshire registration number of the pharmacy;

(2) Name of the pharmacy, old and new, if applicable;

(3) Address of the pharmacy, old and new, if applicable;

(4) Name of the pharmacist-in-charge, old and new, if applicable; and

(5) Name(s), addresses and titles, of new corporate officers, or partners, or owners.

(c) A new registration shall be required for a change of ownership of an established pharmacy to a successor business entity which results in a change in the controlling interest in the pharmacy.

Source.  #7474, eff 4-5-01; ss by #9341, eff 12-4-08; ss by #10663, eff 9-3-14

PART Ph 905 REVOCATION AND DENIAL

Ph 905.01 Effect of Revocation and Denial.

(a) The board shall refuse to issue a registration or shall revoke a registration whenever the board determines that a mail-order pharmacy, its pharmacist-in-charge, owner(s) or corporate officer(s) has, after notice and opportunity for a hearing, except pursuant to (c) below, committed an act such as but not limited to:
(1) Made a materially false representation or withheld material information in connection with obtaining its registration;

(2) Been found guilty of any felony in connection with the practice of pharmacy or distribution of drugs within the past 5 years;

(3) Made false representations in connection with the practice of pharmacy that endanger or are likely to endanger the health or safety of the public, or that defraud any person;

(4) Failed to comply with RSA 318:37, II, the provisions of Ph 900, or both;

(5) Based on an investigation of a complaint resulting from the dispensing of prescription drugs or prescription devices to a resident of New Hampshire been found to be negligent:
   a. By the board of pharmacy of the state in which the pharmacy is located; or
   b. By the New Hampshire board of pharmacy if the board of pharmacy of the state where the pharmacy is located failed to initiate an investigation of such complaint within 45-days after referral of the complaint from the New Hampshire board of pharmacy; or

(6) Been found guilty of any violation of federal, state or local drug law or have entered into any agreement to resolve violations of such.

(b) A mail-order pharmacy shall notify the board within 15 days of any order or decision by a board of pharmacy, or any other state or federal agency, imposing disciplinary action on the pharmacy. Notwithstanding the provisions of paragraph (a) above, if the license, permit or registration in the state where the pharmacy is located, is suspended or revoked, then the pharmacy’s registration in New Hampshire shall, after notice and opportunity for hearing, be suspended or revoked for the same period of time.

(c) Notwithstanding the above the board shall issue a registration or not revoke if:

   (1) No harm resulted from the actions of the applicant or registrant;
   (2) There was no intent to violate any provisions of RSA 318;
   (3) Corrective action has been taken by the registrant;
   (4) Remunerations have been made to the affected party(s); and
   (5) The board determines the action is unlikely to occur again.

PRT Ph 906 RENEWAL OF REGISTRATIONS

Ph 906.01 Renewal Registrations Required. All mail-order pharmacy registrations shall expire annually on December 31.
Ph 906.02 Renewal Application Where Obtained and Filed. Applications for the renewal of a registration for a mail-order pharmacy may be obtained from, and shall be filed at the office of the board, identified in Ph 103.03 or online.

Source. #7474, eff 4-5-01; ss by #9341, eff 12-4-08; ss by #10663, eff 9-3-14

Ph 906.03 Renewal Application Contents and When Filed. Renewal applications shall be filed with the board in accordance with the following:

(a) Applications for renewal of a registration for a mail-order pharmacy shall be made on form MO-2 “Application for Renewal of Registration for Mail-order Pharmacy”;

(b) Each applicant shall provide the following documents via fax, mail, or scanned and emailed to the board, or in the case of items (6) and (7) directly on the renewal form, in order for the renewal application to be processed by December 31st:

1. A copy of an inspection report, created within the last 12 to 18 months, which documents compliance with the State of New Hampshire board of pharmacy rules regarding sterile compounding of injectable drugs and non-sterile compounding in compliance with the United States Pharmacopoeia Chapter 797 and Chapter 795 pursuant to RSA 318:14-a, performed by;
   a. Your home state’s board of pharmacy;
   b. Other responsible state or national regulatory agency; or
   c. New Hampshire board of pharmacy approved third party entity;

2. A signed attestation by the pharmacist-in-charge stating there is a policy and procedures manual available showing compliance with USP 795 and 797;

3. A hood certification inspection report completed under dynamic conditions, not at rest, within the last 6 months;

4. Copy of the pharmacy’s current home state pharmacy license/permit;

5. Copy of the pharmacy’s current federal DEA permit if shipping controlled substances;

6. Name, address, telephone number and Internet address, if applicable, of the pharmacy;

7. The names, corporate or business addresses and titles, of all principal corporate officers, if incorporated, or all partners or owners of the pharmacy if not incorporated;

8. The application and the prescribed fee of $1,000; and

9. Signature of the pharmacist-in-charge and date.

Source. #7474, eff 4-5-01; amd by 9139-B, eff 4-25-08; ss by #9341, eff 12-4-08; ss by #10663, eff 9-3-14

Ph 906.04 Failure to Comply. Failure to comply with any of the provisions of Ph 906 shall result in non-renewal of the pharmacy permit.

Source. #10663, eff 9-3-14
PART Ph 907 CONDITIONS OF REGISTRATION

Ph 907.01 Compliance. As conditions of registration, the mail-order pharmacy shall:

(a) Maintain at all times a valid unexpired permit, license, or registration to conduct the pharmacy in compliance with the laws of the state in which it is a resident;

(b) Maintain in readily retrievable form, records of legend drugs, devices, or both dispensed to New Hampshire patients;

(c) Supply upon request, any and all information needed by the board to carry out its responsibilities under the statutes and rules pertaining to mail-order pharmacies;

(d) Provide for a toll-free telephone communication consultation between New Hampshire patients and a pharmacist at the mail-order pharmacy who has access to the patient’s records, and ensure that such toll-free telephone number(s) shall be placed upon the label affixed to each prescription container;

(e) Provide to the board, upon request, a copy of the policies and procedures governing:

1) Normal delivery protocols and times;

2) Any special packaging or procedures used in delivering temperature-sensitive drug products;

3) The procedure to be followed if the patient’s medication is not available at the mail-order pharmacy, or if delivery will be delayed beyond the normal delivery time;

4) The procedure to be followed upon receipt of a prescription for an acute illness, which shall include a procedure for delivery of the medication to the patient from the mail-order pharmacy at the earliest possible time, such as courier delivery, or an alternative that assures the patient the opportunity to obtain the medication at the earliest possible time; and

5) The procedure to be followed when the mail-order pharmacy is advised that the patient’s medication has not been received within the normal delivery time and that the patient is out of medication and requires interim dosage until mail prescription drugs become available;

(f) All finished prescription products shipped to New Hampshire residents shall be shipped in tamper-evident envelopes or boxes;

(g) A mail-order pharmacy shall not dispense or sell to the public, any drug which is adulterated or misbranded;

(h) A mail-order pharmacy shall supply, upon request from the board, a statement of origin of any specific drug dispensed to a New Hampshire resident; and

(i) Any mail-order pharmacy shipping finished prescription products into the State of New Hampshire shall use the address, but without the name of the pharmacy, on file with the New Hampshire board of pharmacy as the return address on the labels of any package shipped into the State of New Hampshire. The return address shall be placed on the package in a clear and prominent manner.

Source. #7474, eff 4-5-01; ss by #9341, eff 12-4-08; ss by #10663, eff 9-3-14
CHAPTER Ph 1000  EMERGENCY CONTRACEPTION - EXPIRED

PART Ph 1001  COLLABORATIVE PRACTICE FOR EMERGENCY CONTRACEPTION

Ph 1001.01  Collaborative Practice Authorized. Notwithstanding any other provisions of law, a licensed pharmacist who has completed the training required in Ph 1001.02 may initiate emergency contraception drug therapy in accordance with the provisions of Ph 1001.

Source. #8447, INTERIM, eff 10-14-05, EXPIRED: 4-12-06

New. #8708, eff 8-23-06, EXPIRED: 8-23-14

Ph 1001.02  Education and Training.

(a) Any pharmacist initiating emergency contraception drug therapy shall complete a minimum of 0.2 CEU’s, 2 didactic/live hours, of approved training and education prior to participating in the delivery of emergency contraception drug therapy.

(b) Programs for training and education, referenced in (a) above shall be:

(1) Accredited by the Accreditation Council for Pharmacy Education (ACPE); or

(2) Approved by the board of pharmacy according to Ph 403.01(b).

(c) Programs for training and education, as referenced above, shall include study materials and instruction in the following content areas:

(1) Mechanisms of action, contraindication, drug interaction, and monitoring of emergency contraception drug therapy;

(2) Current standards for prescribing emergency contraception drug therapy;

(3) Identifying indications for use of emergency contraception drug therapy;

(4) Interviewing patient to establish need for emergency contraception drug therapy;

(5) Counseling patient regarding the safety, efficacy and potential adverse effects of drug products for emergency contraception;

(6) Evaluating patient’s medical profile for drug interaction;

(7) Referring patient follow-up care with primary healthcare provider;

(8) Informed consent;

(9) Record management;

(10) Management of adverse events, including identification, appropriate response, documentation and reporting;

(11) Management and response to negative public opinion; and
Ph 1001.03 Emergency Contraception Collaborative Agreement.

(a) Each arrangement between a licensed pharmacist and an authorized prescriber relating to the distribution to a patient of emergency contraception drugs shall be documented in a signed collaborative agreement in accordance with form Ph EC-1, which may be obtained from the office of the board identified in Ph 103.03.

(b) By signing the collaborative agreement, which may be modified according to the authorized practitioner, both the pharmacist and the authorized prescriber agree and acknowledge that:

1. The licensed pharmacist shall provide the patient with drug information concerning dosage, potential adverse side effects, and follow-up contraceptive care;

2. The collaborative agreement shall be effective for a period of 2 years unless rescinded in writing earlier by either the pharmacist or the authorized prescriber, with written notice to the other, or unless the board of pharmacy invalidates the agreement or changes the terms of the agreement;

3. At the time the collaborative agreement expires or is rescinded, the licensed pharmacist shall not have authority to dispense emergency contraceptives until another collaborative agreement with an authorized prescriber is completed;

4. Each drug therapy prescription authorized by the prescriber and dispensed by the pharmacist shall be documented in a patient profile; and

5. No refills shall be permitted and the pharmacist shall not be authorized to provide a written, oral or electronic prescription enabling the patient to further obtain emergency contraception pursuant to the patient’s immediate receipt of drug therapy.

(c) Additionally, the licensed pharmacist and the authorized prescriber shall include in the collaborative agreement the following:

1. The name, address, phone number and signature of the licensed pharmacist;

2. The name, address, phone number and signature of the authorized prescriber;

3. A statement indicating the purpose of the collaborative agreement is to permit emergency contraception drug therapy and to ensure that the patient receives appropriate information from the licensed pharmacist regarding the drug therapy;

4. The procedures to be followed by the licensed pharmacist when the patient requests drug therapy, including any applicable referrals;

5. Any limitation agreed upon by both the licensed pharmacist and the authorized prescriber including, but not limited to, approved drugs that may not be dispensed to the patient;

6. A statement that the label placed on the drug therapy product shall contain the names of both the pharmacist and the authorized prescriber of this agreement;
(7) An informed consent format to be used by the licensed pharmacist to inform the patient about the emergency contraception drug therapy; and

(8) A patient assessment format for each patient obtaining emergency contraception drug therapy shall be completed and signed by the licensed pharmacist on form Ph EC-3, which may be obtained from the office of the board identified in Ph 103.03.

(d) The informed consent referenced in (c)(7) above, shall be signed by both the licensed pharmacist and the patient on form Ph EC-2, which may be obtained from the office of the board identified in Ph 103.03.

Source. #8447, INTERIM, eff 10-14-05, EXPIRED: 4-12-06

New. #8708, eff 8-23-06, EXPIRED: 8-23-14

Ph 1001.04  Informed Consent.

(a) The licensed pharmacist shall provide the patient with an informed consent form, in accordance with form Ph EC-2, which may be obtained from the office of the board identified in Ph 103.03.

(b) The informed consent form shall include at least the following:

(1) The indications for use of emergency contraception;

(2) The mechanism of action of the medication;

(3) The appropriate method for taking the medication;

(4) The possible reactions after taking the medication; and

(5) The circumstances that may require follow-up with a physician.

(c) After the patient has read, and/or reviewed with the licensed pharmacist, the statements specified on the informed consent form, both the patient and the licensed pharmacist shall sign and date the form.

Source. #8447, INTERIM, eff 10-14-05, EXPIRED: 4-12-06

New. #8708, eff 8-23-06, EXPIRED: 8-23-14

Ph 1001.05  Patient Assessment.

(a) The licensed pharmacist shall perform a patient assessment, in accordance with form Ph EC-3, which may be obtained from the office of the board identified in Ph 103.03.

(b) The patient assessment form shall include at least the following:

(1) Patient’s name and address;

(2) Patient’s date of birth;

(3) Personal information which requires the use of emergency contraception; and
(4) Determination of any known allergies to medications/drugs.

Source.  #8447, INTERIM, eff 10-14-05, EXPIRED: 4-12-06
New.  #8708, eff 8-23-06, EXPIRED: 8-23-14

Ph 1001.06 Provision of Standardized Fact Sheet Required.

(a) For each emergency contraception drug therapy initiated pursuant to this chapter, the pharmacist shall provide the recipient of the emergency contraceptive drug with a standardized fact sheet developed by the board that includes at least the following:

(1) The indications for use of the drug;

(2) The appropriate method for using the drug;

(3) The need for medical follow-up and referral information; and

(4) Information on sexual assault and referral information.

(b) A copy of the standardized fact sheet Ph EC-4 may be obtained from the office of the board identified in Ph 103.03.

Source.  #8708, eff 8-23-06, EXPIRED: 8-23-14

Ph 1001.07 Records to be Kept. The following completed forms shall be maintained for 4 years at the dispensing pharmacy where emergency contraception drug therapy was provided:

(a) Collaborative Agreement (Ph EC-1), or a copy thereof, in effect during the time emergency contraception drug therapy was delivered to specific patients at that location;

(b) Informed Consent (Ph EC-2), patient specific forms; and

(c) Patient Assessment (Ph EC-3) forms for each patient.

Source.  #8708, eff 8-23-06, EXPIRED: 8-23-14

Ph 1001.08 Confidentiality. Nothing in this chapter shall affect the provisions of law relating to maintaining the confidentiality of medical records.

Source.  #8708, eff 8-23-06, EXPIRED: 8-23-14
CHAPTER Ph 1100  COLLABORATIVE PHARMACY PRACTICE

PART Ph 1101  PURPOSE AND SCOPE

Ph 1101.01 Purpose. The purpose of this chapter is to implement and regulate collaborative pharmacy practice as a means to make the provision of certain aspects of health care more efficient, less costly, and provided in a more timely manner.

Source. #9381, eff 1-31-09

Ph 1101.02 Scope. These rules shall regulate collaborative pharmacy practice only in the following institutions where the practice is permitted pursuant to RSA 318:16-a, III(a) – (d), namely:

(a) Hospitals;

(b) Long-term care facilities;

(c) Licensed inpatient or outpatient hospice settings; and

(d) Ambulatory care clinics with onsite supervision by the attending practitioner and with a collaborating pharmacist who has no connection to any onsite retail pharmacy.

Source. #9381, eff 1-31-09

PART Ph 1102  DEFINITIONS

Ph 1102.01 “Attending practitioner” means “attending practitioner” as defined in RSA 318:1, XXV, namely, “the physician or advanced registered nurse practitioner who has the primary responsibility for the treatment and care of the patient.”

Source. #9381, eff 1-31-09

Ph 1102.02 “Collaborative pharmacy practice” means “collaborative pharmacy practice” as defined in RSA 318:1, XXV, namely, “the practice of pharmacy whereby one or more pharmacists jointly agree, on a voluntary basis, to work in conjunction with one or more attending practitioners under written protocol whereby the collaborating pharmacist or pharmacists may perform medication therapy management authorized by the attending practitioner or practitioners under certain specified conditions and limitations.”

Source. #9381, eff 1-31-09

Ph 1102.03 “Collaborative pharmacy practice agreement” means “collaborative pharmacy practice agreement” as defined in RSA 318:1, XXVII, namely, “a written and signed specific agreement between a pharmacist, an attending practitioner, and the patient or patient's authorized representative who has granted his or her informed consent, that provides for collaborative pharmacy practice for the purpose of medication therapy management for the patient.” For purposes of these rules, the term includes each protocol developed pursuant to RSA 318:16-a, II(a).

Source. #9381, eff 1-31-09

Ph 1102.04 “Medication therapy management” means “medication therapy management” as defined in RSA 318:1, XXVIII, namely, “the review of medication therapy regimens of patients by a pharmacist for the purpose of evaluating and rendering advice to a practitioner, or evaluating and modifying the medication regimen in accordance with the collaborative pharmacy practice agreement” and is limited to:
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(a) Implementing, modifying, and managing medication therapy according to the terms of the collaborative pharmacy practice agreement;

(b) Collecting and reviewing patient histories within the context of needs for pharmacy practice;

(c) Obtaining and checking vital signs, such as pulse, temperature, blood pressure, and respiration;

(d) Ordering laboratory tests as specifically set out in the collaborative pharmacy practice agreement between the pharmacist and the attending practitioner that are specific to the medication or protocol-driven;

(e) Formulating a medication treatment plan that will be shared with the patient's attending practitioner;

(f) Monitoring and evaluating the patient's response to therapy, including safety and effectiveness;

(g) Performing a comprehensive medication review, in conjunction with the attending practitioner, to identify, resolve, and prevent medication-related problems, including adverse drug events;

(h) Documenting the care delivered and, if applicable, communicating essential information to the patient's other health care providers; and

(i) Providing education and training designed to enhance patient understanding and the appropriate use of his or her medications.

Source. #9381, eff 1-31-09

PART Ph 1103  COLLABORATIVE PHARMACIST QUALIFICATIONS AND APPLICATION

Ph 1103.01 Qualifications.

(a) A pharmacist who seeks to engage in collaborative practice shall meet the requirements of:

(1) RSA 318:16-a, I(a) relative to licensure in New Hampshire;

(2) RSA 318:16-a, I(b) relative to professional liability insurance coverage;

(3) RSA 318:16-a, I(c) relative to education or experience;

(4) RSA 318:16-a, I(d) relative to completion of continuing education in any of the subjects or activities listed in RSA 318:1, XXVIII, (a) – (i); and

(5) RSA 318:16-a, I(e) relative to administration of drugs by injection, if the pharmacist will administer drugs in that way.

(b) A pharmacist who seeks to engage in collaborative practice that includes the administration of vaccines shall hold current basic or higher certification in cardiopulmonary resuscitation (CPR) from the American Heart Association, the American Red Cross, or from another organization or entity that is nationally-recognized as an issuer of such certifications.

Source. #9381, eff 1-31-09
Ph 1103.02 Application.

(a) A pharmacist who seeks to engage in collaborative practice in one of the settings allowed under RSA 318:16-a, III, shall provide the following on or with a “Collaborative Pharmacist Application”:

(1) The pharmacist’s name and license number;

(2) The pharmacist’s business and home addresses;

(3) A certificate of insurance from the pharmacist’s professional liability carrier indicating that the pharmacist maintains insurance coverage that complies with RSA 318:16-a, I(b);

(4) A list of all continuing education courses that address the continuing education requirement stated in Ph 1103.01(a)(4);

(5) A copy of the CPR certification that complies with the requirements of Ph 1103.01(b);

(6) Identification of each practice setting in which the pharmacist intends to practice, including the name and address of each such institution;

(7) If intending to administer drugs by injection, a certificate of completion of a training program that meets the requirements of RSA 318:16-a, I(e);

(8) An indication that the information provided on or with the application is true, correct, and complete to the best of the pharmacist’s knowledge and belief; and

(9) The signature of the pharmacist and the date signed.

(b) After receipt of a “Collaborative Pharmacist Application” the board’s staff shall review it for any apparent errors or omissions and inform the applicant in writing if any are found. If informed of errors or omissions, the pharmacist shall correct the error or provide the missing application materials within 30 days of such notification being sent.

(c) Each completed “Collaborative Pharmacist Application” shall be reviewed by the board at the next regular meeting that occurs at least 14 days after the application has been determined by board staff to be without apparent errors or omissions.

(d) The board shall approve a “Collaborative Pharmacist Application” if the applicant meets the requirements of RSA 318:16-a, I and these rules or shall deny the “Collaborative Pharmacist Application” if any such requirement has not been met. The board shall notify the pharmacist in writing as soon as practicable following its decision.

Source. #9381, eff 1-31-09

PART Ph 1104 COLLABORATIVE PRACTICE AGREEMENTS AND PRACTICE THEREUNDER

Ph 1104.01 Collaborative Practice Agreements.

(a) Each protocol developed pursuant to a collaborative practice agreement shall include all the elements specified in RSA 318:16-a, II(a)(1) – (6).

(b) Each collaborative practice agreement, including each protocol developed pursuant thereto, shall be signed by the pharmacist, attending practitioner, and then the patient or the patient’s authorized representative before it is put into effect. The signature of the patient or the patient’s authorized representative shall be the last to be obtained.
(c) The pharmacist shall maintain at the pharmacist’s place of practice a copy of each collaborative practice agreement, including each protocol developed pursuant thereto, to which the pharmacist is a party.

(d) The document referred to in (c) above shall be available for inspection and review by the board or its agents at any time during the pharmacist’s usual or actual hours of practice.

(e) If the pharmacist is the person who secures the patient or patient’s authorized representative’s signature on the collaborative practice agreement and informed consent form required pursuant to Ph 1104.02(b), the pharmacist shall provide the attending practitioner with a copy of the fully executed agreement as soon as practicable but in no case later than 24 hours after the patient or patient’s authorized representative signs.

Source. #9381, eff 1-31-09

Ph 1104.02 Informed Consent of Patient or Patient’s Authorized Representative.

(a) Prior to requesting that the patient or the patient’s authorized representative sign the collaborative practice agreement, the pharmacist shall ensure that:

1. A copy of the agreement, including each protocol developed pursuant thereto, has been provided with sufficient time for the documents to be reviewed;

2. The patient or the patient’s authorized representative has an opportunity to have any questions regarding such documents and their implementation answered to their satisfaction;

3. All benefits and risks accruing under the agreement are fully explained to the patient or the patient’s authorized representative;

4. The patient or the patient’s authorized representative understands that he or she may decline to participate or withdraw from the agreement at any time; and

5. The patient or the patient’s authorized representative is capable of providing informed consent.

(b) Informed consent shall be evidenced by a signed informed consent form that complies with the policies and procedures of the institution in which the collaborative practice agreement will be implemented.

Source. #9381, eff 1-31-09

Ph 1104.03 Practice Under a Collaborative Practice Agreement.

(a) Practice by a pharmacist under a collaborative practice agreement shall not be delegable but shall be performed only by the pharmacist who is a party to the agreement.

(b) Prior to initiation of medication therapy management for a patient, the pharmacist shall review and confirm the patient’s:

1. Name;

2. Gender, and if female, pregnancy and lactation status;

3. Date of birth;

4. Height and weight;
(5) Diagnosis, through consultation with the attending practitioner;

(6) Medication history;

(7) Prior lab values;

(8) Known allergies; and

(9) Emergency contact information.

(c) The pharmacist shall review the collaborative practice agreement and each protocol developed pursuant thereto so as to determine whether changes should be made to reflect the standard of care. If such a review reveals that a change should be made, the pharmacist shall inform the attending practitioner and the patient or the patient’s authorized representative.

(d) Nothing in this chapter shall be construed to prohibit an authorized pharmacist from participating in medication therapy management by protocol or policy approved by the medical staff of the hospital.

Source. #9381, eff 1-31-09
CHAPTER Ph 1200  CENTRAL PRESCRIPTION PROCESSING

PART Ph 1201  PURPOSE AND SCOPE

Ph 1201.01  Purpose.  The purpose of this chapter is to set forth the requirements, limitations, and prohibitions for pharmacies that engage in central prescription processing so as to ensure that, for the protection of the public, all central prescription processing activities regulated by the board are performed in compliance with applicable state law and rules by those who are licensed by the board.

Source.  #9469, eff 5-16-09

Ph 1201.02  Scope.  This chapter shall apply to all persons whose activities come under the jurisdiction of the board and who engage in central prescription processing activities.

Source.  #9469, eff 5-16-09

PART Ph 1202  DEFINITIONS

Ph 1202.01  “Central fill pharmacy” means a licensed pharmacy, in this or any other state, district or commonwealth of the United States, engaging in central prescription handling by filling, refilling, or both, prescriptions including the preparation, packaging, and labeling of the medication.

Source.  #9469, eff 5-16-09

Ph 1202.02  “Central prescription processing” means “central prescription processing” as defined in RSA 318:1, XXIII, namely, “the processing by a pharmacy of a request from another pharmacy to fill or refill a prescription drug order or to perform processing functions, such as dispensing, drug utilization review, claims adjudication, refill authorizations, and therapeutic interventions.”

Source.  #9469, eff 5-16-09

Ph 1202.03  “Central processing pharmacy” means a licensed pharmacy, in this or any other state, district or commonwealth of the United States, that engages in prescription review by performing functions that include but is not limited to:

(a) Data entry;
(b) Prospective drug review;
(c) Refill authorizations;
(d) Interventions;
(e) Patient counseling;
(f) Claims submission;
(g) Claims resolution; and
(h) Adjudication.

Source.  #9469, eff 5-16-09
Ph 1202.04 “Claims adjudication” means the process by which a prescription is submitted and processed through a third-party payor.

Source. #9469, eff 5-16-09

Ph 1202.05 “Dispensing pharmacy” means a licensed pharmacy, in this or any other state, district or commonwealth of the United States, that receives the processed prescription, the filled or refilled prescription, or both, for dispensing to the patient or to the patient’s authorized representative and providing patient counseling as required.

Source. #9469, eff 5-16-09

Ph 1202.06 “Intake pharmacy” means a licensed pharmacy, in this or any other state, district or commonwealth of the United States, that receives the patient’s or prescribing practitioner’s request to fill or refill a prescription, including a central processing pharmacy or a central fill pharmacy, as defined below, if the prescription was transmitted by the prescribing practitioner directly to such pharmacy or if the patient requested the refill from that pharmacy.

Source. #9469, eff 5-16-09

PART Ph 1203 CENTRAL PRESCRIPTION PROCESSING

Ph 1203.01 General Requirements for Engaging in Central Prescription Processing. A pharmacy may perform or outsource central prescription processing and handling services provided that:

(a) All pharmacies involved in the transactions pursuant to which the prescription is dispensed shall have either:

(1) The same owner; or

(2) A written contract outlining the services to be provided and the responsibilities and accountabilities of each party in fulfilling the terms of the contract in compliance with federal and state laws, regulations, and rules;

(b) The pharmacies shall share a database to allow access to information necessary or required to fill or refill a prescription drug order;

(c) All participating pharmacies located in this state shall maintain a pharmacy license for each location or if located in another state shall be registered in New Hampshire as a mail-order pharmacy according to Ph 900;

(d) All pharmacists participating in, providing, or both, central prescription processing services shall be licensed in this state or in the case of a non-resident pharmacy, the state in which the pharmacy is located; and

(e) Each pharmacy and pharmacist engaging in central prescription processing and handling shall be responsible for properly filling the prescription and complying with the requirements of Ph 706 or each relevant and applicable provision adopted by the state in which the pharmacy or pharmacist is registered or licensed. If such other state does not have a relevant or applicable provision, the owner or contract referred to in (a) above shall comply with or require compliance with the substance of Ph 706.

Source. #9469, eff 5-16-09
Ph 1203.02 Policy and Procedure Manual Required.

(a) Each participating pharmacy performing or contracting for the performance of centralized prescription processing and handling shall maintain a paper or electronic policy and procedure manual that includes at least the following:

(1) A policy that shall require every participating intake pharmacy to keep a record that includes at least the name, address and DEA number for each central fill or central processing pharmacy authorized to fill or process prescriptions on its behalf;

(2) A policy that shall require each central fill or central processing pharmacy to keep a record that includes at least the name, address and DEA number of all intake pharmacies for which it is authorized to fill or process prescriptions;

(3) A policy that shall describe comprehensively the responsibilities of each of the participating intake, filling, processing and dispensing pharmacies;

(4) A procedure that shall be used for maintaining records sufficient to allow for tracking a prescription during each stage of the filling and dispensing process including at least:

   a. The following information about the pharmacist(s) and technician(s) involved in filling and dispensing the prescription and counseling the patient:

      1. The pharmacist’s full name;

      2. The state in which the pharmacist is licensed and his or her license number; and

      3. The action or actions taken by the pharmacist; and

   b. The following information about the technician(s) involved in filling and dispensing the prescription:

      1. The technician’s full name;

      2. The state in which the technician is licensed and the license number; and

      3. The action or actions taken by the technician;

(5) The policy and procedure that shall be used for providing adequate security to protect the confidentiality and integrity of patient information;

(6) The procedure that shall be used by the pharmacy in implementing and operating a quality assurance program designed to objectively and systematically monitor, evaluate, and improve the quality and appropriateness of patient care; and

(7) The procedure that shall be followed in dispensing a prescription drug order when the filled order is not received or the patient comes in before the order is received.

(b) Each participating pharmacy and pharmacist shall review the policies and procedures at least annually and such review shall be documented.
(c) Each participating intake, processing, filling and dispensing pharmacy and pharmacist shall make the policies and procedures manual available to the board or its agents upon request.

Source. #9469, eff 5-16-09

Ph 1203.03 Patient Counseling. The dispensing pharmacy shall offer to counsel to the patient as required pursuant to Ph 706.03.

Source. #9469, eff 5-16-09

Ph 1203.04 Prohibitions and Limitations.

(a) Prescriptions for Schedule II controlled substances shall not be allowed for central prescription filling but shall be filled and dispensed at the intake pharmacy.

(b) Prescriptions for Schedule III, IV, or V controlled substances shall be allowed for central prescription processing and filling.

(c) Prescriptions for legend or controlled substances listed in Schedule III, IV, or V may be transmitted electronically, as permitted by state and federal laws, including via facsimile, from an intake pharmacy to a central fill pharmacy, provided that the intake pharmacy transmitting the prescription information complies with all state and federal laws.

(d) An intake pharmacy transmitting prescription information pursuant to (c) above shall keep:

(1) Records that track the prescription drug order during each step in the filling process that shall identify the name(s), initials, or identification code(s) and specific activity(ies) of each pharmacist or pharmacy technician who performed any portion of the process, including:

   a. Transmission;

   b. Filling;

   c. Dispensing; or

   d. Delivery to either the patient or another pharmacy; and

(2) A record of the date the filled prescription was delivered to the intake pharmacy, the method of delivery, such as by private, common or contract carrier, and the identity of the carrier.

Source. #9469, eff 5-16-09

Ph 1203.05 Record Keeping.

(a) The common electronic database shall maintain a record of all pharmacists and pharmacies involved in the intake, processing, filling, and dispensing of all prescriptions.

(b) There shall be record keeping systems between central prescription processing pharmacies with real-time, online access to those services provided by each pharmacy.

(c) Access to prescription information by 2 participating pharmacies shall not be considered a prescription transfer and not subject to the provisions of Ph 704.04.
(d) All records required to be created and maintained pursuant to Ph 1203 shall be maintained for a period of not less than 4 years.

Source. #9469, eff 5-16-09
CHAPTER Ph 1300  PHARMACIST ADMINISTRATION OF VACCINES

PART Ph 1301  PURPOSE AND SCOPE

Ph 1301.01  Purpose. The purpose of this chapter is to implement and regulate pharmacist administration of vaccines as a means to make vaccinations more easily accessible and therefore providing immunity to a larger patient population.

Source. #9552, eff 9-23-09; ss by #10185, eff 9-18-12

Ph 1301.02  Scope. These rules shall regulate pharmacist administration of vaccines where the practice of pharmacy is permitted.

Source. #9552, eff 9-23-09; ss by #10185, eff 9-18-12

PART Ph 1302  DEFINITIONS

Ph 1302.01  “Administer” means “administer” as defined in RSA 318:1, I, namely, “an act whereby a single dose of a drug is instilled into the body of, applied to the body of, or otherwise given to a person or animal for immediate consumption or use.”

Source. #9552, eff 9-23-09; ss by #10185, eff 9-18-12

Ph 1302.02  “Licensed pharmacist” or “pharmacist” means “licensed pharmacist” or “pharmacist” as defined in RSA 318:1, VII, namely, “when not otherwise limited, means a person holding a license under RSA 318:18 and who is, therefore legally authorized to practice the profession of pharmacy in this state.”

Source. #9552, eff 9-23-09; ss by #10185, eff 9-18-12

Ph 1302.03  “Practitioner” or “licensed practitioner” means “practitioner” or “licensed practitioner” as defined in RSA 318:1, XV, namely, “means any person who is lawfully entitled to prescribe, administer, dispense, or distribute legend drugs to patients.”

Source. #9552, eff 9-23-09; ss by #10185, eff 9-18-12

PART Ph 1303  PHARMACIST ADMINISTRATION OF VACCINES QUALIFICATIONS AND APPLICATION

Ph 1303.01  Qualifications.

(a) A pharmacist who seeks to engage in the administration of vaccines shall meet the requirements of:

(1) RSA 318:16-b, I, relative to education or experience;

(2) RSA 318:16-b, II, relative to professional liability insurance coverage; and

(3) RSA 318:16-b, III, relative to completion of continuing education.

(b) A pharmacist who seeks to engage in the administration of vaccines shall hold current basic or higher certification in cardiopulmonary resuscitation (CPR) from the American Heart Association, the American Red Cross, or from another organization or entity that is nationally-recognized as an issuer of such certifications.
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(c) A pharmacist shall not delegate the administration of vaccines to any person.

Source.  #9552, eff 9-23-09; ss by #10185, eff 9-18-12

Ph 1303.02 Application.

(a) A pharmacist who seeks to engage in the administration of vaccines shall file a completed “Pharmacist Administration of Vaccines Application” (February 2015) as specified in RSA 318:16-b, IV.

(b) An application fee of $25.00 shall be filed with the board and included with the above application.

Source.  #9552, eff 9-23-09; ss by #10185, eff 9-18-12; ss by #10842, eff 6-3-15

PART Ph 1304 PHARMACIST ADMINISTRATION OF VACCINES PROCEDURAL AND RECORDKEEPING REQUIREMENTS

Ph 1304.01 Vaccine Administration Requirements. A pharmacist who engages in the administration of vaccines shall comply with the following procedures:

(a) Provide the patient with a Vaccine Information Statement (VIS) as provided by the Centers for Disease Control (CDC);

(b) Ensure that the patient has received and signed the Patient Consent Form and has been counseled and his or her questions answered prior to administration of the vaccine;

(c) Maintain and follow written policies and procedures that establish a course of action the pharmacist shall follow to address:

(1) Adverse reactions;

(2) Anaphylactic reactions including a standard order for treatment;

(3) Accidental needle sticks; and

(4) Handling/disposal of used or contaminated equipment and supplies;

(d) Report all adverse events to the Vaccine Adverse Events Reporting System (VAERS) and to the primary care physician if applicable;

(e) Provide the patient with documentation of the vaccination and when appropriate report it to the immunization section of the New Hampshire department of health and human services to be added to the Vaccination Registry.

(f) Provide notice electronically, in writing or fax by within 30 days to the primary care provider, when the practitioner has been designated by the patient, of the administration of the pneumococcal and varicella zoster vaccine and maintain documentation of the record for a minimum of 4 years; and

(g) Be able to recognize anaphylaxis and maintain at least 2 doses of injectable epinephrine at all times to treat a reaction if it occurs.

Source.  #9552, eff 9-23-09; ss by #10185, eff 9-18-12

Ph 1304.02 Recordkeeping. A pharmacist who engages in the administration of vaccines shall, for a minimum of 4 years, keep a patient consent form that includes the:
(a) Name and date of birth of the patient;
(b) Name of the vaccine, manufacturer, lot number, and expiration date of the vaccine;
(c) Description of the risks and possible side effects of the vaccine;
(d) Date of administration;
(e) Administering pharmacist’s name; and
(f) Signature of the patient.

Source. #9552, eff 9-23-09; ss by #10185, eff 9-18-12
CHAPTER Ph 1400  UNUSED PRESCRIPTION DRUG PROGRAM RULES

PART Ph 1401  PURPOSE

Ph 1401.01  Purpose: The purpose of the rule is to allow the voluntary donation of unused prescription drugs and medical devices to the uninsured and the underinsured individuals.

(a) The rules of Ph 1400 describe the program to take unused prescription drugs and medical devices donated from nursing homes, pharmaceutical manufacturers, and other eligible donators and utilize them for dispensing to uninsured and underinsured persons who opt into the program.

(b) The rules of Ph 1400 describe the eligibility to donate. They describe the eligible prescription drug formulary, the eligible recipients, and the protection for participants. They describe pharmacies eligible to accept and dispense such drugs, and medical devices the requirements for eligible pharmacies, and the responsibilities for consultant pharmacists.

(c) The rules of Ph 1400 describe safe handling of drugs and medical devices to protect drug integrity, tracking, sanitation, security and dispensing requirements for these unused prescription drugs and medical devices. The rules of Ph 1400 describe confidentiality requirements as well as violations.

Source. #10064, eff 12-28-11

PART Ph 1402  DEFINITIONS

Ph 1402.01  “Abandoned drug” means a prescription only drug that was dispensed for a patient that was never in a patient’s possession and is no longer needed by the patient or was left behind at a facility after discharge from the facility. The term includes Patient Assistance Program drugs when the manufacturer does not provide a shipping-paid option for the provider to return the drug to the manufacturer or the manufacturer’s agent and:

(a) The provider has determined and documented that the patient should not receive or is unable to receive the drug, or

(b) The patient has not returned to receive the drug within 8 weeks of the time the prescriber received the drug.

Source. #10064, eff 12-28-11

Ph 1402.02  “Agent” means any person who is legally authorized to make medical decisions for a patient.

Source. #10064, eff 12-28-11

Ph 1402.03  “Charitable Provider” means any pharmacist or practitioner licensed by this state to dispense drugs as defined by RSA 318:42 who chooses to participate in an unused prescription drug program.

Source. #10064, eff 12-28-11
Ph 1402.04  “Dispense” means to distribute, leave with, give away, dispose of, deliver, or sell one or more doses of a drug that will be administered or taken at a later date, time, or location and the transfer of more than a single dose of a medication from one container to another and the labeling or otherwise identifying a container holding more than a single dose of a drug.

Source.  #10064, eff 12-28-11

Ph 1402.05  “Donate” means the giving free of charge of an eligible prescription drug to an unused prescription drug program.

Source.  #10064, eff 12-28-11

Ph 1402.06  “Eligible prescription drug ” (EPD) means any unused prescription only drug that has not reached its expiration date, is contained in an unopened unit dose or other tamper evident packaging, has not been in the possession of the patient and has been stored properly and is not a radiopharmaceutical therapeutic or diagnostic drug. Drugs that can only be dispensed to a patient registered with the drug’s manufacturer in accordance with federal Food and Drug Administration (FDA) requirements are not eligible for the program.

Source.  #10064, eff 12-28-11

Ph 1402.07  “Manifest” means an itemized invoice of EPD donated, accepted or destroyed.

Source.  #10064, eff 12-28-11

Ph 1402.08  “Pharmacy” means “pharmacy” as defined by RSA 318:1 XI.

Source.  #10064, eff 12-28-11

Ph 1402.09  “Practitioner” or "licensed practitioner" as defined by RSA 318:1 XV.

Source.  #10064, eff 12-28-11

Ph 1402.10  “Program Pharmacist” means any licensed pharmacist in New Hampshire that is participating in an unused prescription drug program.

Source.  #10064, eff 12-28-11

Ph 1402.11  “Redispense” means to dispense an EPD that was accepted by an unused prescription drug program for the purpose of providing medication to an individual who is uninsured/underinsured.

Source.  #10064, eff 12-28-11

Ph 1402.12  “Underinsured” means a person who lacks adequate prescription related insurance coverage such that purchasing prescription drugs and/or devices create a financial hardship.

Source.  #10064, eff 12-28-11

Ph 1402.13  “Uninsured” means a person who does not presently have an active insurance policy that reimburses fully or partially for prescription drugs or devices.

Source.  #10064, eff 12-28-11
PART Ph 1403  ELIGIBILITY TO DONATE PRESCRIPTION DRUGS (EDP) AND MEDICAL DEVICES

Ph 1403.01 Eligible Donating Entities. The following entities shall be eligible to donate prescription drugs and medical devices:

(a) A pharmacy;
(b) A licensed practitioner;
(c) A Hospice or outpatient clinic if licensed pursuant to RSA 151;
(d) A New Hampshire nursing home, if it is licensed with the New Hampshire department of health and human services (DHHS) and has a consultant pharmacist or program pharmacist;
(e) A licensed manufacturer/wholesaler/distributor, who voluntarily donates samples or eligible prescription drugs or medical devices to eligible charitable providers in this program; and
(f) A state or county correctional facility if it has a program pharmacist.

Source. #10064, eff 12-28-11

Ph 1403.02 Unused Prescription Property.

(a) A prescription drug shall be the property of the patient for whom it is prescribed, regardless of who paid for the prescription.

(b) The patient or agent of the patient may at any time authorize the donation of the unused prescription drugs or medical device.

(c) An unused prescription may be donated:

   (1) When a patient has died and
   (2) When a drug is abandoned.

(d) Prescription drugs donated under Ph 1400 shall only be transferred to charitable providers.

(e) Prescription drugs or medical devices donated under Ph 1400 shall not be sold, resold, offered for sale, traded, or returned for financial credit. This shall not prohibit transfer between charitable providers.

(f) A charitable provider shall be responsible for determining that the patient has authorized the donation of the drugs or medical devices.

(g) A charitable provider shall make certain that the name of the patient, and all patient information and directions on the label will be redacted or removed before sending to the accepting entity to protect confidentiality.

(h) Manifests shall be maintained for internal and external transfer of product.

Source. #10064, eff 12-28-11
Ph 1403.03  **Conditions Required for Unused Prescription Drugs.** The following conditions shall apply to unused prescription drugs and medical devices.

(a) Licensed healthcare personnel shall in order to be eligible keep control of such unused prescription drugs and medical devices in sanitary and secure conditions as required under RSA 318:58.

(b) Such unused prescription drugs and medical devices, in sanitary and secure conditions shall be eligible for donation.

(c) Nursing homes shall have a consultant pharmacist or a program pharmacist.

Source. #10064, eff 12-28-11

PART Ph 1404  **ELIGIBILITY TO ACCEPT DONATIONS (EAD)**

Ph 1404.01  **Eligible Accepting Entities.** The following entities shall be eligible to accept unused prescription drugs and medical devices.

(a) A pharmacy;

(b) A licensed practitioner;

(c) A hospice or public health clinic including (N.H. Hospital, Glencliff Home and N.H. Veterans Home) RSA 318:58 III;

(d) New Hampshire nursing homes if they are licensed and in good standing with DHHS;

(e) A manufacturer/wholesaler/distributor may accept samples or eligible prescription drugs for eligible charitable providers in this program; and

(f) A state or county correctional facility if it has a program pharmacist or a charitable provider.

Source. #10064, eff 12-28-11

PART Ph 1405  **ELIGIBILITY TO REDISPENSE**

Ph 1405.01  **Eligible Redispensing Entities.** Entities that are eligible to redispense shall include:

(a) A pharmacy; and

(b) Any licensed prescriber.

Source. #10064, eff 12-28-11

PART Ph 1406  **PROGRAM PHARMACIST RESPONSIBILITIES**

Ph 1406.01  **Program Pharmacist.**

(a) All entities eligible to accept shall have the program pharmacist approved by the New Hampshire board of pharmacy.

(b) Program pharmacists for the nursing home eligible to donate unused prescription drugs and medical devices shall:

(1) Review quality and suitability of the unused prescription drugs for reuse as follows:
a. The drugs and medical devices shall be kept under the control of a health care professional;

b. The drugs and medical devices shall be stored properly against heat, cold and moisture;

c. The drugs shall be identifiable; and

d. The drugs are not adulterated, misbranded or mutilated.

(2) Determine that the expiration date exceeds 90 days to allow time for redistribution;

(3) Make sure a manifest contains the following if applicable: supplier (donor) name, and receiver name, donor and receiver address, phone numbers, state permit numbers, signatures, date sent, date received, date destroyed, name, strength and dosage form of drug, NDC #, package size, quantity, initials;

(4) Provide a copy of this manifest to the accepting entity and maintain a copy at the donating entity for at least 2 years;

(5) Assure controlled substances, that is, Drug Enforcement Agency (DEA) controlled substances are not donated or accepted;

(6) Assure that the accepting and donating entities are eligible to receive unused prescription drugs and medical devices under these rules; and

(7) Have transportation of product and manifest be the responsibility of both the donating and accepting entities to ensure that product integrity is maintained.

Source. #10064, eff 12-28-11

PART Ph 1407 ELIGIBLE PRESCRIPTION DRUG FORMULARY

Ph 1407.01 Formulary. All Food and Drug Administration (FDA) approved prescription drugs excluding controlled substances shall be subject to the following:

(a) They shall not have been in the possession of the patient or other member of the public;

(b) They shall not have reached within 90 days of their expiration date;

(c) They shall be contained in unopened unit dose or other tamper-evident packaging and show no evidence of contamination;

(d) Medical devices shall not be unsanitary, broken, dangerous or otherwise unfit for practical use;

(e) They shall not be compounded drugs;

(f) Drugs that require storage temperatures other than normal room temperature as specified by the manufacturer shall only be donated or accepted if the program pharmacist(s) can ascertain the proper storage has been maintained at all times and transferred internally under the same ownership; and
(g) Drugs that can only be dispensed to a patient registered with the drug’s manufacturer in accordance with federal Food and Drug Administration (FDA) requirements shall not be accepted or distributed.

Source. #10064, eff 12-28-11

PART Ph 1408 REQUIREMENTS FOR PHARMACIES DISPENSING UNUSED PRESCRIPTION DRUGS

Ph 1408.01 Dispensing Requirements. Unused prescription drugs shall be dispensed in compliance with the following:

(a) Pharmacies shall follow the requirements established in RSA 318;

(b) New Hampshire licensed pharmacies dispensing unused prescription drugs shall:

(1) Maintain a current drug identification book, or shall have a current computer program or online service for the same;

(2) Provide information to all recipients regarding the program and maintain a participation consent form for each eligible recipient or patient representative agent of any unused prescription drug; and

(3) Maintain samples in the original package as required under federal law, and the samples shall not be removed from original packaging for dispensing.

(c) If it is determined by the pharmacist’s professional judgment that it would be best for the patient, the drugs can be removed from patient specific packaging or unit dose packaging (UDP), commonly referred to as bingo cards, and repackaged.

(d) Eligible New Hampshire pharmacies shall establish the following policies and procedures for the dispensing of unused prescription drugs to the uninsured or underinsured patients as follows:

(1) They may limit the number of prescriptions per patient per visit or per month, to allow a greater number of individuals access to such prescription drugs;

(2) If no underinsured or uninsured patients are available, donated medications may be made available to other patients; and

(3) There shall be a written policy that is enforced equally to prevent discrimination.

(e) Pharmacies may transfer unused prescription drugs to another pharmacy in the program when one pharmacy has the need for a drug and another pharmacy has it available. The transferring pharmacy shall follow the rules of the donating entity and the receiving pharmacy shall follow the rules of the accepting entity.

(f) Unused prescription drugs and medical devices shall not be resold.

Source. #10064, eff 12-28-11
PART Ph 1409  RESPONSIBILITIES OF CHARITABLE PROVIDERS

Ph 1409.01 Charitable Providers. A charitable provider shall:

(a) Coordinate retrieval of donated unused prescription drugs and medical devices from entities eligible to donate;

(b) Check unused prescription drugs (UPD) against the manifest and document any discrepancies and communicate those discrepancies to the entity eligible to donate;

(c) Store and secure these UPDs in a manner that distinguishes them from general stock and store them according to state and federal laws, rules and regulations;

(d) Check the unused prescription drugs for adulteration or misbranding;

(e) Assure expired, adulterated, misbranded, and controlled drugs are not dispensed;

(f) Segregate unacceptable drugs for destruction or return and prepare a manifest that is signed by both the pharmacist and a witness when it comes time for destruction;

(g) Have access to FDA or manufacturer drug recall information. If a drug is recalled by the FDA or manufacturer and the eligible provider can not ascertain the lot number on the label to differentiate between the recall and non-recalled drug, all such donated drugs shall be considered recalled and destroyed or returned in the manner specified by the recall; and

(h) Assure destruction as defined by Department of Environmental Service of expired, adulterated, and/or recalled unused prescription medications as follows:

   (1) A manifest shall be made of unused prescription drugs expired, adulterated, misbranded and/or recalled to be destroyed;

   (2) Following destruction such manifest shall be signed by the pharmacist and witness verifying such destruction; and

   (3) The drug destruction manifest shall be kept in the files of the pharmacy for at least 2 years.

Source. #10064, eff 12-28-11

Ph 1409.02 Labeling. Dispensed prescription(s) shall clearly indicate the final charitable provider and the current patient information to assure clarity for receiving patient and shall be properly labeled according to RSA 318:47 and shall include the expiration date.

Source. #10064, eff 12-28-11

Ph 1409.03 Handling Fee. Whenever possible the dispensing facility or service shall provide at least a 30 day supply and a handling fee may be charged according to RSA 318:58 V.

Source. #10064, eff 12-28-11

Ph 1409.04 Recordkeeping. Charitable providers shall comply with recordkeeping rules set forth by Ph 309.07.

Source. #10064, eff 12-28-11
PART Ph1410  FORMS

Ph 1410.01  Transfer Manifests.

(a) Sample manifests shall be available by the New Hampshire board of pharmacy.

(b) All participants may use their own manifest, provided they include all current information listed on the current manifest. See Ph 1406.01 (b) (3).

Source. #10064, eff 12-28-11

PART Ph1411  PARTICIPANT IMMUNITY

Ph 1411.01  Participant Immunity. Immunity shall be provided to the program as provided in RSA 318:60.

Source. #10064, eff 12-28-11

PART Ph 1412  VIOLATIONS

Ph 1412.01  Violations of the Unused Prescription Drug Program.

(a) Theft or diversion of any of the unused prescription drugs shall be a violation of these rules. This shall include any expired, misbranded drug, adulterated drug, recalled drug, or other drug found to be unusable under the requirements of Ph 1400.

(b) Any violation by any person of the unused prescription drug program shall be reported by the licensed entity upon discovery to the appropriate licensing agency within 30 days and/or other proper authorities for possible action.

(c) Such violation by any person licensed by the board may result in action under RSA 318:55 or any licensee, permittee, registrant or certificate holder as provided in RSA 318:29.

Source. #10064, eff 12-28-11
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

CHAPTER Ph 1500  NEW HAMPSHIRE CONTROLLED DRUG PRESCRIPTION HEALTH AND SAFETY PROGRAM

Statutory authority: RSA 318-B:37

PART Ph 1501  PURPOSE

Ph 1501.01 Purpose. This rule implements the New Hampshire Controlled Drug Prescription Health and Safety Program created by RSA 318-B:31–38, which authorizes the pharmacy board to establish and contract with a third party for the implementation and operation of an electronic system to facilitate the confidential sharing of information relating to the prescribing and dispensing of schedule II–IV controlled substances by prescribers and dispensers within the state to promote public health and safety through the prevention of and treatment for misuse and abuse of controlled substances and the reduction of the diversion of such substances, without interfering with the legal medical use of these substances.

Source. #10526, eff 2-26-14

PART Ph 1502  DEFINITIONS

Ph 1502.01 Definitions.

(a) “Authorized representative” means a parent or guardian of a minor child, or a person who has been authorized in the manner required by law to make health care decisions, or gain access to health care records, on behalf of another.

(b) “Board” means “board” as defined in RSA 318-B:31, I, namely, “the pharmacy board, established in RSA 318:2.”

(c) “Controlled substance” means “controlled substance” as defined in RSA 318-B:31, II, namely, “controlled drugs as defined in RSA 318-B:1, VI.”

(d) “Credential” means information or a device provided by the program to a registered dispenser or prescriber that allows the dispenser or prescriber to electronically submit or access prescription monitoring information. Credentials include, but are not limited to, a user name and password, or an identification device that generates a user name and password.

(e) “Dispense” means “dispense” as defined in RSA 318-B:31, III, namely, “to deliver a controlled substance by lawful means and includes the packaging, labeling, or compounding necessary to prepare the substance for such delivery.”

(f) “Dispenser” means a person or entity lawfully authorized to deliver a schedule II–IV controlled substance, but does not include:

(1) A licensed hospital pharmacy that dispenses for administration in the hospital;

(2) A practitioner, or other authorized person who administers such a substance; or

(3) A wholesale distributor of a schedule II–IV controlled substance or its analog.

(g) “Patient” means “patient” as defined in RSA 318-B:31, V, namely, “the person or animal who is the ultimate user of a controlled substance for whom a lawful prescription is issued and for whom a controlled substance or other such drug is lawfully dispensed.”
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(h) “Practitioner” means a physician, dentist, podiatrist, veterinarian, pharmacist or other person licensed or otherwise permitted to prescribe, dispense, or administer a controlled substance in the course of licensed professional practice.

(i) “Prescribe” means “prescribe” as defined in RSA 318-B:31, VII, namely, “to issue a direction or authorization, by prescription, permitting a patient to lawfully obtain controlled substances.”

(j) “Prescriber” means “prescriber” as defined in RSA 318-B:31, VIII, namely, “a practitioner or other authorized person who prescribes a schedule II, III, and/or IV controlled substance.”

(k) “Program” means “program” as defined in RSA 318-B:31, IX, namely, “the controlled drug prescription health and safety program that electronically facilitates the confidential sharing of information relating to the prescribing and dispensing of controlled substances listed in schedules II-IV, established by the board pursuant to RSA 318-B:32.”

(l) “Program manager” means the person designated by the board to oversee the implementation and operation of the program by the program vendor.

(m) “Program vendor” means a third party with which the board contracts for the implementation and operation of the program.

(n) “Regulatory board” means the New Hampshire board of dentistry, board of medicine, board of nursing, board of registration in optometry, board of podiatry, board of veterinary medicine, and pharmacy board.

Source. #10526, eff 2-26-14

PART Ph 1503 REGISTRATION OF PRESCRIBERS AND DISPENSERS

Ph 1503.01 Registration of Prescribers and Dispensers.

(a) All practitioners authorized to prescribe or dispense schedule II–IV controlled substances within the state of New Hampshire shall register with the program no later than June 30, 2015.

(b) Program registration shall be by one of the following methods:

(1) Automatic registration at the time of the program go-live date or at the time of initial licensure or license renewal, if permitted by the prescriber’s or dispenser’s regulatory board; or

(2) Completing and submitting to the program vendor a registration form provided by the program vendor.

(c) Before a program credential is issued, the registrant shall be verified as having a current and valid license, as follows:

(1) Those prescribers and dispensers who register in accordance with (b)(1) above shall be automatically verified; and

(2) Those prescribers and dispensers who register in accordance with (b)(2) above shall be verified by the program manager by confirming that the registrant has a valid license.

(d) On a monthly basis, each regulatory board shall submit to the program manager or program vendor a list of prescribers and dispensers:
(1) Who have been issued a new license;

(2) Whose license has been renewed; and

(3) Who have had their license revoked, suspended, restricted, or not renewed.

(e) If the credentials issued by the program vendor are lost or missing, or if the security of the credentials is compromised, the prescriber or dispenser shall cause the program manager to be notified by telephone and in writing as soon as possible.

(f) Those dispensers licensed under RSA 318 who have not registered by June 30, 2015 shall be subject to disciplinary action as established pursuant to RSA 318:29.

(g) Those prescribers who are required to register who have not registered by June 30, 2015 shall, pursuant to RSA 318-B:36 III, be subject to penalties established by their respective regulatory board.

Source. #10526, eff 2-26-14

PART Ph 1504 REQUIREMENTS FOR DISPENSERS

Ph 1504.01 Reporting of Controlled Substances Dispensed.

(a) Dispensers shall submit to the program the prescription drug monitoring information required by RSA 318-B:33, IV, and paragraph (b) below, for each dispensing of a schedule II–IV controlled substance, as follows:

(1) Electronically, unless a waiver is requested and granted in accordance with Ph 1504.02 below;

(2) Within 7 days of the controlled substance being dispensed, unless an extension is requested and granted in accordance with Ph 1504.03 below; and

(3) For registered dispensers located outside the state of New Hampshire, information only for patients who reside in New Hampshire.

(b) The required prescription drug monitoring information to be submitted shall be as follows:

(1) Dispenser’s Drug Enforcement Administration (DEA) registration number and, if available, the dispenser’s National Provider Identification (NPI) number;

(2) Prescriber’s DEA registration number and, if available, the prescriber’s NPI number;

(3) Date of dispensing;

(4) Prescription number;

(5) Number of refills granted;

(6) National Drug Code (NDC) of drug dispensed;

(7) Quantity dispensed;

(8) Number of day’s supply of drug;

(9) Patient’s name, including first name, middle initial, if applicable, last name, and, suffix, if applicable;

Source: #10526, eff 2-26-14
(10) Patient’s address;
(11) Patient’s date of birth;
(12) Patient’s phone number, if available;
(13) Date prescription was written by prescriber;
(14) Whether the prescription is new or a refill; and
(15) Source of payment for prescription.

(c) Dispensers licensed by the board under common ownership, including those located outside of New Hampshire, may submit the required prescription drug monitoring information in (b) above in a single joint report provided that each dispenser is clearly identified for each prescription dispensed.

(d) The program vendor shall perform data checks to ensure that the required prescription drug monitoring information submitted is accurate, complete, and timely.

(e) The program vendor shall notify the dispenser, the program manager, and the board:

(1) When the dispenser fails to submit the required prescription drug monitoring information within the required timeframe;
(2) When there are inaccuracies or omissions in the required prescription drug monitoring information submitted; and
(3) When a dispenser fails to correct any inaccuracies or omissions.

(f) Dispensers shall:

(1) Correct any failures, inaccuracies, or omissions, within 7 days of the date of receipt of notice from the program vendor.
(2) Correct their own records and submit corrected information to the program or program vendor whenever they become aware of errors, omissions, or reversals.

(3) Comply with any provision of this section or be subject to disciplinary action as established pursuant to RSA 318:29.

Source. #10526, eff 2-26-14

Ph 1504.02 Waivers.

(a) Dispensers that are unable to submit by electronic means the required prescription drug monitoring information may request a waiver to submit the information by other means by submitting a waiver request to the program manager, along with any supporting documentation.

(b) A waiver request submitted pursuant to this section shall:

(1) Demonstrate that, for any reason, including low volume of controlled substances being dispensed, financial hardship will result from the requirement of electronic submission.
(2) Include an alternative method by which the dispenser will submit the required prescription drug monitoring information with the time frame specified in Ph 1504.01(a)(2). Alternative
methods of submission include, but are not limited to, program vendor website, e-mail, flash drive, CD, or paper.

(c) Dispensers shall be notified of the decision to grant a waiver within 30 days of the date of the receipt of the completed waiver request.

(d) A waiver shall be non-transferable.

(e) A waiver shall be time-limited, not to exceed the dispenser’s license expiration date.

(f) A waiver shall be subject to revocation if the bases for granting the waiver are determined to be no longer true.

Source. #10526, eff 2-26-14

Ph 1504.03 Extensions.

(a) Dispensers that are unable to submit required prescription information within the required timeframe may request from the program manager an extension of the timeframe by telephone confirmed by email from the program manager.

(b) The program manager shall allow an extension for as long as the dispenser is making a good-faith effort to submit the required information, but no later than 10 calendar days after the established 7 day timeframe.

(c) The program manager shall notify the board if a dispenser ceases to demonstrate good faith in its efforts to submit the required information or if the dispenser fails to submit the required information by the extended timeframe.

Source. #10526, eff 2-26-14

PART Ph 1505 ACCESS TO PRESCRIPTION DRUG MONITORING INFORMATION

Ph 1505.01 Patient Access.

(a) A patient for whom a prescription for a schedule II–IV controlled substance is dispensed, or his or her authorized representative, may request and obtain a report listing all prescription monitoring information that pertains to that patient.

(b) The request in (a) above shall be submitted to the program manager, either by mail or in person, on a complete, “Patient Prescription Monitoring Information Request” form (February 2014 Edition) signed by the patient, or the patient’s authorized representative.

(c) Patient information shall not be mailed or otherwise transmitted to the patient, or the patient’s authorized representative, except as allowed by (d) below.

(d) Upon notice that the requested information is available, the patient, or the patient’s authorized representative, shall receive the information in person, only after he or she produces valid government-issued photographic proof of identity. The patient, or the patient’s authorized representative, shall allow the photocopying of the identification.

Source. #10526, eff 2-26-14

Ph 1505.02 Prescriber and Dispenser Access.
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(a) Registered prescribers and dispensers shall have electronic program access to information on a specific patient, and in the case of veterinarians a specific patient’s owner(s), both past and present, for which a prescription was written or an appointment was scheduled or conducted.

(b) Registered prescribers and dispensers for whom a waiver is requested and granted in accordance with Ph 1504.02 shall have program access to information as described in (a) above by written request in accordance with (c) through (e) below.

(c) Requests shall be made by electronic or written request.

(d) Electronic requests shall be made through the program’s secure web portal.

(e) Written requests shall:

   (1) Be made by submitting to the program a completed “Prescriber/Dispenser Prescription Monitoring Information Request” form (February 2014 Edition); and

   (2) Be fulfilled by secure mail or fax.

(f) To enable the timely and efficient delivery of medical or pharmaceutical care for a specific patient, a prescriber or dispenser registered with the program may delegate the task of retrieving program information for a specific patient to an individual working under the direction and supervision of the registered prescriber or dispenser provided that written documentation of the delegation to the individual is provided to the program. Both the prescriber or dispenser who authorized the delegation and the individual to whom the task of retrieving the program information was delegated shall be subject to the provisions and penalties in RSA 318-B:36 regarding proper access to and use of program information.

Source. #10526, eff 2-26-14

Ph 1505.03 Law Enforcement Access.

(a) Authorized law enforcement officials may request and obtain information from the program on a case-by-case basis for the purpose of investigation and prosecution of a criminal offense.

(b) For the purposes of (a) above, a law enforcement official shall be considered authorized if he or she provides a court order based on probable cause, or a search warrant signed by a judge, which includes sufficient information to correctly identify the patient, prescriber, or dispenser whose prescription monitoring information is the subject of the court order.

(c) A law enforcement official shall present the court order or search warrant to the representative of the board designated by the board to receive such orders, who shall notify the program manager to provide the information identified in the court order in the format requested by the court order.

Source. #10526, eff 2-26-14

Ph 1505.04 Regulatory Board Access.

(a) New Hampshire regulatory boards, and equivalent out-of-state boards, may request and obtain information from the program, provided, however, that the request is pursuant to the regulatory board’s official duties and responsibilities and the disclosures to each regulatory board relate only to its licensees and only with respect to those licensees whose prescribing or dispensing activities indicate possible fraudulent conduct.
(b) Requests in (a) above shall be in writing, signed by the regulatory board’s executive director, investigator, or other person authorized to discharge equivalent functions of the regulatory board, and sent to the program manager.

(c) The address for the program shall be:

Pharmacy Board  
Program Manager  
Prescription Drug Monitoring Program  
121 South Fruit Street  
Concord New Hampshire 03301

Source. #10526, eff 2-26-14

Ph 1505.05 Other Access.

(a) Out-of-state prescription drug monitoring programs may request and obtain information from the program on a case-by-case basis provided that an agreement is in place with the other state to ensure that the information is used and disseminated pursuant to the applicable requirements of the NH controlled drug prescription health and safety program.

(b) Requests in (a) above shall be in writing, signed by the director of the out-of-state prescription drug monitoring program, or designee, and sent to the program manager at the address in Ph 1505.04(c).

Source. #10526, eff 2-26-14

PART Ph 1506 REVIEW AND REPORTING OF PRESCRIPTION DRUG MONITORING INFORMATION

Ph 1506.01 Review of Program Data.

(a) The program vendor shall collect and monitor all prescription drug monitoring information required by RSA 318-B:33, IV, and Ph 1504.01(b).

(b) The program vendor shall review and evaluate the collected information in order to identify behavior that suggests possible drug abuse, misuse, or diversion, or possible violations of law or breaches of professional standards.

(e) The program vendor shall consider, at a minimum, the following patient-related factors in its evaluation in (b) above:

(1) Number of in-state prescribers;
(2) Number of out-of-state prescribers;
(3) Number of prescriptions;
(4) Number of doses;
(5) Overlapping prescriptions;
(6) Unhealthy combinations of controlled substances;
(7) Method of payment;
(8) Number and frequency of pharmacies used; and
(9) Dangerous levels of controlled substances.

(d) The program vendor shall consider, at a minimum, the following prescriber/dispenser–related factors in its evaluation in (b) above:

(1) Number of prescriptions;
(2) Number of doses;
(3) Overlapping prescriptions;
(4) Unhealthy combinations of controlled substances;
(5) Number and frequency of pharmacies used;
(6) Dangerous levels of controlled substances;
(7) Electronic program access and use; and
(8) For dispensers only, method of payment.

Source. #10526, eff 2-26-14

Ph 1506.02 Reporting of Program Data.

(a) The program shall report to the appropriate regulatory boards identified in RSA 318-B:35, I(b)(2), relevant information to be used by the regulatory board for further investigation:

(1) When there is cause to believe a potential violation of law or a breach of professional standards may have occurred; and
(2) When there is cause to believe that a failure to report the dispensing of a schedule II–IV controlled substance conceals a potential pattern of diversion of controlled substances into illegal use.

(b) The program shall notify prescribers and dispensers:

(1) When there is cause to believe a potential violation of law or a breach of professional standards may have occurred, unless such notice is likely to interfere with an investigation conducted by the regulatory board; and
(2) When there is cause to believe a patient might be obtaining prescriptions in a manner that may represent misuse or abuse of controlled substances, including obtaining controlled substances from multiple practitioners or dispensers.

(c) The program vendor shall report to the board on at least a quarterly basis all the reports made in (a) and (b) above.

Source. #10526, eff 2-26-14
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

CHAPTER Ph 1600  PHARMACY INTERNS

PART Ph 1601  PURPOSE AND SCOPE

Ph 1601.01  Purpose and Scope. The provisions of this chapter shall apply to, and impose duties upon, all pharmacy interns holding registrations issued by the board.

Source. #10721, eff 11-22-14

PART Ph 1602  DEFINITIONS

Ph 1602.01  Definitions. Except where the context makes another meaning manifest, the following definitions shall apply:

(a) “Registered pharmacy intern” means a person:

(1) Who is enrolled in a professional degree program of a school or college of pharmacy that has been approved by the board and is satisfactorily progressing toward meeting the requirements for licensure as a pharmacist;

(2) Who is a graduate of an approved professional degree program of a school or college of pharmacy or is a graduate who has established educational equivalency by obtaining a Foreign Pharmacy Graduate Examination Committee (FPGEC) certificate, who is currently licensed by the board of pharmacy for the purpose of obtaining practical experience as a requirement for licensure as a pharmacist;

(3) Who is a qualified applicant awaiting examination for licensure or meeting board requirements for re-licensure; or

(4) Who is participating in a residency or fellowship except individuals that hold an active license to practice pharmacy in the State of New Hampshire.

Source. #10721, eff 11-22-14

PART Ph 1603  IDENTIFICATION

Ph 1603.01  Identification. The pharmacy intern shall be so designated in his or her professional relationships, and shall in no manner falsely assume, directly or by inference, to be a pharmacist. The board shall issue to the pharmacy intern a registration for purposes of identification and verification of his or her role as a pharmacy intern, which registration shall be surrendered to the board upon discontinuance of pharmacy practice experiences for any reason including licensure as a pharmacist. Only individuals properly registered by the board as a pharmacy intern shall take, use, or exhibit the title of pharmacy intern, or any other term of similar like or import.

Source. #10721, eff 11-22-14

PART Ph 1604  REGISTRATION

Ph 1604.01  Application.

(a) No person shall perform the functions or duties of a pharmacy intern unless such person is registered by the board.

(b) Application form Pharmacy Intern Registration/Renewal Form (PI-1) for registration of pharmacy interns in New Hampshire may be obtained from and shall be filed at the office of the board, identified in Ph 103.03.
(c) Each applicant shall provide the following on form PI-1:

(1) Name, residence address and home telephone number;
(2) Social security number, date of birth and email address;
(3) Name and address of the college or university where enrolled in pharmacy program;
(4) Anticipated date of graduation from accredited pharmacy program;
(5) Record of convictions of violations of federal, state or local drug or pharmacy related laws or regulations; and
(6) Applicant’s signature and date.

(d) The applicant shall submit with application form PI-1, the prescribed fee of $25.

(e) An applicant for registration as a registered pharmacy intern shall meet the following requirements:

(1) Be at least 18 years of age;
(2) Be enrolled in or possess a pharmacy degree from an accredited college or university pharmacy program;
(3) Be of good moral character; and
(4) Has not been convicted of a felony or a misdemeanor resulting from a violation of any federal, state, or local drug or pharmacy-related law, rule or regulation.

Source. #10721, eff 11-22-14

PART Ph 1605 REGISTRATIONS – CHANGES IN SUPPORTING DATA

Ph 1605.01 Reporting Changes.

(a) The person to whom a pharmacy intern registration has been issued shall notify the board within 15 days if a change of one or more of the following occur:

(1) Name;
(2) Address;
(3) Transfer of enrollment from accredited college or university pharmacy program to another; or
(4) Permanent separation of enrollment from his or her accredited pharmacy program, not to include graduation.

(b) The notice shall contain:

(1) Name of registrant;
(2) Address of the registrant including old and new, if applicable;
(3) Registrant’s registration number;
(4) Name of the school of pharmacy attending, including former and current, if applicable;

(5) Graduation date or anticipated date of graduation from accredited pharmacy program;

(6) Certification status, if applicable; and

(7) All new violations of law, convictions, fines, discipline or any registration, certification or license revocations for violation of pharmacy-related drug laws or regulations in this or any other state.

Source.  #10721, eff 11-22-14

PART Ph 1606 PHARMACY INTERNS – STANDARDS OF PRACTICE

Ph 1606.01 Responsibilities and Duties. Persons subject to these rules shall comply with the following:

(a) It shall be the responsibility of the pharmacist-in-charge to identify pharmacy interns and to assure that such persons are registered with the board as pharmacy interns prior to employment or experiential pharmacy rotation.

(b) All pharmacy interns shall wear a name tag, identifying them as a “Pharmacy Intern” while on duty.

(c) The pharmacist in charge shall determine the duties of each pharmacy intern based upon the needs of the pharmacy. A pharmacy intern shall be allowed to engage in the practice of pharmacy provided that such activities are under the supervision of a pharmacist. A pharmacist shall be in contact with, and actually giving instructions to, the pharmacy intern during all professional activities throughout the entire pharmacy practice experience period.

Source.  #10721, eff 11-22-14

Ph 1606.02 Registered Pharmacy Intern Duties. The duties of which a pharmacy intern is allowed to perform shall include:

(a) Data entry;

(b) Prospective Drug Utilization Review (DUR);

(c) Counseling of patients;

(d) Taking prescription provider orders by phone;

(e) Transfer of prescriptions; and

(f) Compounding of prescriptions.

Source.  #10721, eff 11-22-14

Ph 1606.03 Registered Pharmacy Interns Duty Restrictions. Registered pharmacy intern duties shall not include:

(a) Final verification of prescription orders; or

(b) Administration of vaccines.
PART Ph 1607 REVOCATION AND DENIAL

Ph 1607.01 Effect of Revocation and Denial.

(a) The board shall refuse to issue a registration, or after notice and hearing, shall revoke a registration whenever the board finds by the preponderance of the evidence any of the following:

(1) That the applicant, or registrant, has willfully violated any of the provisions of RSA 318 or Ph 1600;

(2) That the applicant has been convicted of a felony or a misdemeanor resulting from a violation of any federal, state, or local drug or pharmacy-related law, rule or regulation;

(3) That the applicant has attempted to obtain a pharmacy intern registration by fraudulent means;

(4) That the applicant is unable to engage in the performance of pharmacy intern functions with reasonable skill and safety by reason of illness, inebriation, misuse of drugs, narcotics, alcohol, chemicals or any other substance, or as a result of any mental or physical condition;

(5) The suspension, revocation, or probation by another state of the applicant’s license, permit, or registration to practice as a pharmacy intern;

(6) That the applicant refused to appear before the board after having been ordered to do so in writing; or

(7) That the applicant made any fraudulent or untrue statement to the board.

(b) The pharmacist-in-charge or approved pharmacist preceptor shall notify the board, in writing, within 7 calendar days after becoming aware that a pharmacy intern has adulterated, abused, stolen or diverted drugs.

(c) The board shall reinstate a registration after review, provided that the reason for revocation no longer exists, or it is determined that there is no longer a threat to public safety.

Source. #10721, eff 11-22-14

PART Ph 1608 RENEWAL OF REGISTRATIONS

Ph 1608.01 Renewal Registrations Required. All pharmacy intern registrations shall expire annually on September 30.

Source. #10721, eff 11-22-14

Ph 1608.02 Renewal Application Where Obtained and Filed. Applications for the renewal of a registration for a pharmacy intern may be obtained from, and shall be filed at the office of the board, identified in Ph 103.03.

Source. #10721, eff 11-22-14

Ph 1608.03 Renewal Application Contents and When Filed. Renewal applications shall be filed with the board in accordance with the following:
NEW HAMPSHIRE CODE OF ADMINISTRATIVE RULES

(a) Applications for renewal of pharmacy intern registration shall be made on Form PI-1.

(b) Each applicant shall provide the following on Form PI-1 regarding himself/herself:

   (1) Original registration number;

   (2) Name, residence address and home telephone number;

   (3) Social security number, date of birth, and email address;

   (4) Name and address of the college or university where enrolled in a pharmacy program;

   (5) Anticipated date of graduation from accredited pharmacy program;

   (6) Answer questions on convictions, charges, and disciplinary action for violations of federal, state or local drug or pharmacy related laws or regulations; and

   (7) Applicant’s signature and date.

(c) The application and the prescribed fee of $25 shall be filed with the board no later than September 30.

Source. #10721, eff 11-22-14
## APPENDIX

<table>
<thead>
<tr>
<th>Rule</th>
<th>Specific State Statute the Rule Implements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ph 103.01</td>
<td>RSA 318:2</td>
</tr>
<tr>
<td>Ph 104.03</td>
<td>RSA 318:5-a, VII; RSA 318:25, II</td>
</tr>
<tr>
<td>Ph 201-204</td>
<td>RSA 318:5-a, VIII; RSA 318:30 – 31; RSA 541-A:16, I (b)(2)</td>
</tr>
<tr>
<td>Ph 205</td>
<td>RSA 318:31, V; RSA 541-A:16, I (b)(2)</td>
</tr>
<tr>
<td>Ph 206</td>
<td>RSA 541-A:16, I (d)</td>
</tr>
<tr>
<td>Ph 207</td>
<td>RSA 541-A:16, I (c)</td>
</tr>
<tr>
<td>Ph 208</td>
<td>RSA 541-A:16, I (b)(3)</td>
</tr>
<tr>
<td>Ph 209</td>
<td>RSA 541-A:11, VII</td>
</tr>
<tr>
<td>Ph 301.01</td>
<td>RSA 318:5-a, I, III; RSA 318:18</td>
</tr>
<tr>
<td>Ph 301.02</td>
<td>RSA 318:5-a, II; RSA 318:18; RSA 318:19</td>
</tr>
<tr>
<td>Ph 301.03</td>
<td>RSA 318:5-a, I; RSA 318:10; RSA 318:18</td>
</tr>
<tr>
<td>Ph 301.04</td>
<td>RSA 318:5-a, IV; RSA 318:10</td>
</tr>
<tr>
<td>Ph 301.05</td>
<td>RSA 318:5-a, IV</td>
</tr>
<tr>
<td>Ph 301.06, Ph 301.07</td>
<td>RSA 318:10; RSA 318:18, II; RSA 318:29, I</td>
</tr>
<tr>
<td>Ph 302.01</td>
<td>RSA 318:21</td>
</tr>
<tr>
<td>Ph 302.02</td>
<td>RSA 318:21</td>
</tr>
<tr>
<td>Ph 302.03</td>
<td>RSA 318:21</td>
</tr>
<tr>
<td>Ph 302.04, Ph 302.05, Ph 302.06</td>
<td>RSA 318:21</td>
</tr>
<tr>
<td>Ph 302.07</td>
<td>RSA 318:5-a, VII</td>
</tr>
<tr>
<td>Ph 302.08, Ph 302.09</td>
<td>RSA 318:5-a, IV</td>
</tr>
<tr>
<td>Ph 303</td>
<td>RSA 318:5-a, I, II, IV-a, V, VII</td>
</tr>
<tr>
<td>Ph 303.02 (d), (h), and (j)</td>
<td>RSA 318:5-a, XIV</td>
</tr>
<tr>
<td>Ph 304.01</td>
<td>RSA 318:38, I, II, III</td>
</tr>
<tr>
<td>Ph 304.02</td>
<td>RSA 318:38, III; RSA 318:39</td>
</tr>
<tr>
<td>Ph 305, Ph 306</td>
<td>RSA 318-B:23</td>
</tr>
<tr>
<td>Ph 306.01(d)</td>
<td>RSA 318:5-a, II and IV-a</td>
</tr>
<tr>
<td>Ph 306.05(c)</td>
<td>RSA 318:38, III</td>
</tr>
<tr>
<td>Ph 307</td>
<td>RSA 318:38, III; RSA 318-B:25</td>
</tr>
<tr>
<td>Ph 308</td>
<td>RSA 318:5-a, VII</td>
</tr>
<tr>
<td>Ph 309</td>
<td>RSA 318:5-a, I, II, III, V, VII; RSA 318:42, III; RSA 318:51-a; RSA 318-B:3; RSA 318-B:5</td>
</tr>
<tr>
<td>Ph 401.01</td>
<td>RSA 318:5-a, I, III, V, VII, VII-a</td>
</tr>
<tr>
<td>Ph 401.02 (a)(b)</td>
<td>RSA 318:25</td>
</tr>
<tr>
<td>Ph 401.02(c)(d)</td>
<td>RSA 318:5-a, VII and RSA 318:16-b, IV</td>
</tr>
<tr>
<td>Ph 401.02(e)</td>
<td>RSA 318:29-a, VI (b)</td>
</tr>
<tr>
<td>Ph 401.03 - Ph 401.05</td>
<td>RSA 318:26</td>
</tr>
<tr>
<td>Ph 401.06 - Ph 401.07</td>
<td>RSA 318:5-a, II</td>
</tr>
<tr>
<td>Ph 401.07</td>
<td>RSA 318:5-a, VI, VII</td>
</tr>
<tr>
<td>Ph 402.01 - Ph 402.04</td>
<td>RSA 318:5-a, VI, VII</td>
</tr>
<tr>
<td>Ph 403.01 - Ph 403.02</td>
<td>RSA 318:29, I, II, IV, V; RSA 318:5-a, VII-a</td>
</tr>
<tr>
<td>Ph 403.03 - 403.13</td>
<td>RSA 318:25, III</td>
</tr>
<tr>
<td>Ph 404</td>
<td>RSA 318:5-a, II, IV-a</td>
</tr>
<tr>
<td>Ph 405</td>
<td>RSA 318:5-a, II, IV-a</td>
</tr>
<tr>
<td>Ph 500</td>
<td>RSA 318:5-a, VI</td>
</tr>
<tr>
<td>Ph 501.01</td>
<td>RSA 318:5-a, IV</td>
</tr>
<tr>
<td>Ph 601.01 – 601.04</td>
<td>RSA 318:5-a, I, II, III, IV-a, V, VI, and VII; RSA 318:51-b</td>
</tr>
<tr>
<td>Ph 601.05</td>
<td>RSA 318:5-a, VII</td>
</tr>
<tr>
<td>Ph 601.06 – 601.16</td>
<td>RSA 318:5-a, I, II, III, IV-a, V, VI, and VII; RSA 318:51-b</td>
</tr>
<tr>
<td>Ph 601.01 (c)</td>
<td>RSA 318:5-a, VII</td>
</tr>
<tr>
<td>Ph 601.10(d)</td>
<td>21 CFR 1301.72(a)</td>
</tr>
<tr>
<td>Ph 601.10 (h)</td>
<td>RSA 318:51-b, II(b)</td>
</tr>
<tr>
<td>Ph 601.11 (a)</td>
<td>RSA 318:51-b, II(d)</td>
</tr>
<tr>
<td>Ph 601.12(b)</td>
<td>21 CFR 1301.74(h)</td>
</tr>
<tr>
<td>Ph 601.13</td>
<td>RSA 318:51-b, II(b) and (d)</td>
</tr>
<tr>
<td>Ph 601.14 (c)(5)</td>
<td>RSA 318:51-b, II(d)</td>
</tr>
<tr>
<td>Ph 701.01 – 701.02</td>
<td>RSA 318:5-a, IV-a</td>
</tr>
<tr>
<td>Ph 701.03</td>
<td></td>
</tr>
<tr>
<td>Ph 702.01 – 702.04</td>
<td>RSA 318:5-a, II, IV-a</td>
</tr>
<tr>
<td>Ph 702.01 (b)(3)</td>
<td>RSA 318:5-a, II</td>
</tr>
<tr>
<td>Ph 702.05</td>
<td>RSA 318:5-a, XIV</td>
</tr>
<tr>
<td>Ph 702.06 – 702.07</td>
<td>RSA 318:5-a, IV-a</td>
</tr>
<tr>
<td>Ph 703.01 – 703.05</td>
<td>RSA 318:5-a, III, IV-a, IX</td>
</tr>
<tr>
<td>Ph 703.02 (b)(2)</td>
<td>RSA 318:5-a, IV-a</td>
</tr>
<tr>
<td>Ph 703.06</td>
<td>RSA 318:5-a, IV-a</td>
</tr>
<tr>
<td>Ph 703.07</td>
<td>RSA 318:46; RSA 318:47; RSA 318-B:12</td>
</tr>
<tr>
<td>Ph 704.01</td>
<td>RSA 318:5-a, XIV</td>
</tr>
<tr>
<td>Ph 704.02 – 704.06</td>
<td>RSA 318:5-a, II, III, IV-a, XV</td>
</tr>
<tr>
<td>Ph 704.03</td>
<td>RSA 318:5-a, III, and IV-a</td>
</tr>
<tr>
<td>Ph 704.04 intro., (a) – (d)</td>
<td>RSA 318:5-a, III, and IV-a</td>
</tr>
<tr>
<td>Ph 704.06 (b), (c), (f)</td>
<td>RSA 318:5-a, III, IV-a, and XV</td>
</tr>
<tr>
<td>Ph 704.07 (a), (b)</td>
<td>RSA 318:38, I</td>
</tr>
<tr>
<td>Ph 704.08 – 704.13</td>
<td>RSA 318:47-c</td>
</tr>
<tr>
<td>Ph 704.11</td>
<td>RSA 318:5 a, IV-a</td>
</tr>
<tr>
<td>Ph 704.14</td>
<td>RSA 318:52-a</td>
</tr>
<tr>
<td>Ph 704.15 (a), (b), (d), (c)</td>
<td>RSA 318-B:9, I, III, IV</td>
</tr>
<tr>
<td>Ph 704.16</td>
<td>RSA 318:29, V, (g)(h)</td>
</tr>
<tr>
<td>Ph 705.01 – 705.02</td>
<td>RSA 318:5-a, IV-a, RSA 318:38, I</td>
</tr>
<tr>
<td>Ph 705.03 (a) – (d)</td>
<td>RSA 318:38, I</td>
</tr>
<tr>
<td>Ph 706</td>
<td>RSA 318:5-a, IV-a</td>
</tr>
<tr>
<td>Ph 707.01</td>
<td>RSA 318:5-a, IV-a</td>
</tr>
<tr>
<td>Ph 707.02</td>
<td>RSA 318:5-a, II, III, IV-a</td>
</tr>
<tr>
<td>Ph 707.02 (a)</td>
<td>RSA 318:5-a, III, IV-a</td>
</tr>
<tr>
<td>Ph 707.02 (b)(1)</td>
<td>RSA 318:5-a, II</td>
</tr>
<tr>
<td>Ph 707.02 (b) (7)</td>
<td>RSA 318:5-a, III</td>
</tr>
<tr>
<td>Ph 707.03</td>
<td>RSA 318:5-a, IV-a</td>
</tr>
<tr>
<td>Ph 707.04</td>
<td>RSA 318-B:17-a, RSA 318:5-a, IV-a</td>
</tr>
<tr>
<td>Ph 707.05 – 707.06</td>
<td>RSA 318:5-a, IV-a</td>
</tr>
<tr>
<td>Ph 708.01</td>
<td>RSA 318:5-a, III, IV-a, IX</td>
</tr>
<tr>
<td>Ph 708.02</td>
<td>RSA 318:47</td>
</tr>
<tr>
<td>Section</td>
<td>References</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
</tr>
<tr>
<td>Ph 708.03</td>
<td>RSA 318-B:9, II</td>
</tr>
<tr>
<td>Ph 709.01</td>
<td>RSA 318:5-a, IV-a and XV</td>
</tr>
<tr>
<td>Ph 709.02</td>
<td>RSA 318:5-a, IV-a</td>
</tr>
<tr>
<td>Ph 709.03 – 709.06</td>
<td>RSA 318:5-a, IV-a, and XII</td>
</tr>
<tr>
<td>Ph 709.05</td>
<td>RSA 318:5-a, IV-a; RSA 318:42</td>
</tr>
<tr>
<td>Ph 709.07 - 709.09</td>
<td>RSA 318:5-a, IV-a</td>
</tr>
<tr>
<td>Ph 710.01 – 710.02</td>
<td>RSA 318:5-a, IV-a, VII; RSA 318:29, IV</td>
</tr>
<tr>
<td>Ph 801</td>
<td>RSA 318:5-a, X (a)</td>
</tr>
<tr>
<td>Ph 802</td>
<td>RSA 318:5-a, X (a)</td>
</tr>
<tr>
<td>Ph 803</td>
<td>RSA 318:5-a, X (a) &amp; 318:15-a</td>
</tr>
<tr>
<td>Ph 804</td>
<td>RSA 318:5-a, (b)</td>
</tr>
<tr>
<td>Ph 805</td>
<td>RSA 318:5-a, X (d)</td>
</tr>
<tr>
<td>Ph 806</td>
<td>RSA 318:5-a, XI &amp; 318:6-a</td>
</tr>
<tr>
<td>Ph 806.04</td>
<td>RSA 318:5-a, X (a)</td>
</tr>
<tr>
<td>Ph 807</td>
<td>RSA 318:5-a, X (b)</td>
</tr>
<tr>
<td>Ph 900</td>
<td>RSA 318:5-a; RSA 318:37, II</td>
</tr>
<tr>
<td>Ph 901</td>
<td>RSA 541-A:8</td>
</tr>
<tr>
<td>Ph 902</td>
<td>RSA 541-A:7; RSA 541-A:8</td>
</tr>
<tr>
<td>Ph 903 – Ph 907</td>
<td>RSA 318:37; RSA 318:38</td>
</tr>
<tr>
<td>Ph 903.01 (c)(7)</td>
<td>RSA 318:5-a, VII</td>
</tr>
<tr>
<td>Ph 903.01 (d)</td>
<td>RSA 318:5-a, IV-a</td>
</tr>
<tr>
<td>Ph 906.03 intro. and (d)</td>
<td>RSA 318:5-a, I, IV-a</td>
</tr>
<tr>
<td>Ph 1001.01 – 1001.07</td>
<td>RSA 318:5-a, XVI; RSA 318:47-e</td>
</tr>
<tr>
<td>Ph 1101.01</td>
<td>RSA 541-A:8</td>
</tr>
<tr>
<td>Ph 1101.02</td>
<td>RSA 318-:16-a, III; RSA 541-A:8</td>
</tr>
<tr>
<td>Ph 1102</td>
<td>RSA 541-A:7; RSA 541-A:8</td>
</tr>
<tr>
<td>Ph 1103</td>
<td>RSA 318:16-a, I</td>
</tr>
<tr>
<td>Ph 1104</td>
<td>RSA 318:16-a, II</td>
</tr>
<tr>
<td>Ph 1201</td>
<td>RSA 541-A:8</td>
</tr>
<tr>
<td>Ph 1202</td>
<td>RSA 541-A:7; RSA 541-A:8</td>
</tr>
<tr>
<td>Ph 1203</td>
<td>RSA 318:5-a, XIII</td>
</tr>
<tr>
<td>Ph 1301.01</td>
<td>RSA 541-A:8</td>
</tr>
<tr>
<td>Ph 1301.02</td>
<td>RSA 541-A:8; RSA 318:5-a, IV-a</td>
</tr>
<tr>
<td>Ph 1302</td>
<td>RSA 541-A:7; RSA 541-A:8; RSA 318:1, I, VII, and XV</td>
</tr>
<tr>
<td>Ph 1303.01</td>
<td>RSA 318:16-b</td>
</tr>
<tr>
<td>Ph 1303.02</td>
<td>RSA 318:5-a,III and RSA 318:16-b, IV</td>
</tr>
<tr>
<td>Ph 1303.02</td>
<td>RSA 318:5-a,III; RSA 318:16-b,VI</td>
</tr>
<tr>
<td>Ph 1401</td>
<td>RSA 541-A:8; RSA 318:56</td>
</tr>
<tr>
<td>Ph 1402</td>
<td>RSA 541-A:7; RSA 541-A:8; RSA 318:57</td>
</tr>
<tr>
<td>Ph 1403</td>
<td>RSA 318:58 I; RSA 318:58 III</td>
</tr>
<tr>
<td>Ph 1404</td>
<td>RSA 318:58 II; RSA 318:58 III</td>
</tr>
<tr>
<td>Ph 1405</td>
<td>RSA 318:56, VI</td>
</tr>
<tr>
<td>Ph 1406</td>
<td>RSA 318:58</td>
</tr>
<tr>
<td>Ph 1407</td>
<td>RSA 318:56</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Ph 1408</td>
<td>RSA 318:58, III-a</td>
</tr>
<tr>
<td>Ph 1409</td>
<td>RSA 318:56, VI</td>
</tr>
<tr>
<td>Ph 1410</td>
<td>RSA 318:59; RSA 318:58</td>
</tr>
<tr>
<td>Ph 1411</td>
<td>RSA 318:60</td>
</tr>
<tr>
<td>Ph 1412</td>
<td>RSA 318:55</td>
</tr>
<tr>
<td>Ph 1501.01</td>
<td>RSA 318-B:31-38</td>
</tr>
<tr>
<td>Ph 1502.01</td>
<td>RSA 318-B:31</td>
</tr>
<tr>
<td>Ph 1503.01</td>
<td>RSA 318-B:33, I &amp; II</td>
</tr>
<tr>
<td>Ph 1504.01</td>
<td>RSA 318-B:33, III, IV &amp; V</td>
</tr>
<tr>
<td>Ph 1504.02</td>
<td>RSA 318-B:33, VI</td>
</tr>
<tr>
<td>Ph 1504.03</td>
<td>RSA 318-B:33, VII</td>
</tr>
<tr>
<td>Ph 1505.01 – 1505.05</td>
<td>RSA 318-B:35, I</td>
</tr>
<tr>
<td>Ph 1506.01 – 1506.02</td>
<td>RSA 318-B:35, II &amp; III</td>
</tr>
<tr>
<td>Ph 1601-1608</td>
<td>RSA 318:5-a XI-a; 318:5-a XI-b; and 318:15-b</td>
</tr>
</tbody>
</table>